Characterization of P-Cadherin in feline mammary tumours - Association with tumours aggressiveness by Ana Catarina Pais dos Santos Figueira
CHARACTERIZATION OF P-CADHERIN 
IN FELINE MAMMARY TUMOURS
 
ASSOCIATION WITH TUMOUR AGGRESSIVENESS
ANA CATARINA PAIS DOS SANTOS FIGUEIRA
TESE DE DOUTORAMENTO EM CIÊNCIAS VETERINÁRIAS
APRESENTADA AO INSTITUTO DE CIÊNCIAS BIOMÉDICAS ABEL SALAZAR
DA UNIVERSIDADE DO PORTO

ANA CATARINA PAIS DOS SANTOS FIGUEIRA
CHARACTERIZATION OF P-CADHERIN 
IN FELINE MAMMARY TUMOURS
 ASSOCIATION WITH TUMOUR AGGRESSIVENESS
Tese de Candidatura ao grau de Doutor em Ciências 
Veterinárias submetida ao Instituto de Ciências Biomédicas 
Abel Salazar da Universidade do Porto
Orientador | Professora Doutora Maria de Fátima Gärtner 
Categoria | Professora Catedrática
Afiliação | Instituto de Ciências Biomédicas Abel Salazar, 
Universidade do Porto (ICBAS-UP)
Co-orientador | Professor Doutor Augusto de Matos
Categoria | Professor Auxiliar
Afiliação | Instituto de Ciências Biomédicas Abel Salazar, 
Universidade do Porto (ICBAS-UP)
Co-orientador | Professora Doutora Patrícia Dias-Pereira
Categoria | Professora Auxiliar
Afiliação | Instituto de Ciências Biomédicas Abel Salazar, 
Universidade do Porto (ICBAS-UP)

	 	 ‘A quem me pergunta se sou pessimista ou otimista,
respondo que o meu conhecimento é de pessimista, 
mas a minha vontade e a minha esperança são de otimista.’
Albert Schweitzer

FINANCIAL SUPPORT
PhD Fellowship (SFRH/BD/69493/2010) provided by the Portuguese Foundation for Sci-
ence and Technology (FCT) of the Portuguese Ministry of Science, Technology and Higher 
Education
Bolsa Individual de Doutoramento (SFRH/BD/69493/2010) da Fundação Portuguesa para 
a Ciência e a Tecnologia (FCT) do Ministério da Ciência, Tecnologia e Ensino Superior
             

DECLARATION
In accordance to the disposed in “nº 2, alínea a, do Art.º 31º do Decreto-Lei nº 230/2009”, 
the author of this thesis declares to have actively participated in the elaboration and execu-
tion of experimental work that led to the results presented, as well as in its interpretation and 
in the writing of the respective manuscripts.
The following original manuscripts (published and in preparation) are integral parts of this 
PhD thesis:
 
Figueira AC, Gomes C, de Oliveira J, Vilhena H, Carvalheira J, De Matos A, Dias-Pereira P, 
Gärtner F, 2014. Aberrant P-cadherin expression is associated to aggressive feline mam-
mary carcinomas. BMC Vet Res, 10, 270.
Figueira AC, Gomes C, Vilhena H, Miranda S, Carvalheira J, de Matos AJ, Dias-Pereira P, 
Gärtner F, 2015. Characterization of α-, β- and p120-catenin expression in feline mammary 
tissues and their relation with E- and P-cadherin. Anticancer Res, 35, 3361-9.
Figueira AC, Vilhena H, Gomes C, Carvalheira J, de Matos AJ, Dias-Pereira P, Gärtner F, 
Phenotypical, cell-adhesion, hormonal receptors and cell-cycle associated markers: an in-
tegrated immunohistochemical study in feline mammary lesions. Manuscript in preparation. 
Figueira AC, Gomes C, Mendes N, de Matos AJ, Dias-Pereira P, Gärtner F, An in vitro and 
in vivo characterization of the cadherin-catenin adhesion complex in a feline mammary car-
cinoma cell line. Manuscript in preparation. 

ACKNOWLEDGMENTS
To the Instituto de Ciências Biomédicas Abel Salazar, University of Porto for accepted me 
and for giving me the opportunity of making part of a high quality educational training of the 
Veterinary Science PhD programme.
To the Institute of Molecular Pathology and Immunology of the University of Porto, for ac-
cepted me in a team with high technical and scientific skills.
To the Escola Universitária Vasco da Gama, Coimbra, for the encouragement and support 
in this work. 
To the Portuguese Foundation for Science and Technology (FCT) of the Portuguese Min-
istry of Science, Technology and Higher Education, for providing me the PhD Fellowship 
(SFRH/BD/69493/2010). 

13
PERSONAL THANKS 
AGRADECIMENTOS
A todas as pessoas que de uma forma ou outra me acompanharam e apoiaram durante o 
periodo de realização deste trabalho, aqui ficam os meus sinceros agradecimentos.
À Professora Doutora Fátima Gärtner, por me ter permitido realizar este projeto e fazer 
parte do grupo de investigação, conhecendo e contatando de perto com os seus colabora-
dores e colegas, abrindo portas para o mundo da investigação em oncologia. A Professora, 
para além da excelente académica e investigadora, é uma grande amiga, com um coração 
enorme como conheço poucos. Um muito obrigada por todas as lições ao longo destes 
quatro anos.
À Professora Doutora Patrícia Dias-Pereira, que para além da preciosa ajuda na co-orien-
tação deste trabalho, mostrou ser uma amiga que espero para a vida. O apoio em fases 
cruciais do projeto de doutoramento, bem como na minha vida pessoal, foram fundamen-
tais para que pudessem ser ultrapassadas. Obrigada por me mostrares que os passos 
atrás que damos no nosso caminho, por vezes são para ganharmos balanço para seguir 
em frente. 
Ao Professor Doutor Augusto de Matos, por continuar a ser o excelente Professor que 
recordava da licenciatura em Medicina Veterinária. Muito obrigada por todas as críticas, 
sugestões e “food for the brain” que me ajudaram a refletir sobre o trabalho desenvolvido.
Ao Professor Doutor Júlio Carvalheira, por todo o apoio e disponibilidade para as inúmeras 
dúvidas estatísticas. A boa disposição e humor com que sempre me recebeu, tornaram o 
trabalho nesta área mais agradável.
À Dra Filomena Ramalho e à Dra Mariana Portugal pela disponibilidade e amabilidade na 
parceria com o Canil Municipal de Coimbra.
À Catarina Gomes por ter sido sem dúvida um “anjo” que me apareceu em determinada 
altura do trabalho. Sabes bem a importância e valor que tiveste neste projeto e para mim 
foi um privilégio poder trabalhar contigo. 
14
Ao Nuno Mendes por todo o apoio no trabalho no biotério, por todas as trocas de e-mails e 
por teres ajudado a tornar esta parte do trabalho menos penosa. 
À Dra Anália do Carmo e à Sofia Anastácio pela disponibilidade e ajuda com o trabalho de 
ELISA. 
Aos Ipatimupianos um muito obrigada pela amabilidade e carinho com que receberam esta 
“deslocada” de Coimbra. Fizeram-me sentir em casa.
À equipa do Laboratório de Patologia Veterinária do ICBAS, pelo apoio na realização técnica 
do trabalho.
Ao Hugo Vilhena, por seres o melhor colega para trabalhar em investigação clínica. Sempre 
atento, preocupado, disponível e interessado. Foste uma “peça fundamental neste puzzle”. 
À Sónia Miranda, por teres permitido a excelente colaboração com o Hospital Veterinário 
do Baixo Vouga e por toda a ajuda na parte cirúrgica e imagiológica.
Aos meus amigos do coração Raquel, Ana “Espanhola”, Carla, João Paulo, Inês, António, 
Teresa, Marta, Ana Canadas e Pedro e aos eternos amigos da “La Famiglia”, que de alguma 
forma com a vossa amizade permitiram duplicar as minhas alegrias e dividir as minhas 
tristezas. 
Ao Miguel, que continuo a considerar um grande amigo.
À Xana, sei que és de poucas palavras, mas quando as dizes fazem todo o sentido. Só o 
facto de seres a melhor “tia Xana” do mundo, deixa-me mais tranquila e completa.
À minha Mãe por todo o apoio durante esta fase. Sem ti nada disto teria sido possível.
(Ao meu Pai e à avó Regina que de onde estão, continuam a fazer parte da minha vida).
E porque os últimos são sempre os primeiros, à Carolina a minha pequena grande princesa, 
um agradecimento muito especial, por na sua inocência dos 4 anos ter sempre apoiado a 
mãe. A Ti um pedido de desculpa por todos os momentos de ausência e só espero que um 
dia sintas por mim o mesmo orgulho que eu sinto por ti!
15
THESIS OUTLINE
The present thesis has been divided into nine chapters and one appendix.
Chapter 1 is a general introduction on the state of the art in feline mammary tumours, as 
well as the molecules of the cadherin-catenin complex both in human breast cancer and in 
feline mammary tumours. 
Chapter 2 summarizes the objectives of the thesis as well as the motivation for the study of 
P-cadherin in feline mammary carcinogenesis. 
Chapters 3, 4, 5, 6 and 7 encompass original data of this thesis, both published and unpub-
lished, along with ongoing work.
The first study, Chapter 3, focuses on P-cadherin expression in feline mammary tumours. 
This study entitled "Aberrant P-cadherin expression is associated to aggressive feline mam-
mary carcinomas” was published in BMC Vet Res, 2014, 10, 270.
The second study, Chapter 4, focuses on the characterization of the cadherin-catenin com-
plex in feline mammary tumours. This study entitled “Characterization of α-, β- and p120-
catenin expression in feline mammary tissues and their relation with E- and P-cadherin” 
was published in Anticancer Res, 2015, 35, 3361-9.
The third study, Chapter 5, focuses on the molecular characterization of feline mammary 
tumours. This study is entitled “Phenotypical, cell-adhesion, hormonal receptors and cell-
cycle associated markers: an integrated immunohistochemical study in feline mammary 
lesions” and the manuscript is in preparation. 
The fourth study, Chapter 6, focuses on the determination of an in vitro and in vivo models 
for the P-cadherin study in feline mammary tumours. This study is entitled “An in vitro and 
in vivo characterization of the cadherin-catenin adhesion complex in a feline mammary car-
cinoma cell line” and the manuscript is in preparation.
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The fifth study, Chapter 7, is an ongoing work focused on the determination of the soluble 
P-cadherin serum levels in queens with mammary tumours.
A general discussion of the results is presented in Chapter 8, followed by conclusions and 
future perspectives in Chapter 9. 
Appendix includes the published manuscripts.
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ABSTRACT
Mammary cancer in cats have high recurrence and metastatic potential. The need of reli-
able prognostic markers and promising therapeutic approaches to feline mammary carcino-
mas, has led to an intensive research aiming to accomplish a molecular characterization of 
feline mammary tumours that reflects their biological behaviour, similarly to what has been 
previously performed in human breast cancer. 
Cadherins are calcium-dependent cell-to-cell adhesion glycoproteins playing a critical role 
in the formation and maintenance of normal tissue architecture. Abnormal expression or 
function in the major molecules of the cadherin-catenin adhesion complex have been relat-
ed to breast cancer development and associated to cell migration, invasion and metastatic 
dissemination. 
The classical cadherins (P-cadherin and E-cadherin) as well as major catenins (α-, β-, and 
p120-) immunoexpression were studied in a series of feline normal mammary glands, hy-
perplastic/dysplastic lesions, benign and malignant tumours. Phenotypical molecular mark-
ers (AE1/AE3, vimentin, p63), hormonal receptor status (ER, PR) and markers of prolifera-
tive activity (Ki-67) were also characterized.
The results allowed us to conclude that aberrant expression of P-cadherin detected in feline 
mammary tumours is associated to malignant phenotypes, higher histological grade and 
invasive behaviour, suggesting that this protein may be a relevant prognosis biomarker. 
Co-expression of P- and E-cadherin was related with high grade carcinomas, and P-cad-
herin overexpression seems to be a more reliable indicator of prognosis in feline mammary 
carcinomas than the aberrant expression of E-cadherin. Although the prognostic value of 
α-, β- and p120-catenin was not supported by our results, the development of mammary 
carcinomas in cats is associated to a decreased expression of these catenins suggesting 
that they may represent a valuable diagnostic tool. Moreover, aggressive feline mammary 
carcinomas are associated to high histological grade, high proliferative activity, absence of 
ER, aberrant expression of P-cadherin and vimentin. 
Major molecules from the cadherin-catenin complex (E- and P-cadherin, α-, β- and p120-
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catenin) were evaluated in a feline metastatic mammary carcinoma cell line (FMCm). This 
cell line besides expressing P-cadherin also co-expressed E-cadherin and α-, β- and p120-
catenin, and those molecules were in close relation with each other pointing to a preserved 
E-cadherin-catenin complex. The FMCm cell line showed high tumourigenic capacity, 
aggressive and metastatic characteristics in nude mice, with xenograft and metastatic le-
sions expressing P- and E-cadherin as well as α-, β- and p120-catenin. Thus, FMCm cell 
line can be proposed as a useful model for in vitro and in vivo studies of P-cadherin and 
associated molecules of the cadherin-catenin complex for study of feline mammary carci-
noma progression.
In conclusion, the results presented in this study highlighted P-cadherin as a relevant molecule 
in tumour aggressiveness of the feline mammary carcinomas.
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RESUMO
Os carcinomas mamários felinos estão associados a elevadas taxas de recidiva e potencial 
metastático. A necessidade de marcadores de prognóstico fiáveis e de abordagens terapêu-
ticas promissoras para os carcinomas mamários felinos, levou à investigação e caracteriza-
ção molecular destas lesões com o objetivo de determinar o seu comportamento biológico, à 
semelhança do que tem sido realizado em carcinomas mamários na mulher.
As caderinas são glicoproteínas fundamentais na adesão célula a célula, dependentes do 
cálcio que desempenham um papel na formação e manutenção da arquitetura dos tecidos 
normais. A expressão e função alteradas das principais moléculas do complexo de adesão 
caderina-catenina têm sido associadas ao cancro da mama. A sua desregulação tem um papel 
fundamental na migração celular, invasão e disseminação metastática.
A imunoexpressão das caderinas clássicas (caderina P e caderina E) bem como das principais 
cateninas (α, β e p120) foi estudada numa série de tecido normal da glândula mamária felina, 
em lesões hiperplásicas/displásicas, tumores benignos e malignos. Foram também caracter-
izados marcadores moleculares de fenótipo (AE1/AE3, vimentina e p63), recetores hormonais 
(RE, RP) e marcadores de atividade proliferativa (Ki-67).
Os resultados permitiram concluir que a expressão aberrante da caderina P detetada nos tu-
mores mamários felinos está associada ao fenótipo maligno, a grau histológico elevado e a 
um comportamento invasivo, o que sugere que a caderina P seja um biomarcador molecular 
com relevância prognóstica. A co-expressão da caderina P e da caderina E está associada a 
carcinomas de grau histológico elevado e a sobre-expressão da caderina P em carcinomas 
de mama de felinos parece ser um indicador de prognóstico mais fiável do que a expressão 
alterada da caderina E. 
Apesar do valor prognóstico das cateninas α, β e p120 não ter sido confirmado com os nos-
sos resultados, o desenvolvimento de carcinomas mamários em gatas está associado a uma 
diminuição destas cateninas, sugerindo que possam ter valor diagnóstico. Os carcinomas 
mamários felinos com comportamento mais agressivo estão associados a grau histológico el-
evado, elevada atividade proliferativa, ausência de recetores de estrogénio e expressão aber-
rante de caderina P, bem como de vimentina.
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As principais moléculas do complexo caderina-catenina (caderina E e P e cateninas α, β, e 
p120) foram estudadas numa linha celular de metástase de carcinoma mamário felino (FMCm). 
Esta linha celular para além de expressar caderina P também co-expressava caderina E e as 
cateninas α, β e p120. Estas moléculas apresentavam uma relação positiva entre si apontando 
para a presença de um complexo caderina E-catenina preservado. A linha celular FMCm revelou 
capacidade tumorigénica, agressividade e potencial metastático em ratinhos nude, com as 
lesões de xenotransplantes e lesões metastáticas mostrando expressão de caderina E e ca-
derina P, bem como cateninas α, β e p120. Assim, esta linha celular FMCm pode ser proposta 
como um modelo útil para estudos in vitro e in vivo da caderina P e das restantes moléculas do 
complexo caderina-catenina na progressão dos carcinomas mamários felinos. 
Em conclusão, os resultados apresentados neste estudo evidenciam a caderina P como uma 
molécula relevante na agressividade tumoral dos carcinomas mamários felinos. 
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ABBREVIATION LIST
ctn Catenin
BCA Bicinchoninic acid
BLBC Basal-like breast cancer
BRCA1 Breast cancer susceptibility gene 1
BSA Bovine serum albumin
CAMs Cell adhesion molecules
CBD Catenin binding domain
CDH1 Cadherin 1 or E-cadherin gene
CDH3 Cadherin 3 or P-cadherin gene
CK Cytokeratin
CSC Cancer stem cells
DAB 3’ 3’-diaminobenzidine tetrahydrochloride
DAPI 4,6-diamidino-2-phenylindole endihydrochloride
DCIS Ductal carcinoma in situ
DIF Double-labell immunofluorescence
DFI Disease free interval
DNA Desoxyribonucleic acid
EC Extracelular sub-domain
E-cadherin Epithelial cadherin
ECM Extracellular matrix
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
EMT Epithelial to mesenchymal transition
ER Oestrogen receptor
FMCm Feline mammary carcinoma metastatic cell line
HE Haematoxylin eosin
HER2 Receptor tyrosine-protein kinase erbB-2
HR Hormone receptors
IHC Immunohistochemistry
JMD Juxtamembrane domain
LOH Lost of heterozygoty
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MET Mesenchymal to epithelial transition
MMP Matrix metalloproteinases
NAF Nipple aspirate fluid
NS Not significant
OS Overall survival
PBS Phosphate buffered saline
P-cadherin Placental cadherin
PLA Proximity ligation assay
PR Progesterone receptor
SAM Substratum adhesion molecules
sE-cad Soluble fragment of E-cadherin
sP-cad Soluble fragment of P-cadherin
TBS Tris-buffered saline
TNBC Triple-negative breast carcinoma
TNM Tumour-node-metastasis
TS total score
VEGF Vascular endothelial growth factor
WHO World Health Organization
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General introduction Chapter 01 
FELINE MAMMARY TUMOURS
Domestic animals spontaneously develop several diseases, namely cancer, that in many aspects 
parallel human morbidities, and hence are considered excellent natural models of disease [1]. 
Spontaneous feline mammary carcinomas have been proposed by the World Health Organiza-
tion (WHO) as models for human breast cancer based on age of onset, incidence, histopathologic 
features, biologic behaviour, and prognosis [1-3]. 
Mammary neoplasia is the third most common type of tumour affecting female cats, following 
hematopoietic and skin tumours, accounting for 17% of all tumours in the species [2, 4], with 85 
to 90% being malignant [1, 4, 5].
Queens have four pairs of mammary glands, two pairs of thoracic and two pairs of abdominal 
glands [6], localized at the ventral thoracic and abdominal walls [7]. The knowledge of vasculariza-
tion and lymphatic communication of mammary glands is fundamental to understand the meta-
static process in mammary tumours. A lymphatic network connects the glands of the same side 
and the ipsilateral lymph nodes, while in the vascular network some veins of the mammary glands 
cross the midline, eventually allowing for the metastatic dissemination between paired glands [8] 
(Figure 1). 
30
Chapter 01 General introduction
Figure 1. (A) The four pairs of mammary glands in the cat, with their associated lymph nodes and lymphatic 
drainage. (B) Venous drainage of the mammary glands. (Adapted from Gimenez et al., (2010) [8]).
Feline mammary tumours develop as single or multiple nodules in different glands, the lat-
ter being more frequent [3]. All four pairs of mammary glands can be affected, with studies 
reporting different location incidences [9-13]. 
Middle-age to old queens are most commonly affected with an average age at diagnosis of 
10 to 12 years [2, 4, 10, 12, 14]. Although the vast majority of affected cats are females, ap-
proximately 1-5% of the cases have been diagnosed in tom cats [5, 15], with no sex-related 
differences of biologic behaviour or clinical signs [15, 16]. Siamese, Oriental and Domestic 
shorthair cats appear to be associated to higher risk for the development of mammary neo-
plasia [4, 5, 17]. 
The endocrine environment, defined by the length of exposure to sex hormones oestrogen 
and progesterone, has been suggested to have a role in the development of feline mam-
mary carcinomas [18, 19]. In fact, cats spayed before six month and one year of age have 
been reported to have a 91% and 86% reduction risk for the development of the disease, 
when compared to intact cats [18]. The administration of progestogens to prevent oestrus 
Thoracic 1
Thoracic 2
Abdominal 1
Abdominal 2
Axillary nodes
Sternal nodes
Accessory 
axillary nodes
Superficial 
inguinal nodes
(primary & accessory)
Lateral thoracic v.
Internal thoracic v.
Cranial epigastric v.
epigastric v.
Dorsal intercostal vv.
Azygos v.
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General introduction Chapter 01 
increases the risk of mammary tumour development by a dose-related tumourigenic effect 
[19-21]. This outcome appears to be more evident if these drugs are given regularly for long 
periods of time rather than intermittently [20] and male cats are at a similar risk if treated 
with progestogens [22]. 
The clinical detection, by examination and palpation, of mammary nodules or masses is 
suggestive of mammary tumour diagnosis but fine needle aspiration may be helpful for 
ruling out skin and subcutaneous non-mammary malignancies and differentiate mammary 
carcinoma from fibroadenomatous hyperplasia [8]. Although studies revealed a good agree-
ment between cytological and histological diagnosis in feline mammary carcinomas [12, 
23], histopathology is needed to confirm the diagnosis, to classify the type of lesion, and to 
evaluate the extension of surgical margins [3, 12]. 
Clinical staging relies mostly on the modified tumour-node-metastasis (TNM) WHO staging 
system that includes the largest diameter of the primary tumour or tumours and the clinical 
evidence of invasiveness (fixation to skin or fascia), the status of the regional lymph nodes, 
and the detection of distant metastases [4, 24]. 
Tumour size has been significantly correlated to post-surgery survival, and consequently 
considered of prognostic importance [9, 14, 25]. Cats with mammary carcinomas larger 
than 3 cm in diameter have a poor prognosis, with median survival periods ranging from 4 
to 12 months. However, tumour size alone is of limited prognostic value in tumours smaller 
than 3 cm in diameter, due to the wide range of median survival periods (6.8-54 months), so 
additional characteristics are needed for prognostic purposes [13].
Feline mammary carcinomas are characterized by rapidly growing, highly infiltrative and 
invasive lesions with extensive necrotic areas, skin ulceration and metastases [1, 2], fea-
tures associated to poor prognosis [9, 12]. At the time of diagnosis, one quarter of queens 
with carcinomas have lymphatic and blood vessels invasion [2] and metastases are often 
detected, ultimately leading to high morbidity and mortality rates [3]. Metastasis to regional 
lymph nodes (83%), lungs (83%), pleura (22%) and liver (25%) are the most common, 
although the adrenal glands, diaphragm and kidneys have also been documented to be 
involved [5, 9, 11]. 
Histopathology and diagnosis 
The WHO classification (Table 1) is the most widely accepted histological classification of 
feline mammary tumours [26]. More than 80% are classified histologically as carcinomas, 
with tubular, papillary, solid and cribriform being the most common specific types, although 
some carcinomas are a combination of more than one histological type in the same lesion 
[4, 9]. This classification is, however, more morphological than prognostic [26] and has a 
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limited prognostic value [9], although the distinction between in situ and infiltrative carcino-
mas is of relevance [9, 26]. 
The Elston and Ellis histological grading system (also known as the Nottingham grading 
system) is used to determine the histological grade of primary breast carcinoma and with 
significant correlation with prognosis [27]. It is based on three major histopathologic fea-
tures namely tubule formation, nuclear pleomorphism, and mitotic count [27]. Each feature 
is assessed and scored on a scale of 1 to 3 for a possible total of 3 to 9 points (Table 2). 
Table 1. The WHO histological classification of mammary tumours of the cat  
(Misdorp et al., (1999) [26])
Mammary Hyperplasias/Dysplasias
Ductal hyperplasia
Lobular hyperplasia
Epithelial hyperplasia
Adenosis
Fibroadenomatous change (feline mammary hypertrophy, fibroepithelial hypertrophy)
Cysts
Duct ectasia
Focal fibrosis (fibroesclerosis)
Benign Tumours
Adenoma
Simple adenoma
Complex adenoma
Fibroadenoma
Low-cellularity fibroadenoma
High-cellularity fibroadenoma
Benign mixed tumour
Duct papiloma
Malignant Tumours
Noninfiltrating (in situ) carcinoma
Tubulopapillary carcinoma
Solid carcinoma   
Cribriform carcinoma
Squamous cell carcinoma
Mucinous carcinoma
Carcinosarcoma
Carcinoma or sarcoma in benign tumour
Unclassified Tumours
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The total score indicates the histological grade (I-III). The histological grade was allocated 
by an arbitrary division of the total points: grade I (well differentiated) 3, 4 or 5 points; 
grade II (moderately differentiated) 6 or 7 points; and grade III (poorly differentiated) 8 or 9 
points [27]. This method has been widely adopted by veterinary pathologists/researchers 
for grading feline mammary carcinomas [28-31] and considered a reliable and independent 
prognostic factor, identifying groups of queens with distinct risk of developing metastatic 
disease as well as predicting overall and disease free survival [29, 30, 32]. Recently, Mills 
et al. (2015) designed three new grading systems: the mitotic-modified Elston and Ellis 
grading system (with subcategories within the mitotic count category), the revised Elston 
and Ellis grading system (that included nuclear form scoring and lymphovascular invasion) 
and a novel grading system (based solely on lymphovascular invasion, mitotic count and 
nuclear form). They defend that an adaptation of a species-specific system (as the ones 
they proposed) may improve the prognostic value of histological grading in feline mam-
mary carcinomas [33]. A recent study conducted by Zappulli et al. (2015) considered that 
the most reliable prognostic factors in feline malignant mammary tumours are histological 
grade, presence of lymphovascular invasion and of lymph node metastases [34].
Therapy and prognosis
The most widely used treatment for feline mammary tumours is surgical excision, being uni-
lateral or bilateral chain mastectomy with removal of the draining lymph nodes the method 
of choice [4, 17]. The therapeutic approach affects the prognosis, with uni or bilateral chain 
Table 2. Summary of semi-quantitative method for assessing histological grade in feline 
mammary carcinoma (Elston and Ellis, (1998) [27])
Feature      Score
Tubule formation
Majority of tumour (>75%)
Moderate degree (10-75%)
Little or none (<10%) 
1
2
3
Nuclear pleomorphism
Small, regular uniform cells
Moderate increase in size and variability
Marked variation
1
2
3
Mitotic counts* 
0-8 mitosis
9-18 mitosis
>19 mitosis
1
2
3
* Dependent on microscopic field area
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mastectomy significantly increasing the disease-free interval, when compared to partial 
mastectomy, though the same effect has not been demonstrated for overall survival time 
[14, 25]. Although surgery remains the most widely accepted treatment for feline mammary 
tumours, it is not usually an effective treatment [8], and high rates of post-mastectomy re-
currence or metastatic disease continue to be demonstrated [1, 2]. Survival after primary tu-
mour detection averages 12 months in untreated cats, while the post-surgical survival times 
for cats treated with surgery alone are variable and depend on clinical staging [33, 34]. 
Due to low hormone receptor expression in feline mammary carcinomas, hormonal therapy 
does not appear to be beneficial [4, 8] and the benefit of using chemotherapy as an adjunct 
to surgical excision of mammary tumours in cats, is still not clear [3, 4, 17]. In cats with non-
resectable local disease or distant metastatic disease treated with a combined protocol of 
doxorubicin and cyclophosphamide it was demonstrated partial responses [35, 36]. McNeil 
et al. (2009) have not find benefits of adjuvant-based doxorubicin in feline mammary car-
cinomas compared to surgery alone [37]. Studies where doxorubicin-based chemotherapy 
was used alone [38] or with meloxicam [39], both as adjunct to surgical removal, reported 
similar median survival times not supporting the use of this treatment combination. Different 
immunomodulators have been studied in cell culture [40] and as adjuvant to surgical exci-
sion [41], yet they have not been proved to have benefits as additional therapy in the feline 
mammary tumours treatment [40, 41]. Recently a study by Adelfinger et al. (2014) reported 
virotherapy, on the basis of oncolytic vaccinia virus infection, to be a promising candidate 
for therapy of feline mammary carcinoma patients. Despite progresses in the diagnosis 
and treatment of feline mammary cancer, overall patient treatment outcome has not been 
substantially improved [42]. 
One of the major challenges for the veterinary oncologist is to identify prognostic variables 
which allow for the prediction of disease behaviour in individual cases and to identify pa-
tients that may benefit from adjunctive therapeutic modalities. Thus, the characterization 
of mammary tumours according to subsets with specific biologic behaviour is of clinical 
importance [3, 34, 43].
Molecular features 
The search for prognostic and predictive factors in feline mammary tumours led to the study 
of the expression of molecules that, in combination with clinical and histological features, 
may be of importance in the identification of biological tumour aggressiveness [28, 34, 44, 
45]. 
Steroid hormones are associated with the development of mammary tumours, as evidenced 
by the fact that normal and neoplastic mammary tissues have different expressions of hor-
mone receptors (HR) [19, 46, 47]. Oestrogen receptor (ER) is present in most normal tis-
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sues with a statistically significant progressive decrease in ER-positivity between normal 
tissue, dysplastic tissue, benign tumours and invasive carcinomas [48, 49]. The majority 
of feline mammary carcinomas are, therefore, characterized by a large proportion of ER-
negative tumours [48, 49] and the ER-negative status has been associated with high histo-
logical grades [48-50].
Oestrogens are known to stimulate the growth of both interlobular and intralobular ducts 
and to induce the expression of progesterone receptors [11]. Although in human breast 
cancer, progesterone receptor (PR) positivity is frequently related to ER expression and 
considered a good prognostic factor [51], its expression in feline mammary carcinomas is 
not necessarily a good indicator of the integrity of oestrogen receptor pathway, as several 
invasive feline carcinomas are ER-/PR+ [48, 52].
There is a progressive loss of HR expression from non-neoplastic to benign and from those 
to malignant tumours [28, 47, 53, 54]. However, Millanta et al. (2005) described that the 
expression of PR was significantly increased from healthy and dysplastic to neoplastic le-
sions, with higher values in in situ carcinomas and a decrease in invasive tumours [48]. The 
ER and PR expressions are not currently assessed in feline mammary cancer, due to the 
lack of consensual data of the relation of hormone receptor status of the feline mammary 
tumours and prognosis [34, 48, 55, 56]. The lower expression of ER, when compared to 
PR, in feline mammary cancer and the overall lower HR status, when compared to human 
breast carcinomas [45, 57], led to the proposal of feline mammary cancer as a natural 
model of the non-hormone-dependent human mammary carcinomas [1, 47, 49, 58].
Ki-67 is a nuclear protein expressed in all the active phases of cell cycle. As it is only ex-
pressed by cycling cells, the relative number of Ki-67-positive cells indicates the proportion 
of cells in proliferation at any given moment [34, 59]. There is generally a progressive in-
crease of the Ki-67 index from normal mammary tissue to hyperplastic lesions and benign 
and malignant tumours, with the exception of fibroadenomatous lesions that exhibit very 
high proliferative activity, comparable to carcinomas [29, 31]. The Ki-67 index has been cor-
related with histological grade [31, 50, 60], but not with histological type of feline mammary 
tumours [29, 31, 60]. Its prognostic value is debated, with some authors suggesting lack of 
prognostic significance [29, 43, 56, 61], while others defend that it is related with a more 
aggressive behaviour and smaller post-surgical survival times [60]. 
Other molecular markers have been investigated in feline mammary tumours in order to 
elucidate the pathways of tumour progression and assist in the determination of the prog-
nosis. A wealth of literature exists on molecular markers, namely AgNOR [43, 62], PCNA 
[63], HER2 [45, 64-68], COX-2 [50, 69, 70], STAT [71], RON [72], TopBP1 [50], PTEN [73], 
Akt [54], p53 [50, 74, 75], VEGF [76], among others.
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The main goal of prognostic studies is to identify and characterize reliable clinically applicable 
markers to establish a molecular-based model of tumour classification representing clini-
cally distinct entities, as proposed for human breast cancer [77]. Recently, several studies 
were conducted aiming to contribute to such goal [28, 44, 45, 78]. Brunetti et al. (2013) 
characterized a series of 21 feline mammary carcinomas based on ER, PR, c-erB2, CK5,6, 
CK14, CK19 and p63 profiles, and primary tumours were classified as luminal B (52.4%), 
c-erbB2 overexpressing (38.1%) and basal-like (9.5%), with no association between his-
tological diagnosis and molecular phenotypes. The authors described that the molecular 
phenotypes of the primary tumours were not always concordant with their corresponding 
lymph node metastasis, concluding that the evaluation of the molecular profile in both sites 
is crucial for the planning of effective therapy [44]. Wiese et al. (2013) evaluated a series of 
24 feline mammary carcinomas based on the immunoexpression of ER, PR, HER2, CK5/6 
and EGFR, revealing that feline mammary tumours were highly aggressive neoplasms, 
mostly triple negative and with nearly 80% displaying a basal-like subtype, pointing feline 
mammary tumours as a valuable natural occurring animal model for the study of human 
triple negative breast carcinomas (TNBCs) of the basal-like subtype [45]. Other study of 77 
feline malignant mammary tumours conducted by Caliari et al. (2014) was based on ER, 
PR, HER2 and cytoplasmic filament expression, reported that feline mammary carcinomas 
are generally aggressive HR-negative neoplasms (85%) with heterogeneous phenotypes, 
characterized by basal cytokeratin and vimentin expression, sharing similar features with 
human TNBCs [28].
The expression of vimentin by neoplastic epithelial cells has also been described in feline 
mammary tumours and associated to epithelial to mesenchymal transition (EMT) [28, 79-
82], although this abnormal expression failed to be associated to well-established features 
of malignancy, such as regional metastasis or tumour grade. Hence, it is plausible that the 
expression of vimentin may be regarded as a hallmark of carcinoma rather than a marker 
of invasive behaviour [81]. 
Most of the feline oncology studies are retrospective and lack survival data as it is often 
difficult to consistently and systematically follow these patients. The high methodological 
variability hampers the studies comparison and the establishment of consensual guidelines 
on the prognostic significance of many of these molecules expression. Several publications 
defend the need to standardize procedures in prognostic studies of spontaneous feline 
mammary tumours and to follow recommended guidelines in order to facilitate reproduc-
ibility and assessment of results [34, 77, 83]. 
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CELL ADHESION MOLECULES
Cell adhesion is essential for the arrangement of individual cells within the three-dimen-
sional tissues architecture [84, 85]. Several cell adhesion mechanisms are responsible for 
assembling cells together and, along with their connections to the internal cytoskeleton, 
determine the overall architecture of the tissues [84]. The loss of cell-cell adhesion, which 
leads to loss of contact inhibition and escape from the growth control signals, is gener-
ally present in human cancer, and is one of the initial steps in the invasion and metastatic 
cascade. These are followed by other gain or loss of cell characteristics that allows cancer 
cells to abandon the primary mass and invade the surrounding tissues, enter the circulation, 
lodge in distant vascular beds, extravasate into the target organ and proliferate. However, 
there is still a lack of clear understanding of metastatic process of dissemination in cancer 
patients [86, 87]. Moreover, cell-cell and cell-matrix adhesive interactions have a role in 
tumourigenesis, tumour progression, and metastasis [88, 89].
Cell adhesion molecules (CAMs) that mediate cell-to-cell adhesion, and substratum adhe-
sion molecules (SAMs) that mediate adhesion between cell and extracellular matrix proteins, 
participate in events such as morphogenesis, differentiation, cell migration, and intercellular 
communication [88, 89]. CAMs have been classified in four major families: the immuno-
globulin-like family, the integrin family, the cadherin family and the selectin family [90, 91]. 
Cadherins are members of a large family of transmembrane glycoproteins that mediate 
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calcium-dependent homotypic cell-cell adhesion. Cadherins play a role in cell sorting during 
embryogenesis and in the maintenance of specific organ and adult tissue architecture, as 
well as in several signaling pathways [85, 92-94]. The cadherin superfamily encompasses 
at least six sub-families based on the protein domain composition, genomic structure and 
sequences phylogenetic analysis. These sub-families comprise: classical cadherins or type 
I cadherins, atypical or type II cadherins, desmocollins, desmogleins, protocadherins and 
Flamingo cadherins [90]. 
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CLASSICAL CADHERINS
The classical cadherins include CDH1/E-cadherin (epithelial), CDH2/N-cadherin (neuro-
nal), CDH3/P-cadherin (placental) and CDH4/R-cadherin (retinal), designated according to 
their specific tissue distribution [90]. They are localized in the adherens junctions, which are 
responsible for the strong cell-cell adhesions that maintain the epithelial cell shape and po-
larity and the homeostasis of normal adult epithelial tissues [95]. The cadherin subclasses 
display unique patterns of tissue distribution, with each cell type characterized by the ex-
pression of a particular cadherin subclass or set of cadherin subclasses [92]. P-cadherin 
was originally identified as a highly expressed cadherin in the mouse, but not human, pla-
centa throughout pregnancy [96, 97]. P-cadherin is expressed only in the basal or lower 
layers of normal stratified or pseudostratified epithelia with high proliferative potential, but 
not in simple epithelia, while E-cadherin is present in almost all epithelial tissues. This tis-
sue distribution suggests a relationship between P-cadherin and the maintenance of the 
proliferative compartment, while E-cadherin seems to be associated with the formation and 
maintenance of epithelial tissues [98, 99].
Despite their distinct specificities, the cadherin subclasses have a common genetic back-
ground [100, 101], and nearly 50% of their amino acids sequences, mostly in the cytoplas-
mic domain, are conserved [102]. Moreover, homologous cadherin subclasses identified 
across species are generally well conserved [100]. The human epithelial E-cadherin is a 
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120kDa glycoprotein encoded by the gene CDH1 that maps to chromosome 16q22.1 [95, 
103], while the human P-cadherin is a 118kDa glycoprotein, encoded by the gene CDH3 
that is 32 kilobases upstream of the E-cadherin gene and shares 66% of homology with 
CDH1 [96, 104, 105]. 
The cadherin-catenin complex
E- and P-cadherin mature proteins are constituted by three major structural domains: an 
extracellular amino-terminal domain; a single pass transmembrane domain of anchorage 
to the cellular membrane and a cytoplasmic carboxy-terminal domain [85, 106] (Figure 2).  
Figure 2. Schematic representation of structural components of the classical cadherin-catenin complex. 
Classical cadherins mediate calcium-dependent intercellular adhesion. They are composed by: an extracel-
lular domain that interacts with the cadherin extracellular domain of adjacent cells to mediate cell adhesion 
through the extracellular sub-domain (EC1); a transmembrane domain; and a cytoplasmic domain. The latter 
domain comprises a juxtamembrane domain (JMD), which binds p120-catenin, and a catenin-binding domain 
(CBD), which binds β-catenin. α-catenin associates with β-catenin and is directly linked to the actin cytoskel-
eton. (Adapted from Albergaria et al. (2011) [107])
The extracellular domain is directly responsible for the homotypic interaction that medi-
ates cell-cell adhesion. It is composed by five repeated extracellular structural sub-domains 
(EC), which are sequences of 110 amino acids commonly designated as EC1–EC5 [92, 
108, 109] (Figure 2). The EC1 domain is the main responsible for the molecule adhesive 
properties and specificity [110]. The normal conformation of the classical cadherins and 
their adhesion properties are dependent on the presence of Ca2+ in the extracellular domain 
[100, 111]. Calcium-binding sites consist of short highly conserved aminoacid sequences 
that are located between neighbouring EC repeats [92, 109]. Classical cadherins mediate 
the adhesion between adjacent cells by forming homodimers with identical molecules of 
adjacent cells and with cadherins in the same cell, by lateral clustering, forming lateral ho-
modimers [112]. The intercellular binding is achieved through the formation of a cell surface 
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multimolecular structure with a “zipper-like” conformation that is a hallmark of the cadherins 
[113].
Cadherins connect indirectly to the actin cytoskeleton through their cytoplasmic domain, 
via a group of proteins, collectively known as catenins. The catenin family comprises α-, β-, 
γ- and p120-catenin [86, 114]. β-catenin is a 95 kDa protein that shares about 65 per cent 
identity with γ-catenin, an 82 kDa protein also named plakoglobin [106, 115]. Both catenins 
associate directly with classical cadherins in a mutually exclusive way and can substitute 
one another in the cadherin-catenin complex. α-catenin is a 102 kDa protein that indirectly 
associates with classical cadherins through its interaction with β or γ-catenin, mediating the 
interaction between the cadherin-catenin complex and the actin cytoskeleton [106, 115]. 
Additional proteins that provide a link between catenins and the actin cytoskeleton include 
ZO1, α-actinin and vinculin. P120-catenin binds to the cadherin juxtamembrane region, 
but does not link the complex with the actin cytoeskeleton [106, 116, 117]. Thus, the highly 
conserved cytoplasmic domain comprises two main domains: the juxtamembrane domain 
(JMD) that binds p120ctn, and the catenin-binding domain (CBD) that binds β- and γ-catenin 
[90]. The cytoplasmic domain contacts with the cytoskeletal components and regulates the 
cell-cell adhesion function of the extracellular domain [118-120] (Figure 2). In addition to 
the structural role in the adherens junction, catenins act to regulate the adhesive function of 
cadherins, since a cadherin-catenin complex integrity is indispensable for the proper cad-
herin function and normal cell–cell adhesion [119, 121].
Besides their participation in the anchorage of E-cadherin to the actin cytoskeleton, caten-
ins also have other cell functions [106]. α-catenin plays an important role in the regulation 
of several signalling pathways involved in cell proliferation, apoptosis, growth, migration 
and invasion, hence being considered a molecule with tumour suppressor function [122, 
123]. β-catenin is involved in cell–cell adhesion by interacting with the cadherin cytoplasmic 
tail [124] and participates in cell signalling, in the Wnt signalling pathway [106, 124-127], 
regulating the transcription of genes involved in inhibition of apoptosis and promoting cel-
lular proliferation and migration [86]. β-catenin is suggested to have a dual role as a tumour 
suppressor and as a oncogene in human cancer [86]. P120-catenin stabilizes the cadherin–
catenin complex and modulates cadherin intracellular trafficking and cell stability, adhesive-
ness and motility [128-131].
Besides the recognised adhesion functions, the cadherin-catenin complex is involved in 
major modulatory transcription mechanisms of specific genes, regulating several cellular 
processes such as proliferation, survival, polarization, differentiation, shape and migration 
[112, 132]. In this context, disorders of the molecules of the cadherin-catenin complex may 
affect the formation and maintenance of cellular and tissue integrity, and are involved in 
pathological events, such as cancer [94, 95, 99, 107, 133-135].
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THE CADHERIN-CATENIN COMPLEX 
AND THE MAMMARY GLAND
The mammary gland is structurally composed by two layers of epithelium, an inner luminal 
cell layer and an outer myoepithelial cell layer, forming the mammary ducts and the terminal 
end buds [136]. Cap cells are localized at the tip of each terminal end bud that are thought 
to generate descendants cells of both myoepithelial and epithelial cell lineages [99, 107]. 
Two members of the cadherin family are expressed by the normal adult mature non-lactat-
ing human mammary gland: E-cadherin is present in both luminal epithelial and myoepithe-
lial cells [137-139], whereas P-cadherin is confined to the myoepithelium [137, 140, 141]. 
The interconnection between the luminal and the myoepithelial layers seems to be related 
to desmosomal cadherins (desmogleins and desmocollins) and are critical for establishing 
this bilayered arrangement [126] (Figure 3). 
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Figure 3. Schematic representation of the structure of the terminal mammary end bud and duct. (A) Cap 
cells, localized at the tip of terminal end bud, are P-cadherin positive. (B) Cross-section through the mammary 
duct. P-cadherin is expressed at sites of myoepithelial cell-cell contact in the adherens junctions and E-cadherin 
between luminal epithelial cells. Desmosomal cadherins link the two cell types. Basal/intermediate cells, which 
are a putative stem/progenitor population, are also indicated. (Adapted from Cowin et al., (2005) [126])
P-cadherin has an essential role in the development of mammary gland, particularly during 
ductal mammary branching, being expressed by the monolayer of cap cells at the terminal 
end buds [142] (Figure 3). P-cadherin mediated cell-cell interactions and signalling are 
regulatory determinants of the negative growth of the luminal epithelium, important for the 
maintenance of an undifferentiated state of normal mammary gland [143]. In normal mature 
non-lactating mammary gland, P-cadherin is expressed at sites of cell-cell contact by the 
myoepithelial [137, 142, 144], but not in the luminal epithelial cells [144, 145]. The selective 
expression of E- and P-cadherin is necessary for the correct architecture of normal breast, 
with epithelial cells facing the lumen and myoepithelial cells facing the basement membrane 
[142, 146]. 
During late pregnancy and lactation, P-cadherin is present in human mammary luminal 
epithelial cells, but not at the cell-cell border, as expected for a cadherin. It moves into 
the cytoplasm, at the apical surface of epithelial cells, the typical distribution of a secreted 
protein. This observation suggests that, during lactation, P-cadherin is secreted by luminal 
epithelium [145] (Figure 4). In fact, a soluble fragment of P-cadherin (sP-cad) with 80kDa, 
which corresponds to the extracellular domain of the molecule, was found in human milk 
at significant higher concentrations when compared to the levels found in serum [145, 147, 
148]. There are currently some theories trying to explain this secretion, namely that sP-cad 
has a role in the alveolar differentiation during lactation, in the immune response of the 
mother or the infant, or has a signalling role between epithelial and myoepithelial cells, but 
its function in normal breast is still not clear [107, 145, 147]. 
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Epithelial luminal cells
E-cadherin P-cadherin
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Figure 4. During late pregnancy and lactation, P-cadherin is present in human mammary luminal epithelial cells. 
Secretory cells in the breast alveoli become P-cadherin positive at the cytoplasm, and secrete a soluble form of 
this protein (sP-cad) that is detected in the milk. (Adapted from Albergaria et al., (2011) [107]).
E-cadherin and breast cancer
E-cadherin, the prototype member of the classical cadherin family, is the predominant 
cadherin of the adherens junctions in most epithelial cells with paramount importance in 
maintaining cell polarity and epithelial integrity [87, 95]. The suppression of E-cadherin ex-
pression is regarded as one of the main molecular events responsible for the dysfunction 
of cell-cell adhesion [95]. Besides its function in normal cells, it can play a major role in 
malignant cell transformation, tumour development and progression [95, 114, 149]. In fact, 
the E-cadherin gene can act as an invasion and tumour suppressor, and its alterations have 
been associated with dedifferentiation, invasiveness and metastasis of tumour cells [87, 95, 
114, 150, 151]. In breast carcinoma several studies reported alterations of the E-cadherin 
expression, particularly partial or total loss [152-159]. 
Infiltrating ductal breast carcinomas, the predominant histological subtype of breast cancer, 
show no significant reduction of E-cadherin expression, while the less prevalent infiltrating 
lobular carcinoma has significantly reduced or absent expression of the molecule [114, 141, 
156, 159-161].
Loss or down-regulation of E-cadherin, along the multistage carcinogenesis, can occur by 
several different mechanisms, both irreversible and reversible, including genetic and epi-
genetic events [162, 163], and the prevalence of each phenomenon is related to the his-
tological subtype of breast cancer [126]. Lobular breast carcinomas have been associated 
with germline mutations of the E-cadherin gene [116, 164, 165]. The loss of heterozygoty 
(LOH) at 16q22.1, which involves the E-cadherin gene CDH1, is frequently combined with 
Alveoli sP-Cad
Milk
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mutations (nearly 50%) or epigenetic silencing of the remaining allele [114, 126, 160, 166, 
167]. Ductal breast carcinomas often show LOH at 16q but lack mutational inactivation of 
the remaining CDH1 allele [114, 160]. These evidences suggest that the E-cadherin dys-
function results from a two-hit mechanism, as occurs in the classical tumour suppressor 
genes [162, 168]. However, the majority of malignant carcinomas lack mutations in this 
gene [116], signifying that other mechanisms are responsible for the protein expression 
alterations [86, 166, 169, 170], namely epigenetic silencing such as hypermethylation of the 
CDH1/E-cad promoter [162, 163, 171-173] or by transcription modulators [116, 124, 126, 
139, 164, 174] or even controlled post-transcriptionally [175].
Alternative mechanisms that have been suggested to play a role in the regulation of tumour 
cell adhesion include alterations in the composition of the cadherin-catenin complex, phos-
phorylation of its components, alterations of the interaction of the complex with the actin 
cytoskeleton and N-glycosylation of E-cadherin [106, 117, 176]. Phosphorylation of the cad-
herin-catenin complex [86, 106, 162, 177-179] or reduced expression of either α-catenin, 
β-catenin or plakoglobin (γ-catenin) may result in disruption of the intercellular adhesion 
and acquisition of the invasive phenotype, that is independent of the E-cadherin expression 
[92, 177, 179-181].
Although stromal and vascular invasion is facilitated by the down-regulation of E-cadherin, 
the retention of its expression and adhesive properties seems to confer an advantage once 
the vasculature has been entered. There is some evidence that a “switch on-switch off” 
dynamic process regulates loss or gain of cell–cell adhesion [182] and transient E-cadherin 
down regulating mechanisms may be involved in malignant tumours without irreversible 
inactivation of the E-cadherin gene [114]. In fact, the expression of E-cadherin in metastatic 
lesions is frequently different from that of the primary tumour, with both E-cadherin-positive 
and E-cadherin-negative metastatic lesions being reported [116, 183], while the levels of 
E-cadherin are increased in intravascular breast cancer cells [116]. It is possible that tempo-
rary or localized downregulation of E-cadherin expression or function promotes the detach-
ment of cells from the primary tumour and invasion of the local environment [164], whereas 
its re-expression favours survival of intravascular and metastatic cancer cells [116]. 
There are conflicting reports regarding the relationship between E-cadherin expression 
and pathological features and prognostic factors. One study revealed a relationship be-
tween E-cadherin and tumour size [174], while others failed to demonstrate this association 
[139, 156, 184]. A reduced E-cadherin expression was related to high histological grades 
by some authors [139, 156, 159, 174], while others were unable to find such association 
[184]. A correlation between loss of E-cadherin and the presence of nodal metastases was 
found by some investigators [174], but this has not been widely reported [139, 156, 184, 
185]. Some evidence in the breast cancer literature relates a reduction in E-cadherin ex-
pression to poor outcome [139, 161], whilst other studies reveal no independent value for 
the E-cadherin status over established prognostic factors [139, 184, 186]. Indeed, there are 
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studies reporting strong E-cadherin immunostaining of tumours affecting patients with poor 
survival and of cells in the most aggressive forms of breast cancer [185, 187, 188]. There-
fore, the expression of E-cadherin in human breast cancer as an independent predictor of 
tumour behaviour seems, at this time, unsubstantiated. However, some authors postulated 
that it has a value as a phenotypic marker, particularly in the distinction between lobular and 
ductal carcinomas [139, 141]. 
Catenins and breast cancer
It is important to notice that E-cadherin immunoreactivity does not always imply the pres-
ence of a functionally normal cadherin-catenin complex [86], and that a reduced cell–cell 
adhesion may be present in an apparently preserved membrane-bound cadherin tumour 
[185]. Thus, to predict tumour invasion and metastasis in carcinomas, it is useful to inves-
tigate not only the expression of E-cadherin but also the expression of the catenins [86]. In 
fact, the simultaneous expression of E-cadherin and one of the catenins has been pointed 
to be of higher prognostic value than the evaluation of each molecule individually [182]. 
Abnormal α-catenin expression (such as reduced membrane expression and cytoplasmic 
or nuclear location) has been described in breast cancer [183, 189-191] and several reports 
documented an association between down-regulation or loss of α-catenin and high tumour 
grades [123], metastasis [123, 182, 189] and poor survival [123], raising the possibility that 
it may be considered a prognostic marker. Loss of membrane-bound β-catenin, as well as 
its cytoplasmic or nuclear expression, have been described in human breast cancer [182, 
189, 192-194], suggesting that upstream elements of the Wnt and/or other pathways that 
stabilize β-catenin are deregulated in breast cancer [195]. However, the prognostic value of 
β-catenin in breast cancer has not been clarified, with different studies revealing contradic-
tory results [122, 159, 182, 186, 189, 196]. P120-catenin is thought to play a dual role in 
breast carcinogenesis, acting as a tumour/metastasis suppressor or as an oncogene/me-
tastasis promoter when found in the cell membrane or when translocated to the cytoplasm, 
respectively [130, 131]. 
P-cadherin and breast cancer
P-cadherin has been reported to be altered in various human tumour models, but its effective 
role in the carcinogenesis process remains elusive, as it seems to behave differently de-
pending on the tumour cell model and context. In colorectal cancer and melanoma tumour 
cell models, P-cadherin has been suggested to act as an invasion suppressor [197-199], 
while in several other models, namely breast, bladder, pancreas, gastric, endometrial and 
ovarian cancer, P-cadherin behaves as an oncogene [198, 200-206]. 
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In breast carcinomas, the luminal epithelial aberrant expression of P-cadherin is character-
ized by a simultaneous membranous and cytoplasmic expression and has been described 
in 20–50% of invasive ductal carcinomas [99, 137, 140, 144, 186, 207], as well as in 25% 
of ductal carcinomas in situ (DCIS) [99, 137, 203]. In fact, the majority of P-cadherin posi-
tive tumours are invasive ductal carcinomas, or carcinomas with metaplastic or medul-
lary features (carcinosarcomas and sarcomatoid breast carcinomas) [144, 208, 209], which 
supports a myoepithelial/basal cell histogenic origin or line of differentiation for these neo-
plasms [208, 210]. However, no significant correlation was observed between this cell ad-
hesion protein and a specific breast cancer histological type [144, 208-210]. 
P-cadherin expression has been positively associated with poorly differentiated and high 
histological grade carcinomas [137, 140, 144, 186, 207, 209, 211, 212] and with high pro-
liferation indexes [144, 209]. However, it was not related to tumour size and lymph node 
metastasis [144, 186, 209]. In the clinical setting, abnormal P-cadherin expression in mam-
mary carcinomas is associated with poor prognosis [99, 144, 186, 207, 209, 213], with a 
relation with shorter overall survival [144, 186, 196, 214] and disease-free survival [196, 
214, 215].
P-cadherin has been extensively studied in breast cancer, but the mechanisms that regulate 
its expression are still poorly known. Mechanisms regulating CDH3/P-cad are essentially 
at the promoter region. It is known that the CDH3 promoter can be activated through direct 
binding of several transcription factors, leading to P-cadherin overexpression [216-219]. 
One of the important activators of the CDH3 promoter is p63, a p53-family related transcrip-
tion factor and a key regulator of the adhesion and survival of the mammary gland basal 
cells [220]. In a non-cancer model, P-cadherin revealed to be a direct p63 transcriptional 
target, denoting a functional relationship between these two molecules [219]. In fact, p63 is 
co-expressed with P-cadherin in the basal layer of stratified and pseudo-stratified epithelia 
[221]. 
β-catenin is also associated with the CDH3 promoter activation and P-cadherin expression 
in basal mammary epithelial cells, suggesting that a β-catenin-dependent modulation of 
P-cadherin expression can contribute to the establishment of the basal phenotype [216]. 
Both P-cadherin and the transcription factor CCAAT/enhancer binding protein β (C/EBPβ) 
are co-localized in breast cancer cells, indicating a physical interaction between this tran-
scription factor and the CDH3 gene promoter [217]. C/EBPβ was able to activate the CDH3 
promoter in breast cancer cells and high levels of C/EBPβ have been associated with tu-
mour progression and unfavourable prognostic factors in breast cancer [218].
Conversely, some regulators of the CDH3 gene promoter act as repressors of the P-cad-
herin expression, namely the BRCA1/c-Myc-complex. In BRCA1-deficient hereditary tu-
mours there is no repression of CDH3 and consequently there is P-cadherin expression 
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[222]. Moreover, the expression profiling of BRCA1-deficient hereditary tumours has identi-
fied a pattern of gene expression that is similar to human basal-like breast tumours, strongly 
associated with P-cadherin expression [107, 223-225].
ER is also a CDH3 repressor and the absence of ER-signalling leads to an increased P-
cadherin expression [204]. In fact, P-cadherin positive breast tumours are essentially ER-
negative [204, 211, 212, 226]. Moreover, when ER-positive breast cancer cells are treated 
with anti-oestrogens, a specific transcription site of the CDH3 promoter suffers chromatin 
remodelling exposing it to transcription regulators and leading to P-cadherin overexpres-
sion. Thus, selective ER modulators and anti-oestrogens can induce expression of normally 
repressed genes, thus playing an important role in the capacity of breast cancer cells to 
evade their growth inhibitory effects, and contribute, in the appropriate context, to a breast 
cancer cell invasive phenotype [218]. 
Besides the epigenetic regulation through promoter chromatin remodelling [218], it is likely 
that CDH3 can be regulated by other epigenetic events, such as methylation [144]. Nor-
mal P-cadherin-negative breast epithelial cells showed methylation of the P-cadherin gene, 
while hypomethylation of a specific region of the CDH3 promoter was significantly associat-
ed to P-cadherin overexpression in breast cancer [144]. Methylation of the P-cadherin gene 
promoter in breast cancer may be regarded as a novel therapeutic approach to silence its 
expression and, consequently, block tumour progression [144].
The mechanisms by which P-cadherin overexpression in breast cancer cells promotes the 
oncogene-associated effects such as increased motility, migration and invasiveness remain 
poorly known [204, 227]. A significant association between P-cadherin overexpression and 
the invasive capacity of breast cancer cells that maintain the wild-type E-cadherin expres-
sion was reported [227]. Moreover, P-cadherin promotes oncogenic-associated events by 
inducing the secretion of matrix metalloproteinases, such as MMP-1 and MMP-2, leading 
to the cleavage of its extracellular domain, thus producing a soluble P-cadherin fragment 
(sP-cad) that is able to induce and maintain the secretion of active MMPs. Furthermore, sP-
cad has a critical role in the induction of invasion of breast cancer cells co-expressing both 
cadherins [227]. Recently, Ribeiro et al. (2013) described that the P-cadherin ability to in-
duce breast cancer cell invasion is dependent on the expression of E-cadherin [228]. When 
co-localized with E-cadherin, P-cadherin was able to promote cell invasion by disrupting 
the interaction between E-cadherin and both p120- and β-catenin [228]. E- and P-cadherin 
co-expression by breast cancer cells significantly enhanced in vivo tumour growth [228]. 
Moreover, aberrant P-cadherin expression in E-cadherin positive tumours was also associ-
ated with p120-catenin cytoplasmic expression and activation of signalling pathways, alter-
ing the actin cytoskeleton polymerization and promoting cell migration and motility [229]. It 
is also known that the pro-invasive activity of P-cadherin is dependent on the presence of 
its intact juxtamembrane domain, more specifically the binding site of p120-catenin [204]. 
These findings clarify the mechanisms associated to cell invasion and may explain the rela-
49
General introduction Chapter 01 
tion between E- and P-cadherin co-expression and high-grade breast carcinomas, biologi-
cally aggressive and with poor patient survival, being this co-expression suggested a strong 
prognostic factor in breast cancer [228, 229]. Recently, it was described a positive relation-
ship between P-cadherin, the laminin receptor α6β4 integrin and the adhesion of breast 
cancer cells to extracellular matrix. Moreover, there was a crosstalk between P-cadherin 
and the laminin oncogenic signalling pathways in the induction of cancer cell invasion and 
survival [230].
P-cadherin as a potential therapeutic target
In contrast with the significant low levels of P-cadherin in several normal tissues [206], 
overexpression of the protein is frequently observed in various malignant tumours, including 
breast, endometrial, colorectal and pancreatic carcinomas [144, 200, 205, 206, 231]. Thus, 
interruption of P-cadherin signalling may represent a potential novel therapeutic approach 
for cancer therapy [232, 233]. 
The human monoclonal antibody against P-cadherin (PF-03732010) is a highly specific 
and selective antibody, able to interrupt P-cadherin signalling pathway in a large panel of 
P-cadherin overexpressing tumour models, including mammary cancer models. In xeno-
graft model, PF-03732010 resulted in inhibition of growth and metastatic progression of 
high P-cadherin expression tumours, with no apparent adverse effects [232]. PF-03732010 
negatively modulates P-cadherin and β-catenin membrane levels and suppresses cyto-
plasmic vimentin, resulting in antiproliferation and metastatic activities, as well as increased 
apoptosis [232]. More recently, Bernardes et al. (2013) reported that azurin, a small copper 
bacterial protein, acts as an anticancer agent in vitro and promotes tumour regression in xe-
nografted mice [234]. Azurin decreased membranous P-cadherin expression and presented 
anti-invasive effects in P-cadherin overexpressing breast cancer cells, with no interference 
with the expression of E-cadherin [234]. The effects of azurin may be related to a decreased 
MMP-2 activity and reduction of the sP-cad levels [234]. Thus, the use of azurin and/or PF-
03732010 may constitute new therapeutic strategies to treat aggressive breast carcinomas 
overexpressing P-cadherin in a wild type E-cadherin context.
P-cadherin aberrant expression is associated to hypoxic/glycolitic and acid-resistant phe-
notypes in breast cancer carcinomas, and seems to have a role in the metabolic repro-
gramming of breast cancer cells that may be responsible for tumours aggressiveness and 
resistance to standard therapies [235]. 
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Cadherins and epithelial to mesenchymal transition (EMT)
in breast cancer
The epithelial to mesenchymal transition (EMT) is a multistep program in which epithelial 
cells lose their epithelial characteristics and acquire properties that are typical of mesen-
chymal cells [236, 237]. One of the hallmarks of this process is the cadherin switch, charac-
terized by a modification of the expression of cadherins, from those expressed in epithelial 
cells to those expressed mainly in mesenchymal cells. There is a progressive downregu-
lation of the cell-cell adhesion epithelial-specific proteins (e.g. E-cadherin) and de novo 
expression of mesenchymal markers (e.g. vimentin, N-cadherin), resulting in numerous 
phenotypical changes, such as the loss of cell-cell adhesion and cell polarity and acquisition 
of migratory and invasive properties [124, 236-238]. 
In cancer, the EMT process leads to the development of cells that are chemoresistant, able to 
escape to immune cells and with stem cell properties that support tumour cell migration, resis-
tance to apoptosis, invasion and metastatic dissemination [236, 237]. Cancer cells that have 
gone through EMT migrate to a secondary site in the body where they sometimes go through 
mesenchymal to epithelial transition (MET), reverting to a more epithelial phenotype [124].
There are, however, examples of highly aggressive and invasive tumours, such as basal-
like tumours, where the expression of E-cadherin is rarely lost, and overexpression of other 
classical cadherins, namely P-cadherin, is observed [213, 228, 229, 237]. Most cancer cells 
undergo partial EMT, an intermediate state in which they retain epithelial characteristics but 
gain some migratory ability [237]. The end result is a group of cells with particular character-
istics, such as collective cell migration and invasive potential associated with the acquisition 
of stem cell properties [228], the so called “metastable phenotype” [228, 237]. Thus, Ribeiro 
et al. (2015) consider that P-cadherin may also be used as an EMT marker, mainly to iden-
tify intermediate and transient EMT state associated with a metastable phenotype [237]. 
In fact, they defend a three-protein EMT signature (E-, P-cadherin and vimentin) where 
P-cadherin identifies an intermediate stage between the epithelial and mesenchymal phe-
notypes [237]. In human breast cancer, some authors stated that the expression of vimentin 
represents one of the first steps in tumour progression and that vimentin-positive cells are 
prone to develop subsequent EMT changes, such as loss of cadherins [239].
In human breast cancer, gene profiling provided a molecular classification into different 
subtypes of invasive breast carcinoma: luminal A, luminal B, normal breast-like, HER2-
overexpressing and basal-like [240, 241]. This classification revealed subtypes of breast 
cancer with distinct clinical behaviours, namely the basal-like breast cancer (BLBC) that is 
of particular clinical interest. Currently there is no known effective therapy for BLBC, hence 
this subtype is considered to imply a poorer prognosis [214, 225, 242]. Most BLBC are 
triple negative (ER-/PR-/HER2-) and several additional markers have been proposed for its 
precise immunohistochemical identification, a work still in progress [243]. The most com-
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monly used markers are ER, PR and HER2, together with EGFR or CK5/6, but additional 
markers such as basal cytokeratins, P-cadherin, vimentin, and p63, have been suggested 
to improve the sensitivity panel for identifying BLBC [99, 153, 209, 213, 214, 223, 225, 242, 
244-246].
There are evidences supporting the concept that a subset of cancer cells, the cancer stem 
cells (CSCs), are responsible for tumour heterogeneity, resistance to therapy (radiation and 
chemotherapy), relapse and metastasis [107, 237, 247]. The identification and analysis of 
those CSCs are mandatory especially in carcinomas with high patient mortality rate, early 
relapses, and lack of a targeted therapy, such as BLCB [247]. Besides being considered one 
of the biomarkers of BLBC, P-cadherin has been pointed as a good marker in the identifica-
tion of basal-like breast cancer cells with stem cell properties [107, 235, 237, 247]. Vieira 
et al., (2012) found that the inhibition of P-cadherin sensitizes cancer cells to x-ray-induced 
death [247]. Thus, future therapies to the aggressive BLBC can eventually involve the target-
ing of P-cadherin of CSCs and possible improve radiation therapy in those patients [237].
Cadherin fragments in body fluids
The cleavage of the external domain of cadherins is a normal part of their cellular turnover 
and not an event typically associated with cancer [147, 248-250]. The ectodomain shedding 
generates soluble 80kDa fragments of E-cadherin (sE-cad) and P-cadherin (sP-cad) [227], 
released in the extracellular space [148, 250]. However, the increased protein ectodomain 
shedding is a process that has also been suggested to be associated to cancer progression 
as a consequence of the general increased proteolysis that characterizes most neoplasms 
[147, 148]. Although the mechanisms and regulation of the cadherin extracellular domain 
fragment release are not fully understood, they involve proteases, namely matrix metallo-
proteinases [148]. 
It has been suggested that the cadherin fragments levels in circulation could be useful as 
a non-invasive tools for cancer diagnosis [147, 148], however there is no consensus about 
the clinical significance of serum sE-cad and sP-cad levels in patients with cancer [148, 
250-253]. 
Serum levels of sE-cad are known to be increased in patients affected by cancer (e.g., 
breast, gastric, and colorectal cancers) when compared to healthy persons [249, 250, 252-
254]. In breast cancer patients, high serum levels of sE-cad have been associated with TNM 
stage, tumour grade, lymph node metastases, overall survival and disease-free survival in 
breast cancer [250, 253, 255]. In contrast, Knudsen et al. (2000) failed to demonstrate a 
correlation between serum levels of this cadherin and the presence of breast cancer [148]. 
Considering the serum sP-cad levels, it was reported no significant differences among no-
cancer and breast cancer patients [147, 148].
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THE CADHERIN-CATENIN COMPLEX 
IN FELINE MAMMARY TISSUES
Only a small number of studies have assessed the expression of cadherins in feline mam-
mary tumours [81, 256-258] and research concerning catenins are scarcer and restricted to 
β-catenin [81, 259]. 
In normal feline mammary glands, E- and P-cadherin have distinct expression patterns. 
E-cadherin is expressed at the cell-cell boundaries in luminal epithelial cells and there is 
no myoepithelial membranous expression [257, 259], while P-cadherin is restricted to myo-
epithelium [256]. The expression of β-catenin is membranous in the luminal epithelial cells 
[259].
In hyperplastic lesions and benign neoplasms, the expression of E-cadherin changes from 
an exclusive membranous expression to a simultaneous cytoplasmic staining in the luminal 
epithelium and cytoplasmic staining in the myoepithelium [257]. Such changes in the E-cad-
herin pattern have been particularly significant in malignant tumours, where a reduced or no 
membranous expression parallels cytoplasmic staining [81, 257-259]. E-cadherin expres-
sion was demonstrated to be lowest in tubulopapillary [259], cribriform and solid carcino-
mas [257], although the statistical significance of such differences was never assessed. No 
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significant association with tumour grade has been described, and it has been claimed that 
a preserved expression of E-cadherin is a significant feature of non-metastatic carcinomas 
[81], while others failed to find associations between the protein expression and survival, 
recurrence or metastases [259]. When studies were extended to β-catenin, although all 
samples exhibited a membranous expression there was a significant decrease and cyto-
plasmic translocation in malignant tumours and metastases when compared with normal 
tissues, hyperplastic/dysplastic lesions and benign tumours. No relationship has been dem-
onstrated with histological grade, survival, recurrence or metastases [259]. Penafiel-Verdu 
et al. (2012) revealed that the preserved expression of E-cadherin and β-catenin are sig-
nificant features of non-metastatic carcinomas, whereas carcinomas with metastasis loose 
one or both adhesion molecules [81]. The membrane labelling intensity and scoring were 
higher in primary tumours than in metastases for both E-cadherin and β-catenin, while 
the cytoplasmic expression of the two molecules increased in metastases compared with 
primary tumours [259]. An association was also found between the combined E-cadherin 
and β-catenin preservation and tumour grade, with grade I carcinomas preserving the ex-
pression of both molecules [81]. The association between the combined preservation of E-
cadherin and β-catenin and metastasis was stronger than that of each individual biomarker, 
suggesting that the former combination would be a better prognostic factor than E-cadherin 
alone [81].
To the best of our knowledge, only our group assessed the expression of P-cadherin in 
feline mammary tumours. In a series of feline mammary normal tissues and mammary le-
sions, we observed that the expression pattern of P-cadherin in hyperplastic and benign 
feline mammary lesions was similar to that of normal mammary gland, being restricted to 
myoepithelial cells [256]. The molecule has been aberrantly expressed in epithelial cells 
of malignant tumours, with a membranous and cytoplasmic staining pattern observed pre-
dominantly in cells of the tumours periphery and in invading cellular nests [256]. In these 
tumours, P-cadherin expression was related to histological grade, although no relationship 
was observed with histological type [256]. 
54
Chapter 01 General introduction
REFERENCES 
1. Martín De Las Mulas J, Reymundo C, 2000. Animal models of human breast carci-
noma: canine and feline neoplasms. Revista de Oncología, 2:274-281.
2. Misdorp W, Weijer K, 1980. Animal model of human disease: breast cancer. Am J 
Pathol, 98(2):573-576.
3. Zappulli V, De Zan G, Cardazzo B, Bargelloni L, Castagnaro M, 2005. Feline mam-
mary tumours in comparative oncology. Journal of Dairy Research, 72(S1):98.
4. Sorenmo KU, Worley DR, Goldschmidt MH, 2013. Tumours of the Mammary Gland. 
In: WITHROW, S. J., VAIL, D. M. & PAGE, R. L. (eds.) Withrow & MacEwen´s Small 
Animal Clinical Oncology. 5th edition ed. Missouri: Elsevier Saunders.
5. Hayes HM, Jr., Milne KL, Mandell CP, 1981. Epidemiological features of feline mam-
mary carcinoma. Vet Rec, 108(22):476-479.
6. Barone R, 2001. Chapitre IV - Mamelles. Anatomie Comparée des Mammifères 
Domestiques. Troisiéme Edition ed.
7. Bevier D, 1993. Integumentary System. In: HUDSON, L. P. H., W.P. (ed.) Atlas of feline 
anatomy for veterinarians Philadelphia: W.B. Saunders Company.
8. Gimenez F, Hecht S, Craig LE, Legendre AM, 2010. Early detection, aggressive 
therapy: optimizing the management of feline mammary masses. J Feline Med Surg, 
12(3):214-224.
9. Weijer K, Hart AA, 1983. Prognostic factors in feline mammary carcinoma. J Natl Cancer 
Inst, 70(4):709-716.
55
General introduction Chapter 01 
10. Weijer K, Head KW, Misdorp W, Hampe JF, 1972. Feline malignant mammary tumors. 
I. Morphology and biology: some comparisons with human and canine mammary car-
cinomas. J Natl Cancer Inst, 49(6):1697-1704.
11. Hahn KA, Bravo L, Avenell JS, 1994. Feline breast carcinoma as a pathologic and 
therapeutic model for human breast cancer. In vivo, 8(5):825-828.
12. Amorim FV, Souza HJ, Ferreira AM, Fonseca AB, 2006. Clinical, cytological and his-
topathological evaluation of mammary masses in cats from Rio de Janeiro, Brazil. J 
Feline Med Surg, 8(6):379-388.
13. Viste JR, Myers SL, Singh B, Simko E, 2002. Feline mammary adenocarcinoma: tumor 
size as a prognostic indicator. Can Vet J, 43(1):33-37.
14. Ito T, Kadosawa T, Mochizuki M, Matsunaga S, Nishimura R, Sasaki N, 1996. Progno-
sis of malignant mammary tumor in 53 cats. J Vet Med Sci, 58(8):723-726.
15. Skorupski KA, Overley B, Shofer FS, Goldschmidt MH, Miller CA, Sorenmo KU, 
2005. Clinical characteristics of mammary carcinoma in male cats. J Vet Intern Med, 
19(1):52-55.
16. Gregorio H, Pires I, Seixas F, Queiroga F, 2012. Mammary invasive micropapillary 
carcinoma in a male cat: Immunohistochemical description and clinical follow-up. Acta 
Vet Hung, 60(2):257-261.
17. Novosad CA, 2003. Principles of treatment for mammary gland tumors. Clin Tech 
Small Anim Pract, 18(2):107-109.
18. Overley B, Shofer FS, Goldschmidt MH, Sherer D, Sorenmo KU, 2005. Association be-
tween ovarihysterectomy and feline mammary carcinoma. J Vet Intern Med, 19(4):560-
563.
19. Rutteman GR, Misdorp W, 1993. Hormonal background of canine and feline mammary 
tumours. J Reprod Fertil Suppl, 47:483-487.
20. Misdorp W, Romijn A, Hart AA, 1991. Feline mammary tumors: a case-control study of 
hormonal factors. Anticancer Res, 11(5):1793-1797.
21. Misdorp W, 1991. Progestagens and mammary tumours in dogs and cats. Acta Endocrinol 
(Copenh), 125 Suppl 1:27-31.
22. Jacobs TM, Hoppe BR, Poehlmann CE, Ferracone JD, Sorenmo KU, 2010. Mammary 
adenocarcinomas in three male cats exposed to medroxyprogesterone acetate (1990-
2006). J Feline Med Surg, 12(2):169-174.
23. Shafiee R, Javanbakht J, Atyabi N, Bahrami A, Kheradmand D, Safaei R, Khadivar F, 
Hosseini E, 2013. Comparative value of clinical, cytological, and histopathological fea-
tures in feline mammary gland tumors; an experimental model for the study of human 
breast cancer. Diagn Pathol, 8:136.
24. Von Euler H, 2011. Tumours of the mammary glands. In: DOBSON, J. M. & LAS-
CELLES, B. D. (eds.) BSAVA Manual of Canine and Feline Oncology. 3rd Edition ed. 
Gloucester: BSAVA British Small Animal Veterinary Association.
25. Macewen EG, Hayes AA, Harvey HJ, Patnaik AK, Mooney S, Passe S, 1984. Prognos-
tic factors for feline mammary tumors. J Am Vet Med Assoc, 185(2):201-204.
26. Misdorp W, Else RW, Hellmén E, Lipscomb TP, 1999. Histological Classification of 
56
Chapter 01 General introduction
Mammary Tumors of the Dog and the Cat., Washington, D.C. USA, WHO, Armed 
Forces Institute of Pathology, American Registry of Pathology.
27. Elston CW, Ellis IO, 1998. Assessment of histological grade. In: ELSTON, C. W. & 
ELLIS, I. O. (eds.) The Breast. Systemic pathology. Third Edition ed. Edinburgh: 
Churchill-Livingstone.
28. Caliari D, Zappulli V, Rasotto R, Cardazzo B, Frassineti F, Goldschmidt MH, Castagn-
aro M, 2014. Triple-negative vimentin-positive heterogeneous feline mammary carci-
nomas as a potential comparative model for breast cancer. BMC Vet Res, 10(1):185.
29. Millanta F, Lazzeri G, Mazzei M, Vannozzi I, Poli A, 2002. MIB-1 Labeling index in fe-
line dysplastic and neoplastic mammary lesions and its relationship with postsurgical 
prognosis. Vet Pathol, 39(1):120-126.
30. Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M, 1998. 
Tumour grading and the one-year post-surgical prognosis in feline mammary carcino-
mas. J. Comp. Path., 119:263-275.
31. Dias Pereira P, Carvalheira J, Gartner F, 2004. Cell proliferation in feline normal, hy-
perplastic and neoplastic mammary tissue-an immunohistochemical study. Vet J, 
168(2):180-185.
32. Seixas F, Palmeira C, Pires MA, Bento MJ, Lopes C, 2011. Grade is an independent 
prognostic factor for feline mammary carcinomas: a clinicopathological and survival 
analysis. Vet J, 187(1):65-71.
33. Mills SW, Musil KM, Davies JL, Hendrick S, Duncan C, Jackson ML, Kidney B, Philibert 
H, Wobeser BK, Simko E, 2015. Prognostic value of histologic grading for feline mam-
mary carcinoma: a retrospective survival analysis. Vet Pathol, 52(2):238-249.
34. Zappulli V, Rasotto R, Caliari D, Mainenti M, Pena L, Goldschmidt MH, Kiupel M, 2015. 
Prognostic evaluation of feline mammary carcinomas: a review of the literature. Vet 
Pathol, 52(1):46-60.
35. Jeglum KA, Deguzman E, Young KM, 1985. Chemotherapy of advanced mammary 
adenocarcinoma in 14 cats. J Am Vet Med Assoc, 187(2):157-160.
36. Mauldin GN, Matus RE, Patnaik AK, Bond BR, Mooney SC, 1988. Efficacy and toxic-
ity of doxorubicin and cyclophosphamide used in the treatment of selected malignant 
tumors in 23 cats. J Vet Intern Med, 2(2):60-65.
37. Mcneill CJ, Sorenmo KU, Shofer FS, Gibeon L, Durham AC, Barber LG, Baez JL, Over-
ley B, 2009. Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment 
of feline mammary carcinoma. J Vet Intern Med, 23(1):123-129.
38. Novosad CA, Bergman PJ, O'brien MG, Mcknight JA, Charney SC, Selting KA, Gra-
ham JC, Correa SS, Rosenberg MP, Gieger TL, 2006. Retrospective evaluation of 
adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 
cases. J Am Anim Hosp Assoc, 42(2):110-120.
39. Borrego JF, Cartagena JC, Engel J, 2009. Treatment of feline mammary tumours using 
chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study 
of 23 cases (2002-2007). Vet Comp Oncol, 7(4):213-221.
40. Penzo C, Ross M, Muirhead R, Else R, Argyle DJ, 2009. Effect of recombinant feline 
57
General introduction Chapter 01 
interferon-omega alone and in combination with chemotherapeutic agents on putative 
tumour-initiating cells and daughter cells derived from canine and feline mammary 
tumours. Vet Comp Oncol, 7(4):222-229.
41. Macewen EG, Hayes AA, Mooney S, Patnaik AK, Harvey HJ, Passe S, Hardy WD, Jr., 
1984. Evaluation of effect of levamisole on feline mammary cancer. J Biol Response 
Mod, 3(5):541-546.
42. Adelfinger M, Gentschev I, Grimm De Guibert J, Weibel S, Langbein-Laugwitz J, Hartl 
B, Murua Escobar H, Nolte I, Chen NG, Aguilar RJ, Yu YA, Zhang Q, Frentzen A, 
Szalay AA, 2014. Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-
5b451 for feline mammary carcinoma therapy. PLoS One, 9(8):e104337.
43. Preziosi R, Sarli G, Benazzi C, Mandrioli L, Marcato PS, 2002. Multiparametric survival 
analysis of histological stage and proliferative activity in feline mammary carcinomas. 
Res Vet Sci, 73(1):53-60.
44. Brunetti B, Asproni P, Beha G, Muscatello LV, Millanta F, Poli A, Benazzi C, Sarli G, 
2013. Molecular phenotype in mammary tumours of queens: correlation between pri-
mary tumour and lymph node metastasis. J Comp Pathol, 148(2-3):206-213.
45. Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M, 2013. Feline mammary bas-
al-like adenocarcinomas: a potential model for human triple-negative breast cancer 
(TNBC) with basal-like subtype. BMC Cancer, 13:403.
46. Martin PM, Cotard M, Mialot JP, Andre F, Raynaud JP, 1984. Animal models for hor-
mone-dependent human breast cancer. Relationship between steroid receptor profiles 
in canine and feline mammary tumors and survival rate. Cancer Chemother Pharmacol, 
12(1):13-17.
47. Burrai GP, Mohammed SI, Miller MA, Marras V, Pirino S, Addis MF, Uzzau S, Antuo-
fermo E, 2010. Spontaneous feline mammary intraepithelial lesions as a model for 
human estrogen receptor- and progesterone receptor-negative breast lesions. BMC 
Cancer, 10:156.
48. Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Poli A, 2005. Comparison 
of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline 
mammary tissues. Res Vet Sci, 79(3):225-232.
49. Martin De Las Mulas J, Van Niel M, Millan Y, Blankenstein MA, Van Mil F, Misdorp W, 
2000. Immunohistochemical analysis of estrogen receptors in feline mammary gland 
benign and malignant lesions: comparison with biochemical assay. Domest Anim 
Endocrinol, 18(1):111-125.
50. Morris JS, Nixon C, Bruck A, Nasir L, Morgan IM, Philbey AW, 2008. Immunohisto-
chemical expression of TopBP1 in feline mammary neoplasia in relation to histological 
grade, Ki67, ERα and p53. Vet J, 175(2):218-226.
51. Clark GM, Mcguire WL, 1983. Progesterone receptors and human breast cancer. 
Breast Cancer Res Treat, 3(2):157-163.
52. Martin De Las Mulas J, Van Niel M, Millan Y, Ordas J, Blankenstein MA, Van Mil F, 
Misdorp W, 2002. Progesterone receptors in normal, dysplastic and tumourous fe-
line mammary glands. Comparison with oestrogen receptors status. Res Vet Sci, 
72(2):153-161.
58
Chapter 01 General introduction
53. Millanta F, Calandrella M, Vannozzi I, Poli A, 2006. Steroid hormone receptors in nor-
mal, dysplastic and neoplastic feline mammary tissues and their prognostic signifi-
cance. Vet Rec, 158(24):821-824.
54. Maniscalco L, Iussich S, De Las Mulas JM, Millan Y, Biolatti B, Sasaki N, Nakagawa T, 
De Maria R, 2012. Activation of AKT in feline mammary carcinoma: a new prognostic 
factor for feline mammary tumours. Vet J, 191(1):65-71.
55. Hughes K, Dobson JM, 2012. Prognostic histopathological and molecular markers in 
feline mammary neoplasia. Vet J, 194(1):19-26.
56. Morris J, 2013. Mammary tumours in the cat: size matters, so early intervention saves 
lives. J Feline Med Surg, 15(5):391-400.
57. Rutteman GR, Blankenstein MA, Minke J, Misdorp W, 1991. Steroid receptors in mam-
mary tumours of the cat. Acta Endocrinol (Copenh), 125 Suppl 1:32-37.
58. Cardazzo B, Zappulli V, Frassineti F, Patarnello T, Castagnaro M, Bargelloni L, 2005. 
Full-length sequence and expression analysis of estrogen receptor α mRNA in feline 
mammary tumors. J Steroid Biochem Mol Biol, 96(2):109-118.
59. Dowsett M, Nielsen TO, A'hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, 
Hugh JC, Lively T, Mcshane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter 
J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF, 2011. Assessment of Ki67 in 
breast cancer: recommendations from the International Ki67 in Breast Cancer working 
group. J Natl Cancer Inst, 103(22):1656-1664.
60. Castagnaro M, De Maria R, Bozzetta E, Ru G, Casalone C, Biolatti B, Caramelli M, 
1998. Ki-67 index as indicator of the post-surgical prognosis in feline mammary carci-
nomas. Research in Veterinary Science, 65:223-226.
61. Sarli G, Preziosi R, Benazzi C, Castellani G, Marcato PS, 2002. Prognostic value of 
histologic stage and proliferative activity in canine malignant mammary tumors. J Vet 
Diagn Invest, 14(1):25-34.
62. Castagnaro M, Casalone C, Ru G, Nervi GC, Bozzetta E, Caramelli M, 1998. Argyro-
philic nucleolar organiser regions (AgNORs) count as indicator of post-surgical prog-
nosis in feline mammary carcinomas. Research in Veterinary Science, 64:97-100.
63. Preziosi R, Sarli G, Benazzi C, Marcato PS, 1995. Detection of proliferating cell nuclear 
antigen (PCNA) in canine and feline mammary tumours. J Comp Pathol, 113(4):301-
313.
64. De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF, 2005. 
Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor 
prognosis human breast cancer. Cancer Res, 65(3):907-912.
65. Millanta F, Calandrella M, Citi S, Della Santa D, Poli A, 2005. Overexpression of HER-2 
in feline invasive mammary carcinomas: an immunohistochemical survey and evalua-
tion of its prognostic potential. Vet Pathol, 42(1):30-34.
66. Winston J, Craft DM, Scase TJ, Bergman PJ, 2005. Immunohistochemical detection 
of HER-2/neu expression in spontaneous feline mammary tumours. Vet Comp Oncol, 
3(1):8-15.
67. Ordas J, Millan Y, Dios R, Reymundo C, De Las Mulas JM, 2007. Proto-oncogene 
59
General introduction Chapter 01 
HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohisto-
chemical and chromogenic in situ hybridization study. BMC Cancer, 7:179.
68. Rasotto R, Caliari D, Castagnaro M, Zanetti R, Zappulli V, 2011. An Immunohistochem-
ical study of HER-2 expression in feline mammary tumours. J Comp Pathol, 144(2-
3):170-179.
69. Millanta F, Citi S, Della Santa D, Porciani M, Poli A, 2006. COX-2 expression in canine 
and feline invasive mammary carcinomas: correlation with clinicopathological features 
and prognostic molecular markers. Breast Cancer Res Treat, 98(1):115-120.
70. Sayasith K, Sirois J, Dore M, 2009. Molecular characterization of feline COX-2 and 
expression in feline mammary carcinomas. Vet Pathol, 46(3):423-429.
71. Petterino C, Ratto A, Podesta G, Drigo M, Pellegrino C, 2007. Immunohistochemical 
evaluation of STAT3-p-tyr705 expression in feline mammary gland tumours and cor-
relation with histologic grade. Res Vet Sci, 82(2):218-224.
72. De Maria R, Maggiora P, Biolatti B, Prat M, Comoglio PM, Castagnaro M, Di Renzo MF, 
2002. Feline STK gene expression in mammary carcinomas. Oncogene, 21(11):1785-
1790.
73. Ressel L, Millanta F, Caleri E, Innocenti VM, Poli A, 2009. Reduced PTEN protein 
expression and its prognostic implications in canine and feline mammary tumors. Vet 
Pathol, 46(5):860-868.
74. Nakano M, Wu H, Taura Y, Inoue M, 2006. Immunohistochemical detection of Mdm2 
and p53 in feline mammary gland tumors. J Vet Med Sci, 68(5):421-425.
75. Murakami Y, Tateyama S, Rungsipipat A, Uchida K, Yamaguchi R, 2000. Immunohis-
tochemical analysis of cyclin A, cyclin D1 and P53 in mammary tumors, squamous cell 
carcinomas and basal cell tumors of dogs and cats. J Vet Med Sci, 62(7):743-750.
76. Millanta F, Lazzeri G, Vannozzi I, Viacava P, Poli A, 2002. Correlation of vascular en-
dothelial growth factor expression to overall survival in feline invasive mammary carci-
nomas. Vet Pathol, 39(6):690-696.
77. Webster JD, Dennis MM, Dervisis N, Heller J, Bacon NJ, Bergman PJ, Bienzle D, 
Cassali G, Castagnaro M, Cullen J, Esplin DG, Pena L, Goldschmidt MH, Hahn KA, 
Henry CJ, Hellmen E, Kamstock D, Kirpensteijn J, Kitchell BE, Amorim RL, Lenz SD, 
Lipscomb TP, Mcentee M, Mcgill LD, Mcknight CA, Mcmanus PM, Moore AS, Moore 
PF, Moroff SD, Nakayama H, Northrup NC, Sarli G, Scase T, Sorenmo K, Schulman 
FY, Shoieb AM, Smedley RC, Spangler WL, Teske E, Thamm DH, Valli VE, Vernau 
W, Von Euler H, Withrow SJ, Weisbrode SE, Yager J, Kiupel M, 2011. Recommended 
guidelines for the conduct and evaluation of prognostic studies in veterinary oncology. 
Vet Pathol, 48(1):7-18.
78. Beha G, Muscatello LV, Brunetti B, Asproni P, Millanta F, Poli A, Benazzi C, Sarli G, 
2014. Molecular Phenotype of Primary Mammary Tumours and Distant Metastases in 
Female Dogs and Cats. J Comp Pathol.
79. Martin De Las Mulas J, Espinosa De Los Monteros A, Bautista MJ, Gomez-Villaman-
dos JC, Morales C, 1994. Immunohistochemical distribution pattern of intermediate 
filament proteins and muscle actin in feline and human mammary carcinomas. J Comp 
Pathol, 111(4):365-381.
60
Chapter 01 General introduction
80. Sarli G, Brunetti B, Benazzi C, 2006. Mammary mucinous carcinoma in the cat. Vet 
Pathol, 43(5):667-673.
81. Penafiel-Verdu C, Buendia AJ, Navarro JA, Ramirez GA, Vilafranca M, Altimira J, San-
chez J, 2012. Reduced expression of E-cadherin and β-catenin and high expression of 
basal cytokeratins in feline mammary carcinomas with regional metastasis. Vet Pathol, 
49(6):979-987.
82. Martin De Las Mulas J, Reymundo C, Espinosa De Los Monteros A, Millan Y, Ordas J, 
2004. Calponin expression and myoepithelial cell differentiation in canine, feline and 
human mammary simple carcinomas. Vet Comp Oncol, 2(1):24-35.
83. Matos AJ, Baptista CS, Gartner MF, Rutteman GR, 2012. Prognostic studies of canine 
and feline mammary tumours: the need for standardized procedures. Vet J, 193(1):24-31.
84. Gumbiner BM, 1996. Cell adhesion: the molecular basis of tissue architecture and 
morphogenesis. Cell, 84(3):345-357.
85. Takeichi M, 1990. Cadherins: a molecular family important in selective cell-cell adhe-
sion. Annu Rev Biochem, 59:237-252.
86. Wijnhoven BP, Dinjens WN, Pignatelli M, 2000. E-cadherin-catenin cell-cell adhesion 
complex and human cancer. Br J Surg, 87(8):992-1005.
87. Yilmaz M, Christofori G, 2010. Mechanisms of motility in metastasizing cells. Mol Cancer 
Res, 8(5):629-642.
88. Ohene-Abuakwa Y, Pignatelli M, 2000. Adhesion Molecules as Diagnostic Tools in Tu-
mor Pathology. International Journal of Surgical Pathology, 8(3):191-200.
89. Christofori G, 2003. Changing neighbours, changing behaviour: cell adhesion mole-
cule-mediated signalling during tumour progression. The EMBO Journal, 22(20):2318-
2323.
90. Nollet F, Kools P, Van Roy F, 2000. Phylogenetic analysis of the cadherin superfamily 
allows identification of six major subfamilies besides several solitary members. J Mol 
Biol, 299(3):551-572.
91. Elangbam CS, Qualls CW, Jr., Dahlgren RR, 1997. Cell adhesion molecules - update. 
Vet Pathol, 34(1):61-73.
92. Takeichi M, 1991. Cadherin cell adhesion receptors as a morphogenetic regulator. 
Science, 251:1451-1455.
93. Takeichi M, Nakagawa S, Aono S, Usui T, Uemura T, 2000. Patterning of cell assem-
blies regulated by adhesion receptors of the cadherin superfamily. Philos Trans R Soc 
Lond B Biol Sci, 355(1399):885-890.
94. Knudsen KA, Frankowski C, Johnson KR, Wheelock MJ, 1998. A role for cadherins in 
cellular signaling and differentiation. J Cell Biochem Suppl, 30-31:168-176.
95. Pecina-Slaus N, 2003. Tumor suppressor gene E-cadherin and its role in normal and 
malignant cells. Cancer Cell Int, 3(1):17.
96. Nose A, Takeichi M, 1986. A novel cadherin cell adhesion molecule: its expression 
patterns associated with implantation and organogenesis of mouse embryos. J Cell 
Biol, 103(6 Pt 2):2649-2658.
97. Shimoyama Y, Yoshida T, Terada M, Shimosato Y, Abe O, Hirohashi S, 1989. Molecu-
lar cloning of a human Ca2+-dependent cell-cell adhesion molecule homologous to 
61
General introduction Chapter 01 
mouse placental cadherin: its low expression in human placental tissues. J Cell Biol, 
109(4 Pt 1):1787-1794.
98. Shimoyama Y, Hirohashi S, Hirano S, Noguchi M, Shimosato Y, Takeichi M, Abe O, 
1989. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. 
Cancer Res, 49(8):2128-2133.
99. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC, 2007. P-
cadherin expression in breast cancer: a review. Breast Cancer Research, 9(5):214.
100. Shirayoshi Y, Hatta K, Hosoda M, Tsunasawa S, Sakiyama F, Takeichi M, 1986. Cad-
herin cell adhesion molecules with distinct binding specificities share a common struc-
ture. EMBO J, 5(10):2485-2488.
101. Nose A, Nagafuchi A, Takeichi M, 1987. Isolation of placental cadherin cDNA: identi-
fication of a novel gene family of cell-cell adhesion molecules. EMBO J, 6(12):3655-
3661.
102. Hatta K, Nose A, Nagafuchi A, Takeichi M, 1988. Cloning and expression of cDNA en-
coding a neural calcium-dependent cell adhesion molecule: its identity in the cadherin 
gene family. J Cell Biol, 106(3):873-881.
103. Berx G, Staes K, Van Hengel J, Molemans F, Bussemakers MJ, Van Bokhoven A, Van 
Roy F, 1995. Cloning and characterization of the human invasion suppressor gene E-
cadherin (CDH1). Genomics, 26(2):281-289.
104. Bussemakers MJ, Van Bokhoven A, Voller M, Smit FP, Schalken JA, 1994. The genes 
for the calcium-dependent cell adhesion molecules P- and E-cadherin are tandemly 
arranged in the human genome. Biochem Biophys Res Commun, 203(2):1291-1294.
105. Hatta M, Miyatani S, Copeland NG, Gilbert DJ, Jenkins NA, Takeichi M, 1991. Ge-
nomic organization and chromosomal mapping of the mouse P-cadherin gene. Nucleic 
Acids Res, 19(16):4437-4441.
106. Nollet F, Berx G, Van Roy F, 1999. The role of the E-cadherin/catenin adhesion complex 
in the development and progression of cancer. Mol Cell Biol Res Commun, 2(2):77-85.
107. Albergaria A, Ribeiro AS, Vieira AF, Sousa B, Nobre AR, Seruca R, Schmitt F, Pare-
des J, 2011. P-cadherin role in normal breast development and cancer. Int J Dev Biol, 
55:811-822.
108. Yagi T, Takeichi M, 2000. Cadherin superfamily genes: functions, genomic organiza-
tion, and neurologic diversity. Genes Dev, 14(10):1169-1180.
109. Takeichi M, 1995. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol, 
7(5):619-627.
110. Nose A, Tsuji K, Takeichi M, 1990. Localization of specificity determining sites in cad-
herin cell adhesion molecules. Cell, 61(1):147-155.
111. Cailliez F, Lavery R, 2005. Cadherin mechanics and complexation: the importance of 
calcium binding. Biophys J, 89(6):3895-3903.
112. Angst BD, Marcozzi C, Magee AI, 2001. The cadherin superfamily: diversity in form 
and function. J Cell Sci, 114(4):629-641.
113. Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, Grubel G, Legrand JF, 
Als-Nielsen J, Colman DR, Hendrickson WA, 1995. Structural basis of cell-cell adhe-
sion by cadherins. Nature, 374(6520):327-337.
62
Chapter 01 General introduction
114. Berx G, Van Roy F, 2001. The E-cadherin/catenin complex: an important gatekeeper 
in breast cancer tumorigenesis and malignant progression. Breast Cancer Research, 
3(5):289-293.
115. Ozawa M, Kemler R, 1992. Molecular organization of the uvomorulin-catenin complex. 
J Cell Biol, 116(4):989-996.
116. Wheelock MJ, Soler AP, Knudsen KA, 2001. Cadherin junctions in mammary tumors. 
J Mammary Gland Biol Neoplasia, 6(3):275-285.
117. Gumbiner BM, 2000. Regulation of cadherin adhesive activity. J Cell Biol, 148(3):399-404.
118. Nagafuchi A, Takeichi M, 1989. Transmembrane control of cadherin-mediated cell ad-
hesion: a 94 kDa protein functionally associated with a specific region of the cytoplas-
mic domain of E-cadherin. Cell Regul, 1(1):37-44.
119. Ozawa M, Baribault H, Kemler R, 1989. The cytoplasmic domain of the cell adhesion 
molecule uvomorulin associates with three independent proteins structurally related in 
different species. EMBO J, 8(6):1711-1717.
120. Nagafuchi A, Takeichi M, 1988. Cell binding function of E-cadherin is regulated by the 
cytoplasmic domain. EMBO J, 7(12):3679-3684.
121. Ozawa M, Ringwald M, Kemler R, 1990. Uvomorulin-catenin complex formation is 
regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. 
Proc Natl Acad Sci U S A, 87(11):4246-4250.
122. Goyal A, Martin TA, Mansel RE, Jiang WG, 2008. Real time PCR analyses of expres-
sion of E-cadherin, α-, β- and γ-catenin in human breast cancer for predicting clinical 
outcome. World J Surg Oncol, 6:56.
123. Sun Y, Zhang J, Ma L, 2014. α-Catenin: A tumor suppressor beyond adherens junc-
tions. Cell Cycle, 13(15).
124. Andrews JL, Kim AC, Hens JR, 2012. The role and function of cadherins in the mam-
mary gland. Breast Cancer Res, 14(1):203.
125. Morin PJ, 1999. β-catenin signaling and cancer. Bioessays, 21(12):1021-1030.
126. Cowin P, Rowlands TM, Hatsell SJ, 2005. Cadherins and catenins in breast cancer. 
Curr Opin Cell Biol, 17(5):499-508.
127. Behrens J, 1999. Cadherins and catenins: role in signal transduction and tumor pro-
gression. Cancer Metastasis Rev, 18(1):15-30.
128. Reynolds AB, Carnahan RH, 2004. Regulation of cadherin stability and turnover by 
p120ctn: implications in disease and cancer. Semin Cell Dev Biol, 15(6):657-663.
129. Reynolds AB, Daniel J, Mccrea PD, Wheelock MJ, Wu J, Zhang Z, 1994. Identification 
of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin 
complexes. Mol Cell Biol, 14(12):8333-8342.
130. Thoreson MA, Reynolds AB, 2002. Altered expression of the catenin p120 in human 
cancer: implications for tumor progression. Differentiation, 70(9-10):583-589.
131. Anastasiadis PZ, Reynolds AB, 2001. Regulation of Rho GTPases by p120-catenin. 
Curr Opin Cell Biol, 13(5):604-610.
132. Berx G, Van Roy F, 2009. Involvement of members of the cadherin superfamily in can-
cer. Cold Spring Harb Perspect Biol, 1(6):a003129.
63
General introduction Chapter 01 
133. Cavallaro U, Schaffhauser B, Christofori G, 2002. Cadherins and the tumour progres-
sion: is it all in a switch? Cancer Lett, 176(2):123-128.
134. Stemmler MP, 2008. Cadherins in development and cancer. Mol Biosyst, 4(8):835-850.
135. Conacci-Sorrell M, Zhurinsky J, Ben-Ze’ev A, 2002. The cadherin-catenin adhesion 
system in signaling and cancer. Journal of Clinical Investigation, 109(8):987-991.
136. Mulligan AMOMFR, 2012. The Breast. In: STRAYER, D. S. (ed.) Rubin´s Patholo-
gy Clinicopathologic Foundations of Medicine. 7th Ed ed. Baltimore: Wolters Kluwer 
Health.
137. Paredes J, Milanezi F, Viegas L, Amendoeira I, Schmitt F, 2002. P-cadherin expression 
is associated with high-grade ductal carcinoma in situ of the breast. Virchows Archiv, 
440(1):16-21.
138. Glukhova M, Koteliansky V, Sastre X, Thiery JP, 1995. Adhesion systems in normal 
breast and in invasive breast carcinoma. Am J Pathol, 146(3):706-716.
139. Parker C, Rampaul RS, Pinder SE, Bell JA, Wencyk PM, Blamey RW, Nicholson RI, 
Robertson JF, 2001. E-cadherin as a prognostic indicator in primary breast cancer. Br 
J Cancer, 85(12):1958-1963.
140. Palacios J, Benito N, Pizarro A, Suarez A, Espada J, Cano A, Gamallo C, 1995. Anom-
alous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin ex-
pression and pathological features. Am J Pathol, 146(3):605-612.
141. Rasbridge SA, Gillett CE, Sampson SA, Walsh FS, Millis RR, 1993. Epithelial (E-) 
and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J 
Pathol, 169(2):245-250.
142. Daniel CW, Strickland P, Friedmann Y, 1995. Expression and functional role of E- 
and P-cadherins in mouse mammary ductal morphogenesis and growth. Dev Biol, 
169(2):511-519.
143. Radice GL, Ferreira-Cornwell MC, Robinson SD, Rayburn H, Chodosh LA, Takeichi 
M, Hynes RO, 1997. Precocious mammary gland development in P-cadherin-deficient 
mice. J Cell Biol, 139(4):1025-1032.
144. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC, 2005. P-
cadherin overexpression is an indicator of clinical outcome in invasive breast carci-
nomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res, 
11(16):5869-5877.
145. Peralta Soler A, Russo J, Russo IH, Knudsen KA, 2002. Soluble Fragments of P-cad-
herin Adhesion Protein Found in Human Milk. J. Cell. Biochem., 85:180-184.
146. Chansona L, Brownfieldb D, Garbeb JC, Kuhnb I, Stampferb MR, Bissellb MJ, La-
bargeb AA, 2010. Self-organization is a dynamic and lineage-intrinsic property of 
mammary epithelial cells. PNAS, 108(8):3264–3269.
147. Mannello F, Tonti GA, Medda V, Pederzoli A, Sauter ER, 2008. Increased shedding of 
soluble fragments of P-cadherin in nipple aspirate fluids from women with breast can-
cer. Cancer Sci, 99(11):2160-2169.
148. Knudsen KA, Lin CY, Johnson KR, Wheelock MJ, Keshgegian AA, Soler AP, 2000. 
Lack of correlation between serum levels of E- and P-cadherin fragments and the pres-
ence of breast cancer. Hum Pathol, 31(8):961-965.
64
Chapter 01 General introduction
149. Van Roy F, Berx G, 2008. The cell-cell adhesion molecule E-cadherin. Cell Mol Life 
Sci, 65(23):3756-3788.
150. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier 
W, 1991. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human car-
cinoma cells. J Cell Biol, 113(1):173-185.
151. Sommers CL, Thompson EW, Torri JA, Kemler R, Gelmann EP, Byers SW, 1991. Cell 
adhesion molecule uvomorulin expression in human breast cancer cell lines: relation-
ship to morphology and invasive capacities. Cell Growth Differ, 2(8):365-372.
152. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van De Vijver MJ, Litvinov S, Van Roy F, 
Cornelisse CJ, Cleton-Jansen AM, 1997. Simultaneous loss of E-cadherin and catenins 
in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol, 183(4):404-411.
153. Liu T, Zhang X, Shang M, Zhang Y, Xia B, Niu M, Liu Y, Pang D, 2013. Dysregulated 
expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in 
patients with basal-like breast cancer. J Surg Oncol, 107(2):188-194.
154. Rieger-Christ KM, Pezza JA, Dugan JM, Braasch JW, Hughes KS, Summerhayes IC, 
2001. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. 
Mol Pathol, 54(2):91-97.
155. Mastracci TL, Tjan S, Bane AL, O'malley FP, Andrulis IL, 2005. E-cadherin alterations 
in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol, 
18(6):741-751.
156. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, Cano A, 1993. 
Correlation of E-cadherin expression with differentiation grade and histological type in 
breast carcinoma. Am J Pathol, 142(4):987-993.
157. Harigopal M, Shin SJ, Murray MP, Tickoo SK, Brogi E, Rosen PP, 2005. Aberrant E-
cadherin staining patterns in invasive mammary carcinoma. World J Surg Oncol, 3:73.
158. Goldstein NS, Bassi D, Watts JC, Layfield LJ, Yaziji H, Gown AM, 2001. E-cadherin 
reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the 
interpretation of problematic lesions. Am J Clin Pathol, 115(4):534-542.
159. Gonzalez MA, Pinder SE, Wencyk PM, Bell JA, Elston CW, Nicholson RI, Robertson 
JF, Blamey RW, Ellis IO, 1999. An immunohistochemical examination of the expres-
sion of E-cadherin, α- and β/γ-catenins, and α2- and β1-integrins in invasive breast 
cancer. J Pathol, 187(5):523-529.
160. Berx G, Cleton-Jansen A-M, Nollet, De Leeuwl WJF, Van De Vijverl MJ, Cornelisse C, 
Van Roy F, 1995. E-cadherin is a tumour/invasion suppressor gene mutated in human 
lobular breast cancers. The EMBO Journal, 14(24):6107-6115.
161. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ, 1996. Reduced 
E-cadherin expression is associated with invasiveness and unfavorable prognosis in 
breast cancer. Am J Clin Pathol, 105(4):394-402.
162. Hirohashi S, 1998. Inactivation of the E-cadherin-mediated cell adhesion system in 
human cancers. Am J Pathol, 153(2):333-339.
163. Van Horssen R, Hollestelle A, Rens JA, Eggermont AM, Schutte M, Ten Hagen TL, 
2012. E-cadherin promotor methylation and mutation are inversely related to motility 
capacity of breast cancer cells. Breast Cancer Res Treat, 136(2):365-377.
65
General introduction Chapter 01 
164. Knudsen KA, Wheelock MJ, 2005. Cadherins and the mammary gland. J Cell Biochem, 
95(3):488-496.
165. Berx G, Becker KF, Hofler H, Van Roy F, 1998. Mutations of the human E-cadherin 
(CDH1) gene. Hum Mutat, 12(4):226-237.
166. Cleton-Jansen A-M, 2002. E-cadherin and loss of heterozygosity at chromosome 16 in 
breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? 
Breast Cancer Res, 4(1):5-8.
167. Berx G, Cleton-Jansen A-M, Strumane K, De Leeuw WJ, Nollet F, Van Roy F, Cor-
nelisse C, 1996. E-cadherin is inactivated in a majority of invasive human lobular 
breast cancers by truncation mutations throughout its extracellular domain. Oncogene, 
13(9):1919-1925.
168. Oda T, Kanai Y, Oyama T, Yoshiura K, Shimoyama Y, Birchmeier W, Sugimura T, Hiro-
hashi S, 1994. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc 
Natl Acad Sci U S A, 91(5):1858-1862.
169. Semb H, Christofori G, 1998. The tumor-suppressor function of E-cadherin. Am J Hum 
Genet, 63(6):1588-1593.
170. Baranwal S, Alahari SK, 2009. Molecular mechanisms controlling E-cadherin expres-
sion in breast cancer. Biochem Biophys Res Commun, 384(1):6-11.
171. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S, 1995. Silencing 
of the E-cadherin invasion-suppressor gene by CpG methylation in human carcino-
mas. Proc Natl Acad Sci U S A, 92(16):7416-7419.
172. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, 
Davidson NE, Baylin SB, 1995. E-cadherin expression is silenced by DNA hypermeth-
ylation in human breast and prostate carcinomas. Cancer Res, 55(22):5195-5199.
173. Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, Doggett N, John-
son K, Wheelock M, Herman J, Baylin S, Pinkel D, Gray J, 1998. Mechanisms of inac-
tivation of E-cadherin in breast cancer cell lines. Cancer Res, 58(9):1972-1977.
174. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y, Mat-
suyoshi N, Hirano S, Takeichi M, Et al., 1993. Expression of E-cadherin cell adhesion 
molecules in human breast cancer tissues and its relationship to metastasis. Cancer 
Res, 53(7):1696-1701.
175. Liu Y, Zhao J, Zhang PY, Zhang Y, Sun SY, Yu SY, Xi QS, 2012. MicroRNA-10b targets 
E-cadherin and modulates breast cancer metastasis. Med Sci Monit, 18(8):BR299-308.
176. Zhao H, Liang Y, Xu Z, Wang L, Zhou F, Li Z, Jin J, Yang Y, Fang Z, Hu Y, Zhang L, Su 
J, Zha X, 2008. N-glycosylation affects the adhesive function of E-Cadherin through 
modifying the composition of adherens junctions (AJs) in human breast carcinoma cell 
line MDA-MB-435. J Cell Biochem, 104(1):162-175.
177. Matsuyoshi N, Hamaguchi M, Taniguchi S, Nagafuchi A, Tsukita S, Takeichi M, 1992. 
Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in 
metastatic fibroblasts. J Cell Biol, 118(3):703-714.
178. Braga VMM, 1999. Small GTPases and regulation of cadherin dependent cell–cell 
adhesion. J Clin Pathol: Mol Pathol, 52:197–202.
179. Kawanishi J, Kato J, Sasaki K, Fujii S, Watanabe N, Niitsu Y, 1995. Loss of E-cadherin-
66
Chapter 01 General introduction
dependent cell-cell adhesion due to mutation of the β-catenin gene in a human cancer 
cell line, HSC-39. Mol Cell Biol, 15(3):1175-1181.
180. Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S, Hirohashi S, 
1992. Cadherin dysfunction in a human cancer cell line: possible involvement of loss 
of α-catenin expression in reduced cell-cell adhesiveness. Cancer Res, 52(20):5770-
5774.
181. Shimoyama Y, Hirohashi S, 1991. Expression of E- and P-cadherin in gastric carcino-
mas. Cancer Res, 51(8):2185-2192.
182. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL, 1998. E-Cad-
herin and α-, β-, and γ-catenin protein expression in relation to metastasis in human 
breast carcinoma. J Pathol, 185(3):262-266.
183. Bukholm IK, Nesland JM, Borresen-Dale AL, 2000. Re-expression of E-cadherin, 
α-catenin and β-catenin, but not of γ-catenin, in metastatic tissue from breast cancer 
patients. J Pathol, 190(1):15-19.
184. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K, 1994. Expression of E-
cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J 
Pathol, 174(2):101-109.
185. Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby 
AM, 2001. Retention of the expression of E-cadherin and catenins is associated with 
shorter survival in grade III ductal carcinoma of the breast. J Pathol, 193(4):433-441.
186. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA, 1999. P-cadherin 
expression in breast carcinoma indicates poor survival. Cancer, 86(7):1263-1272.
187. Tan DS, Potts HW, Leong AC, Gillett CE, Skilton D, Harris WH, Liebmann RD, Hanby 
AM, 1999. The biological and prognostic significance of cell polarity and E-cadherin in 
grade I infiltrating ductal carcinoma of the breast. J Pathol, 189(1):20-27.
188. Howard EM, Lau SK, Lyles RH, Birdsong GG, Umbreit JN, Kochhar R, 2005. Expres-
sion of E-cadherin in high-risk breast cancer. J Cancer Res Clin Oncol, 131(1):14-18.
189. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramo-
poulos A, Davaris P, Pignatelli M, 2002. Abnormal α-catenin expression in invasive 
breast cancer correlates with poor patient survival. Histopathology, 40(6):536-546.
190. Pedersen KB, Nesland JM, Fodstad O, Maelandsmo GM, 2002. Expression of S100A4, 
E-cadherin, α- and β-catenin in breast cancer biopsies. Br J Cancer, 87(11):1281-1286.
191. Tsang JY, Mendoza P, Lam CC, Yu AM, Putti TC, Karim RZ, Scolyer RA, Lee CS, Tan 
PH, Tse GM, 2012. Involvement of α- and β-catenins and E-cadherin in the develop-
ment of mammary phyllodes tumours. Histopathology, 61(4):667-674.
192. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH, 2010. 
WNT/β-catenin pathway activation is enriched in basal-like breast cancers and 
predicts poor outcome. Am J Pathol, 176(6):2911-2920.
193. Esposito NN, Chivukula M, Dabbs DJ, 2007. The ductal phenotypic expression of the 
E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohisto-
chemical and clinicopathologic study. Mod Pathol, 20(1):130-138.
194. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, Keramopoulos A, Davaris PS, Pig-
67
General introduction Chapter 01 
natelli M, 2001. Expression patterns of β-catenin in in situ and invasive breast cancer. 
Eur J Surg Oncol, 27(1):31-36.
195. Incassati A, Chandramouli A, Eelkema R, Cowin P, 2010. Key signaling nodes in mam-
mary gland development and cancer:  β-catenin. Breast Cancer Res, 12(6):213.
196. Fanelli MA, Montt-Guevara M, Diblasi AM, Gago FE, Tello O, Cuello-Carrion FD, Calle-
gari E, Bausero MA, Ciocca DR, 2008. P-Cadherin and β-catenin are useful prognostic 
markers in breast cancer patients; β-catenin interacts with heat shock protein Hsp27. 
Cell Stress Chaperones, 13(2):207-220.
197. Van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, Vander Haeghen Y, 
Bracke M, 2005. P-cadherin promotes cell-cell adhesion and counteracts invasion in 
human melanoma. Cancer Res, 65(19):8774-8783.
198. Van Marck V, Stove C, Jacobs K, Van Den Eynden G, Bracke M, 2011. P-cadherin in 
adhesion and invasion: opposite roles in colon and bladder carcinoma. Int J Cancer, 
128(5):1031-1044.
199. Bauer R, Bosserhoff AK, 2006. Functional implication of truncated P-cadherin expres-
sion in malignant melanoma. Exp Mol Pathol, 81(3):224-230.
200. Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa 
O, Katagiri T, Nakamura Y, 2005. Overexpressed P-cadherin/CDH3 promotes motility 
of pancreatic cancer cells by interacting with p120ctn and activating rho-family GT-
Pases. Cancer Res, 65(8):3092-3099.
201. Mandeville JA, Silva Neto B, Vanni AJ, Smith GL, Rieger-Christ KM, Zeheb R, Loda M, 
Libertino JA, Summerhayes IC, 2008. P-cadherin as a prognostic indicator and a mod-
ulator of migratory behaviour in bladder carcinoma cells. BJU Int, 102(11):1707-1714.
202. Cheung LW, Leung PC, Wong AS, 2010. Cadherin switching and activation of p120 
catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor 
cell migration and invasion in ovarian cancer. Oncogene, 29(16):2427-2440.
203. Paredes J, Lopes N, Milanezi F, Schmitt FC, 2007. P-cadherin and cytokeratin 5: use-
ful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Archiv 
450(1):73-80.
204. Paredes J, Stove C, Stove V, Milanezi F, Van Marck V, Derycke L, Mareel M, Bracke 
M, Schmitt F, 2004. P-cadherin is up-regulated by the antiestrogen ICI 182,780 and 
promotes invasion of human breast cancer cells. Cancer Res, 64(22):8309-8317.
205. Stefansson IM, Salvesen HB, Akslen LA, 2004. Prognostic impact of alterations in P-
cadherin expression and related cell adhesion markers in endometrial cancer. J Clin 
Oncol, 22(7):1242-1252.
206. Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda 
T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y, 2008. Identifica-
tion of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target 
for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res, 
14(20):6487-6495.
207. Gamallo C, Moreno-Bueno G, Sarrio D, Calero F, Hardisson D, Palacios J, 2001. The 
prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Modern 
pathology 14(7):650-654.
68
Chapter 01 General introduction
208. Reis-Filho JS, Milanezi F, Paredes J, Silva P, Pereira EM, Maeda SA, De Carvalho 
LV, Schmitt FC, 2003. Novel and classic myoepithelial/stem cell markers in metaplas-
tic carcinomas of the breast. Applied immunohistochemistry & molecular morphology 
11(1):1-8.
209. Turashvili G, Mckinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, Los 
G, Rejto PA, Aparicio SA, 2011. P-cadherin expression as a prognostic biomarker in a 
3992 case tissue microarray series of breast cancer. Modern pathology 24(1):64-81.
210. Han AC, Soler AP, Knudsen KA, Salazar H, 1999. Distinct cadherin profiles in special 
variant carcinomas and other tumors of the breast. Hum Pathol, 30(9):1035-1039.
211. Paredes J, Milanezi F, Reis-Filho JS, Leitão D, Athanazio D, Schmitt F, 2002. Cor-
relação entre as expressões de P-caderina e de receptores de estrógeno no câncer 
da mama. Correlation between P-cadherin and estrogen receptor expression in breast 
cancer. Jornal Brasileiro de Patologia e Medicina Laboratorial, 38:307-331.
212. Kovacs A, Dhillon J, Walker RA, 2003. Expression of P-cadherin, but not E-cadherin or 
N-cadherin, relates to pathological and functional differentiation of breast carcinomas. 
Journal of clinical pathology: molecular pathology, 56(6):318-322.
213. Sousa B, Paredes J, Milanezi F, Lopes N, Martins D, Dufloth R, Vieira D, Albergaria A, 
Veronese L, Carneiro V, Carvalho S, Costa JL, Zeferino L, Schmitt F, 2010. P-cadherin, 
vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an 
immunohistochemical study. Histol Histopathol, 25(8):963-974.
214. Liu N, Yu Q, Liu TJ, Gebreamlak EP, Wang SL, Zhang RJ, Zhang J, Niu Y, 2012. P-
cadherin expression and basal-like subtype in breast cancers. Med Oncol, 29(4):2606-
2612.
215. Faria G, Cardoso MJ, Martins D, Bettencourt H, Amendoeira I, Schimitt F, 2012. P-
cadherin as prognostic factor for loco-regional relapse in breast cancer. Acta Med Port, 
25(2):97-105.
216. Faraldo MM, Teuliere J, Deugnier MA, Birchmeier W, Huelsken J, Thiery JP, Cano A, 
Glukhova MA, 2007. β-Catenin regulates P-cadherin expression in mammary basal 
epithelial cells. FEBS Lett, 581(5):831-836.
217. Albergaria A, Resende C, Nobre AR, Ribeiro AS, Sousa B, Machado JC, Seruca R, 
Paredes J, Schmitt F, 2013. CCAAT/enhancer binding protein beta (C/EBPbeta) iso-
forms as transcriptional regulators of the pro-invasive CDH3/P-cadherin gene in hu-
man breast cancer cells. PLoS One, 8(2):e55749.
218. Albergaria A, Ribeiro AS, Pinho S, Milanezi F, Carneiro V, Sousa B, Sousa S, Oliveira 
C, Machado JC, Seruca R, Paredes J, Schmitt F, 2010. ICI 182,780 induces P-cadherin 
overexpression in breast cancer cells through chromatin remodelling at the promoter 
level: a role for C/EBPβ in CDH3 gene activation. Hum Mol Genet, 19(13):2554-2566.
219. Shimomura Y, Wajid M, Shapiro L, Christiano AM, 2008. P-cadherin is a p63 target gene 
with a crucial role in the developing human limb bud and hair follicle. Development, 
135(4):743-753.
220. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, Brugge JS, Ellisen LW, 
2006. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat 
Cell Biol, 8(6):551-561.
69
General introduction Chapter 01 
221. Faraldo MM, Teuliere J, Deugnier MA, Taddei-De La Hosseraye I, Thiery JP, Gluk-
hova MA, 2005. Myoepithelial cells in the control of mammary development and tu-
morigenesis: data from genetically modified mice. J Mammary Gland Biol Neoplasia, 
10(3):211-219.
222. Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE, Mcdyer FA, 
Kennedy RD, Wilson RH, Mullan PB, Harkin DP, 2010. BRCA1 transcriptionally regu-
lates genes associated with the basal-like phenotype in breast cancer. Breast Cancer 
Res Treat, 122(3):721-731.
223. Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, 
Foulkes WD, 2005. Placental cadherin and the basal epithelial phenotype of BRCA1-
related breast cancer. Clin Cancer Res, 11(11):4003-4011.
224. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudo-
sa JC, Diez O, Alonso C, Lerma E, Sanchez L, Rivas C, Benitez J, 2003. Immunohis-
tochemical characteristics defined by tissue microarray of hereditary breast cancer not 
attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas aris-
ing in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res, 9(10 Pt 1):3606-3614.
225. Paredes J, Albergaria A, Carvalho S, Schmitt F, 2006. “Basal-like” Breast Carcinomas: 
Identification by P-cadherin, P63 and EGFR Basal Cytokeratins Expression. Applied 
Cancer Research, 26(2):41-55.
226. Paredes J, Milanezi F, Reis-Filho JS, Leitao D, Athanazio D, Schmitt F, 2002. Aberrant 
P-cadherin expression: is it associated with estrogen-independent growth in breast 
cancer? Pathol Res Pract, 198(12):795-801.
227. Ribeiro AS, Albergaria A, Sousa B, Correia AL, Bracke M, Seruca R, Schmitt FC, Pare-
des J, 2010. Extracellular cleavage and shedding of P-cadherin: a mechanism under-
lying the invasive behaviour of breast cancer cells. Oncogene, 29(3):392-402.
228. Ribeiro AS, Sousa B, Carreto L, Mendes N, Nobre AR, Ricardo S, Albergaria A, Cam-
eselle-Teijeiro JF, Gerhard R, Soderberg O, Seruca R, Santos MA, Schmitt F, Paredes 
J, 2013. P-cadherin functional role is dependent on E-cadherin cellular context: a proof 
of concept using the breast cancer model. J Pathol, 229(5):705-718.
229. Paredes J, Correia AL, Ribeiro AS, Milanezi F, Cameselle-Teijeiro J, Schmitt FC, 2008. 
Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin 
cytoplasmic localisation and poor patient survival. J Clin Pathol, 61(7):856-862.
230. Vieira AF, Ribeiro AS, Dionisio MR, Sousa B, Nobre AR, Albergaria A, Santiago-Gomez 
A, Mendes N, Gerhard R, Schmitt F, Clarke RB, Paredes J, 2014. P-cadherin signals 
through the laminin receptor α6β4 integrin to induce stem cell and invasive properties 
in basal-like breast cancer cells. Oncotarget, 5(3):679-692.
231. Hardy RG, Tselepis C, Hoyland J, Wallis Y, Pretlow TP, Talbot I, Sanders DS, Matthews 
G, Morton D, Jankowski JA, 2002. Aberrant P-cadherin expression is an early event in 
hyperplastic and dysplastic transformation in the colon. Gut, 50(4):513-519.
232. Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, 
Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes 
K, Christensen JG, Vanarsdale T, 2010. PF-03732010: a fully human monoclonal an-
70
Chapter 01 General introduction
tibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res, 
16(21):5177-5188.
233. Park J, Park E, Han SW, Im SA, Kim TY, Kim WH, Oh DY, Bang YJ, 2012. Down-
regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in 
gastric cancer. Invest New Drugs, 30(4):1404-1412.
234. Bernardes N, Ribeiro AS, Abreu S, Mota B, Matos RG, Arraiano CM, Seruca R, Paredes 
J, Fialho AM, 2013. The bacterial protein azurin impairs invasion and FAK/Src signal-
ing in P-cadherin-overexpressing breast cancer cell models. PLoS One, 8(7):e69023.
235. Sousa B, Ribeiro AS, Nobre AR, Lopes N, Martins D, Pinheiro C, Vieira AF, Albergaria 
A, Gerhard R, Schmitt F, Baltazar F, Paredes J, 2014. The basal epithelial marker 
P-cadherin associates with breast cancer cell populations harboring a glycolytic and 
acid-resistant phenotype. BMC Cancer, 14:734.
236. Thiery JP, Acloque H, Huang RY, Nieto MA, 2009. Epithelial-mesenchymal transitions 
in development and disease. Cell, 139(5):871-890.
237. Ribeiro AS, Paredes J, 2015. P-Cadherin Linking Breast Cancer Stem Cells and Inva-
sion: A Promising Marker to Identify an "Intermediate/Metastable" EMT State. Front 
Oncol, 4(371):1-6.
238. Thiery JP, 2002. Epithelial-mesenchymal transitions in tumour progression. Nat Rev 
Cancer, 2(6):442-454.
239. Maeda M, Johnson KR, Wheelock MJ, 2005. Cadherin switching: essential for behav-
ioral but not morphological changes during an epithelium-to-mesenchyme transition. 
Journal of Cell Science, 118(5):873-887.
240. Perou CM, Sorlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross 
DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lon-
ning PE, Borresen-Dale AL, Brown PO, Botstein D, 2000. Molecular portraits of human 
breast tumours. Nature, 406(6797):747-752.
241. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, 
Van De Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, 
Lonning PE, Borresen-Dale AL, 2001. Gene expression patterns of breast carcino-
mas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 
98(19):10869-10874.
242. Tsang JY, Au SK, Ni YB, Shao MM, Siu WM, Hui SW, Chan SK, Chan KW, Kwok YK, 
Chan KF, Tse GM, 2013. P-cadherin and vimentin are useful basal markers in breast 
cancers. Hum Pathol, 44(12):2782-2791.
243. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H, 2008. Basal 
carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol, 
61(5):553-560.
244. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F, 2005. p63, cytokeratin 5, and P-
cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. 
Virchows Archiv, 447(4):688-694.
245. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM, 
2006. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. 
Mod Pathol, 19(2):264-271.
71
General introduction Chapter 01 
246. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO, 2007. Breast car-
cinoma with basal differentiation: a proposal for pathology definition based on basal 
cytokeratin expression. Histopathology, 50(4):434-438.
247. Vieira AF, Ricardo S, Ablett MP, Dionisio MR, Mendes N, Albergaria A, Farnie G, Ger-
hard R, Cameselle-Teijeiro JF, Seruca R, Schmitt F, Clarke RB, Paredes J, 2012. P-
cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in 
basal-like breast cancer. Stem Cells, 30(5):854-864.
248. De Wever O, Derycke L, Hendrix A, De Meerleer G, Godeau F, Depypere H, Bracke M, 
2007. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis, 24(8):685-697.
249. Okugawa Y, Toiyama Y, Inoue Y, Iwata T, Fujikawa H, Saigusa S, Konishi N, Tanaka 
K, Uchida K, Kusunoki M, 2012. Clinical significance of serum soluble E-cadherin in 
colorectal carcinoma. J Surg Res, 175(2):e67-73.
250. Repetto O, De Paoli P, De Re V, Canzonieri V, Cannizzaro R, 2014. Levels of soluble 
E-cadherin in breast, gastric, and colorectal cancers. Biomed Res Int, 2014:408047.
251. Katayama M, Hirai S, Yasumoto M, Nishikawa K, Nagata S, Otsuka M, Kamihagi K, 
Kato I, 1994. Soluble fragments of E-cadherin cell-adhesion molecule increase in 
urinary-excretion of cancer-patients, potentially indicating its shedding from epithelial 
tumor-cells. Int J Oncol, 5(5):1049-1057.
252. Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M, Kato I, 1994. Soluble E-
cadherin fragments increased in circulation of cancer patients. Br J Cancer, 69(3):580-585.
253. Liang Z, Sun XY, Xu LC, Fu RZ, 2014. Abnormal expression of serum soluble E-cad-
herin is correlated with clinicopathological features and prognosis of breast cancer. 
Med Sci Monit, 20:2776-2782.
254. Perez-Rivas LG, Jerez JM, Fernandez-De Sousa CE, De Luque V, Quero C, Pajares 
B, Franco L, Sanchez-Munoz A, Ribelles N, Alba E, 2012. Serum protein levels fol-
lowing surgery in breast cancer patients: a protein microarray approach. Int J Oncol, 
41(6):2200-2206.
255. Hofmann G, Balic M, Dandachi N, Resel M, Schippinger W, Regitnig P, Samonigg 
H, Bauernhofer T, 2013. The predictive value of serum soluble E-cadherin levels in 
breast cancer patients undergoing preoperative systemic chemotherapy. Clin Biochem, 
46(15):1585-1589.
256. Figueira AC, Teodosio AS, Carvalheira J, Lacerda M, De Matos A, Gartner F, 2012. P-
cadherin expression in feline mammary tissues. Vet Med Int, 2012:687424.
257. Dias Pereira P, Gärtner F, 2003. Expression of E-cadherin in normal, hyperplastic and 
neoplastic feline mammary tissue. The veterinary record 153(10):297-302.
258. Buendia AJ, Penafiel-Verdu C, Navarro JA, Vilafranca M, Sanchez J, 2014. N-cadherin 
expression in feline mammary tumors is associated with a reduced E-cadherin expres-
sion and the presence of regional metastasis. Vet Pathol, 51(4):755-758.
259. Zappulli V, De Cecco S, Trez D, Caliari D, Aresu L, Castagnaro M, 2012. Immunohisto-
chemical expression of E-cadherin and β-catenin in feline mammary tumours. J Comp 
Pathol, 147:161-170.

           02
AIMS AND OBJECTIVES

75
Aims and objectives Chapter 02
GENERAL AIMS
Cadherins are cell-to-cell adhesion glycoproteins with important roles in morphogenesis, 
development and maintenance of tissues and organs. Changes in these adhesion mol-
ecules and their associated molecules, namely catenins, result in destabilization of the cell 
adhesion interfering with regulation process of differentiation of epithelial structures. Thus, 
loss of function, down or overexpression of cadherins and catenins are involved in the complex 
process of mammary carcinogenesis. 
This study aims to characterize P-cadherin and associated molecules of the cadherin-
catenin complex in feline mammary tumours in order to determine its contribution to tumou-
rigenesis and to the invasive and metastatic behaviour of feline mammary carcinomas. 
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SPECIFIC AIMS
This work consisted of several stages, namely:
1. Determination of P-cadherin expression in feline mammary tumours
The purposes of this study were to examine the expression of P-cadherin in a series of 
normal mammary gland tissues and spontaneous hyperplastic and tumour mammary le-
sions, and to determine its relationship with the expression of E-cadherin as well as tumour 
clinicopathological features with potential prognostic value. 
2. Determination of the expression of the molecules of cadherin-catenin complex in feline 
mammary tumours
In this study our purpose was to characterize the molecules that compose the cadherin–
catenin complex in feline mammary tumours by assessing the immunoexpression of α-, 
β- and p120-catenin in a series of hyperplastic/dysplastic lesions and benign and malignant 
mammary tumours, determine the relation with the expression of classical P- and E-cad-
herin and with clinicopathological parameters with potential prognostic value.
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3. Contribute to the molecular characterization of feline mammary tumours
The intention was to contribute, by immunohistochemistry, for the molecular character-
ization of hyperplastic/dysplastic, benign and malignant feline mammary tumours, using 
phenotypic markers (AE1AE3, vimentin, p63), hormone receptors (ER, PR) and cell-cycle 
associated molecules (Ki-67), as well as P- and E-cadherin. With this, we pretend to add 
knowledge to feline mammary molecular markers with assist in the determination of the 
biological behaviour of individual tumours, as well as with potential prognostic and therapeutic 
value.
4. Characterization of a feline mammary carcinoma cell line
There are still few and contradictory information about the cadherins and catenins role in 
feline mammary tumours. In this context, we search for a feline mammary carcinoma cell 
line in order to determine a suitable in vitro and in vivo model systems to evaluate the ex-
pression and functions of cadherin-catenin complex molecules, namely P and E-cadherin, 
as well as α-, β-, and p120-catenin, point toward a better understanding of their role in feline 
mammary tumours progression.
5. Determination of the soluble P-cadherin serum levels in queens with mammary tumours
The ectodomain cleavage P-cadherin generates a soluble fragment (sP-cad) that may be 
increased during tumourigenesis. In this context we planned to determine the serum levels 
of the sP-cad fragment in a group of queens with spontaneous mammary lesions and in a 
group of healthy queens, in order to determine if sP-cad can be considered a tumour marker 
for mammary tumour in feline species as a diagnostic/prognostic marker, as well as in the 
follow-up monitoring. 
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ABERRANT P-CADHERIN EXPRESSION
IS ASSOCIATED TO AGGRESSIVE FELINE
MAMMARY CARCINOMAS
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ABSTRACT
Background: Cadherins are calcium-dependent cell-to-cell adhesion glycoproteins play-
ing a critical role in the formation and maintenance of normal tissue architecture. In normal 
mammary gland, E-cadherin is expressed by luminal epithelial cells, while P-cadherin is re-
stricted to myoepithelial cells. Changes in the expression of classical E- and P-cadherin have 
been observed in mammary lesions and related to mammary carcinogenesis. P-cadherin 
and E-cadherin expressions were studied in a series of feline normal mammary glands, hy-
perplastic/dysplastic lesions, benign and malignant tumours by immunohistochemistry and 
double-label immunofluorescence.
Results: In normal tissue and in the majority of hyperplastic/dysplastic lesions and be-
nign tumours, P-cadherin was restricted to myoepithelial cells, while 80% of the malig-
nant tumours expressed P-cadherin in luminal epithelial cells. P-cadherin expression was 
significantly related to high histological grade of carcinomas (p<0.0001), tumour necrosis 
(p=0.001), infiltrative growth (p=0.0051), and presence of neoplastic emboli (p=0.0401). 
Moreover, P-cadherin positive carcinomas had an eightfold likelihood of developing neo-
plastic emboli than negative tumours. Cadherins expression profile in high grade and in in-
filtrative tumours was similar, the majority expressing P-cadherin, regardless of E-cadherin 
expression status. The two cadherins were found to be co-expressed in carcinomas with 
aberrant P-cadherin expression and preserved E-cadherin.
Conclusions: The results demonstrate a relationship between P-cadherin expression 
and aggressive biological behaviour of feline mammary carcinomas, suggesting that P-
cadherin may be considered an indicator of poor prognosis in this animal species. More-
over, it indicates that, in queens, the aberrant expression of P-cadherin is a better marker of 
mammary carcinomas aggressive behaviour than the reduction of E-cadherin expression. 
Further investigation with follow-up studies in feline species should be conducted in order to 
evaluate the prognostic value of P-cadherin expression in E-cadherin positive carcinomas.
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BACKGROUND
Cadherins are calcium-dependent cell-to-cell adhesion glycoproteins with critical roles in the 
formation and maintenance of normal tissue architecture [1-4], including in normal mamma-
ry gland [4-7]. E-cadherin (epithelial) and P-cadherin (placental), are the best characterised
members of the cadherin superfamily [8], similarly expressed in normal mammary epithe-
lium of different species, namely human [4,6,9-13], canine [14-17] and feline [18-20]: E-cad-
herin is expressed by luminal epithelial cells while P-cadherin is restricted to myoepithelial
cells. Changes in their expression have been observed in mammary tumours and related 
to mammary carcinogenesis, both in humans [5,9,11-13,21-27], dogs [14,16,17,28-30], as 
well as in cats [18-20,31,32]. Loss of expression and/or abnormal function of E-cadherin 
increase the ability of cells to invade neighbouring tissues, thus favouring mammary tumour 
progression and spread [4,13,33-35], whereas overexpression of P-cadherin is related to 
increased cell proliferation, motility, invasiveness, and metastatic progression, thus being 
considered an invasion-promoting protein in breast cancer [5,22,25,26,36-38]. Moreover, 
P-cadherin inhibition has anti-tumoural and anti-metastatic effects, suggesting that inter-
rupting the P-cadherin signalling pathway may be a novel therapeutic approach for breast 
cancer [5,39,40].
Mammary gland tumours are the third most common neoplasm in queens and have been 
proposed as excellent model for the study of human mammary carcinogenesis, due to his-
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topathological and clinical similarities with human breast cancer [41,42]. As opposed to the 
large body of knowledge on E- and P-cadherin expressions in human breast carcinomas, 
there are only a few studies of these molecules in feline mammary tumours [18-20,31,32,43], 
and their role is still poorly understood in this species. Studies on E-cadherin protein in 
feline mammary tumours demonstrated its reduction or absent expression in carcinomas 
when compared to benign lesions [18,19,31,32]. The prognostic value of this molecule in 
feline carcinomas is still controversial: while no statistically significant association between 
E-cadherin expression and tumour histological grade has been found [31], one study dem-
onstrated a negative correlation between E-cadherin expression and regional lymph node 
metastases at the time of diagnosis [31], however another revealed no correlation between 
the expression of E-cadherin and survival, recurrence or metastases [19].
To the best of our knowledge, only one study addressed the P-cadherin expression in feline 
mammary tumours, demonstrating that the protein is aberrantly expressed by neoplastic epi-
thelial cells in malignant tumours and significantly associated to high grade carcinomas [20]. 
The purposes of this study were to examine the expression of P-cadherin in a series of 
normal mammary gland tissues and spontaneous hyperplastic and tumour mammary le-
sions, and to determine its relationship with the expression of E-cadherin as well as tumour 
clinicopathological features with recognized prognostic value [44-49], namely neoplastic 
intravascular emboli and lymph node metastases.
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MATERIAL AND METHODS
Tissue samples
Samples from 75 queens with naturally occurring mammary lesions, surgically excised with 
curative intents, and nine normal mammary glands (obtained from queens that were hu-
manely euthanized for reasons not related to a neoplastic disease) were included in this 
study. In each case an informed consent was granted by the owners. All specimens were 
fixed in 10% neutral buffered formalin. After tissue dehydration and embedding in paraffin 
wax, sequential 2 μm sections were cut from each block. One section was stained with 
haematoxylin and eosin (HE) for routine histological examination and diagnosis, and sub-
sequent sections were used for immunohistochemical studies. When available, local and 
regional lymph nodes were processed and examined for the presence of metastases.
The histological classification of tumours was independently performed by three observers 
(ACF, PDP and FG) based on the criteria of the World Health Organization (WHO) for the 
histological classification of mammary tumours of domestic animals [50].
Carcinomas were graded in accordance with the Nottingham grading system for human 
breast carcinomas [51]. Grading was based on the assessment of three morphological 
features: degree of tubule formation, nuclear pleomorphism, and mitotic counts, and tu-
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mours were classified as grade I (well differentiated), grade II (moderately differentiated) 
and grade III (poorly differentiated) [51]. Variables with known prognostic value, such as the 
mode of growth (infiltrative or expansive), tumour largest diameter (<2 cm, 2–3 cm, >3 cm), 
presence of necrosis, skin ulceration, lymph node metastases, and presence of intravascu-
lar neoplastic emboli [41,44], were also recorded.
Evaluation of P-cadherin and E-cadherin immunohistochemistry labelling
Immunohistochemistry (IHC) was performed using a polymer based system (Novolink Max 
Polymer Detection System, Product No: RE7280-K Leica Biosystems, Newcastke, UK), 
according to the manufacturer’s instructions. Sections were dewaxed in xylene, rehydrated 
through graded alcohols and treated with extran for 10 minutes in microwave oven for an-
tigen retrieval. Endogenous peroxidase activity was blocked by treating the sections with 
hydrogen peroxide 3% in methanol for 10 minutes and rinsed in Tris-buffered saline (TBS, 
pH 7.6, 0.5 M). Sections were incubated overnight at 4°C in a humid chamber with a specific 
mouse anti-human monoclonal antibody against P-cadherin (clone 56, BD Transduction 
Laboratories, Lexington, Kentucky, USA) directed at the extracellular domain of this adhe-
sion molecule, and a specific mouse anti-monoclonal antibody against E-cadherin (clone 
4A2C7, Zymed/Invitrogen, Camarillo, CA, USA) that recognizes the cytoplasmic domain 
of this molecule. The antibodies were diluted 1:50 in TBS with 5% bovine serum albumin 
(BSA). Labelling was visualized with 3,3’-diaminobenzidine (DAB) incubated at room tem-
perature and sections were then counterstained with Mayer’s haematoxilin, dehydrated and 
mounted. For negative controls, the primary antibody was replaced by TBS. Sections of 
feline normal mammary gland were used as positive controls. In the sections of mammary 
lesions, adjacent normal mammary tissues or skin were also used as internal positive con-
trols.
In the lymph nodes sections, additional immunohistochemical analysis was performed in 
order to determine the presence of tumour cell micrometastases, as suggested by Matos 
et al. (2006) [52]. However, we used the antibody antipancytokeratin AE1/AE3 and anti-p63 
protein, since p63 protein is a sensitive and highly specific marker of myoepithelial cells 
[53].
Assessment of P-cadherin expression was based on a semi quantitative analysis, accord-
ing to the percentage of immunoreactive luminal epithelial cells with membranous and/or 
cytoplasmic patterns, and graded as 0 - <10%, 1 - 10-25%, 2 - 26-50% and 3 - >50%. For 
statistical analysis, cases with less than 10% positive luminal epithelial cells were consid-
ered negative and those with ≥10% stained cells were considered positive [16,20].
E-cadherin expression was assessed semi quantitatively in accordance with the percent-
age of immunoreactive luminal epithelial cells with membranous labelling, and graded as 
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0 - <25%, 1 - 25-50%, 2 - 51-75% and 3 - >75% [54]. Cases with >75% stained cells were 
considered to have preserved expression and those with ≤75% positive cells as having re-
duced expression of E-cadherin [55].
To evaluate the combined expression of P-cadherin and E-cadherin, samples were grouped 
according to the expression of both molecules as P
+
/E
+
, P
+
/E
−
, P
−
/E
+
, and P
−
/E
−
, (P
+
= P
−
cadherin positive; P
−
 = P-cadherin negative; E
+
 = Preserved E-cadherin; E
−
 = Reduced 
E-cadherin) [56].
Evaluation of P-cadherin and E-cadherin double-labelling 
immunofluorescence
Double-label immunofluorescence (DIF) was performed for simultaneous visualization of 
P- and E-cadherin expressions. Tissue sections of normal mammary gland, hyperplastic/
dysplastic lesions, benign and malignant mammary tumours were selected and sections 
with neoplastic intravascular emboli and lymph node metastases were also included.
Tissue sections were dewaxed in xylene, rehydrated through a series of graded alcohols 
and treated with extran for 10 minutes in microwave oven for antigen retrieval. Then, tis-
sues sections were blocked with 10% BSA for 20 minutes, followed by incubation with the 
primary antibodies mouse anti P-cadherin (mouse anti-human monoclonal antibody against 
P-cadherin, clone 56, BD Transduction Laboratories, Lexington, Kentucky, USA) and rabbit 
anti E-cadherin (rabbit anti-human monoclonal antibody against E-cadherin, clone 24E10, 
Cell Signaling Technology, MA, USA) diluted 1:50 and 1:100, respectively, in 5% BSA for 
two hours in a wet chamber. After washing in phosphate buffered saline (PBS), slides were 
incubated with Alexa Fluor® 488 goat anti-mouse IgG (A11029, Life Technology, Carlsbad, 
CA, USA) and Alexa Fluor® 594 goat anti-rabbit IgG (A11037, Life Technology, Carlsbad, 
CA, USA) secondary antibodies diluted 1:500 in 5% BSA, for one hour. Washes were per-
formed with PBS and slides incubated with 4,6-diamidine-2-phenylindolendihydrochoride 
(DAPI) 100 μg/mL for 15 minutes. Slides were mounted in glycerol-based Vectashield me-
dium (Vector, Burlingame, CA, USA).
Immunostained sections were analyzed by fluorescence microscopy (Zeiss Imager Z1 mi-
croscope) with appropriated filters. Separate images for Alexa 488 and Alexa 594 were 
captured at x200 magnification and then merged to allow for the visualization of P-cadherin 
and E-cadherin double immunostaining. For negative controls, the primary antibody was 
replaced by PBS.
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Statistical methods
Data was organized in contingency tables and the likelihood ratio chi-square test of asso-
ciations was used to determine the significance of the relationship between the expression 
of the cadherins and the tumours’ clinicopathological parameters. Whenever biologically 
consistent, 2x2 tables of contingency were built and Fisher’s exact test was performed. 
The odds ratio was calculated to estimate the relative risk of lymph node metastasis and 
neoplastic intravascular emboli in tumours expressing P- and E-cadherin molecules, with 
a confidence interval of 95%. All statistical analysis was performed using SAS/STAT, 1989 
(SAS Institute Inc., Cary, NC, USA) [57] and, in all instances, p <0.05 was considered to be 
statistically significant.
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RESULTS
The present study comprised 9 normal mammary gland samples, 13 hyperplastic/dysplastic le-
sions (7 fibrocystic diseases and 6 fibroadenomatous changes), 10 benign tumours (7 simple ad-
enomas and 3 fibroadenomas) and 60 malignant tumours (32 tubulopapillary carcinomas, 16 solid 
carcinomas, 4 cribriform carcinomas, 6 mucinous carcinomas and 2 carcinosarcomas). Seven 
malignant tumours were grade I, 25 grade II and 28 grade III. Twenty-one carcinomas (36.21%) 
had neoplastic intravascular emboli and, within the 35 cases where lymph nodes were available, 
18 (51.43%) had metastases.
P-Cadherin and E-cadherin expression by immunohistochemistry
In normal mammary tissue, the expression of P-cadherin was restricted to myoepithelial cells 
surrounding lobular and ductal structures (Figure 1Aa). However, in lobules with secretory activity 
P-cadherin was present in the cytoplasm of luminal epithelial cells as well as in the secretion.
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Figure 1 
P- and E-cadherin expression by immunohistochemistry (IHC) and by double-label immunofluores-
cence (DIF) in feline mammary tissue. 
A. P-cadherin immunohistochemistry (IHC) - (a) Normal mammary gland with strong expression of P-cadherin 
by myoepithelial cells and lack of immunoreactivity in luminal epithelial cells. x400; (b) Strong P-cadherin ex-
pression in high atypical neoplastic cells from a grade III tubulopapillary carcinoma. x200; (c) Neoplastic in-
travascular embolus showing strong P-cadherin expression. x400; (d) Lymph node metastases showing P-
cadherin expression by neoplastic cells. x100.
B. P- and E-cadherin double-label immunofluorescence (DIF) - (a) Normal mammary gland tissue with P-cad-
herin in myoepithelial cells (green colour) and E-cadherin in luminal epithelial cells (red colour). x200; (b) Tu-
bulopapillary carcinoma with tumour cell populations co-expressing P-cadherin and E-cadherin (yellow colour). 
x200; (c) Neoplastic intravascular embolus. x200. and (d) lymph node metastatic cells. x200. with a pattern of 
expression similar to primary malignant neoplasia, with tumour cell populations co-expressing P-cadherin and 
E-cadherin (yellow colour). 
A similar staining pattern to normal mammary tissue was evident in the majority (84.62%) of hyper-
plastic mammary lesions, although two fibroadenomatous changes exhibited P-cadherin expres-
sion in 10 to 25% of luminal epithelial cells. In benign tumours, P-cadherin was restricted to myo-
epithelial cells in most cases (70%). All 7 simple adenomas were P-cadherin negative while the 
three fibroadenomas were positive, one with 10-25% and the other two with 26-50% positive cells.
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Within the 60 malignant tumours, 48 (80%) had aberrant luminal epithelial P-cadherin ex-
pression (Figure 1Ab), most noticeable in the tumour periphery, in invasive clusters, in 
tubulopapillary areas and in the most atypical cells (large cells, with bizarre shapes, large 
nucleus, multiple nucleolus). In mucinous carcinomas, the cells surrounding mucus were P-
cadherin positive although the mucus itself was negative. P-cadherin expression was also 
observed in squamous cells, particularly in the most undifferentiated basal cells, and in the 
mesenchymal cells component of carcinosarcomas.
P-cadherin expression was analysed in the neoplastic intravascular emboli of 16 malig-
nant tumours (in 5 cases no representative sections for immunohistochemical evaluation 
were available) and 18 lymph node metastases. Amongst the former, 13 (81.25%) were 
P-cadherin positive (Figure 1Ac) and 17 (94.4%) of the later were also P-cadherin positive 
(Figure 1Ad).
E-cadherin was expressed at the membrane of more than 75% acinar and ductal luminal 
epithelial cells of normal mammary gland samples, while myoepithelial cells were E-cad-
herin negative. Eleven (84.6%) hyperplastic lesions preserved this pattern of expression, 
while two cases of fibrocystic disease had less than 75% positive cells. Benign tumours 
preserved E-cadherin expression by luminal epithelial cells, except in one simple adenoma 
where only 51-75% of the epithelial cells were stained. 
E-cadherin immunohistochemical expression was reduced in almost half (46.67%) of the 
malignant tumours. Five of the six mucinous carcinomas showed reduced E-cadherin ex-
pression, most obvious in the areas with mucus secretion; the mucus itself did not stain for 
E-cadherin. Squamous cells stained positive while mesenchymal and myoepithelial cells 
were negative to this protein.
Intravascular emboli of 17 malignant tumours were evaluated for E-cadherin expression (in 
four cases it was not possible to obtain representative sections for evaluation) and the pro-
tein was expressed by more than 75% cells in 13 cases (76.5%). More than half (55.6%) of 
the 18 lymph node metastases had more than 75% cells expressing E-cadherin.
P-Cadherin and E-cadherin expression by double-labelling 
immunofluorescence
The P-cadherin and E-cadherin double-labelling immunofluorescence analysis demonstrated 
that they were expressed in normal, hyperplastic and benign mammary tissues in different cell 
types, with luminal epithelial cells expressing E-cadherin, while myoepithelial/basal cells ex-
pressed P-cadherin (Figure 1Ba). In carcinomas it was possible to observe aberrant P-cadherin 
expression by luminal epithelial cells, frequently co-expressed with E-cadherin (Figure 1Bb), 
particularly at the peripheral invasive front. The same expression pattern was observed in the 
intravascular neoplastic emboli (Figure 1Bc) and in lymph node metastases (Figure 1Bd).
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Relationship between the expression of P-cadherin,  
E-cadherin and clinicopathological parameters
Benign and malignant tumours diverged significantly with respect to both P- and E-cadherin 
immunoexpression, with most of the malignant tumours (80%) overexpressing P-cadherin 
and the vast majority of the benign tumours (90%) preserving the expression of E-cadherin 
(Table 1). When the combined expression of P- and E-cadherin was considered, most (60%) 
of the benign tumours were P
−
/E
+
 while the most common pattern in malignant tumours was 
P
+
/E
−
 (41.67%).
Table 1. Cadherin expression profiles of benign and malignant tumours
 
Tumour type
 
n
P-cadherin E-cadherin P-cadherin/E-cadherin
Negative Positive Preserved Reduced +/+ +/– –/+ –/–
Benign 10 7 3 9 1 3 0 6 1
Malignant 60 12 48 32 28 23 25 9 3
p 0.0029 0.0384 0.0027
In malignant tumours, there was a statistically significant association between P-cadherin 
overexpression and higher histological grade, presence of necrosis, infiltrative mode of 
growth, and neoplastic intravascular emboli (Table 2). In the majority of malignant tumours, 
the expression of P-cadherin by neoplastic intravascular emboli and lymph node metastases 
was similar to that observed in corresponding primary tumours (81.25%, p=0.0012 and 
77.78%, p=0.0008, respectively). Furthermore, the expression of P-cadherin was associ-
ated to a nearly 8.5 odds ratio for vascular invasion.
The reduced expression of E-cadherin, although significantly related to the malignant his-
tological tumour type (p = 0.0243), was not related with the other parameters; neither there 
was a statistical significant association between the expression of E-cadherin in primary 
tumours and in their neoplastic intravascular emboli and lymph node metastases.
The P-cadherin/E-cadherin combined expression patterns were significantly associated 
with histological grade of carcinomas, mode of growth and presence of necrosis. In fact, 
71.4% of grade I tumours were P
−
/E
+
, while nearly 90% of grade II and III tumours (n=53) 
were P
+
/E
−
 (n = 25, 47.2%) or P
+
/E
+
 (n = 23, 43.4%). All tumours with expansive growth were 
P
−
/E
+
, a staining pattern that was present in less than 10% of the infiltrative ones. Half of the 
tumours with necrosis were P
+
/E
−
, while the most common pattern of non-necrotic cases 
was P
−
/E
+
 (41.67%).
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Table 2. Cadherin expression profiles and clinicopathological parameters  
of malignant tumours
Clinicopathological  
parameters
 
n
P-cadherin E-cadherin P-cadherin/E-cadherin
Negative Positive Preserved Reduced +/+ +/– –/+ –/–
Histological type
      Tubulopapillary carcinoma 
      Solid carcinoma 
      Cribriform carcinoma 
      Mucinous carcinoma 
      Carcinosarcoma
32
16
4
6
2
8
3
1
0
0
24
13
3
6
2
16
9
4
1
2
16
7
0
5
0
11
6
3
1
2
13
7
0
5
0
5
3
1
0
0
3
0
0
0
0
p NS 0.0243 NS
Histological grade*
      Grade I 
      Grade II 
      Grade III
7
25
28
7
2
3
0
23
25
5
12
12
2
13
13
0
10
13
0
13
12
5
2
2
2
0
1
p <0.0001 NS <0.0001
Mode of growth**
      Expansive 
      Infiltrative
3
56
3
6
0
48
3
28
0
28
0
23
0
25
2
5
0
3
p 0.0051 NS 0.0044
Tumour largest diameter
      <2 cm
      2–3 cm
      >3 cm
33
10
17
7
2
3
26
8
14
19
7
6
14
3
11
13
5
5
13
3
9
6
2
1
1
0
2
p NS NS NS
Ulceration
      Absent
      Present
48
12
10
2
38
10
27
5
21
7
19
4
19
6
8
1
2
1
p NS NS NS
Necrosis
      Absent
      Present
12
48
7
5
5
43
9
23
3
25
4
19
1
24
5
4
2
1
p 0.0010 NS 0.0026
Neoplastic intravascular emboli
      Absent
      Present
37
21
11
1
26
20
19
12
18
9
11
11
15
9
8
1
3
0
p 0.0401 NS NS
Odds ratio 8.4615 (1.0071-71.0959)
Lymph node metastases
      Absent
      Present
17
18
3
0
14
18
10
10
7
8
7
10
7
8
3
0
0
0
p NS NS NS
NS -not significant. 
*According to Elston & Ellis, (1998) [51]. 
**In one case the margins were not included in sample.
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DISCUSSION
In the present work, feline normal mammary tissue presented E-cadherin expression in 
luminal epithelial cells and P-cadherin in myoepithelial cells of lobular and ductal struc-
tures, without any evidence of overlapping between the two cadherins, similarly to what is 
described in normal mammary gland tissue in humans [4,6,9-13], dogs [14-17] and cats 
[18-20]. In lactating or pseudolactating mammary tissue, P-cadherin immunoreactivity was 
observed in the cytoplasm of luminal epithelial cells and in luminal secretion, in line with 
data from previous studies in human breast [58] and canine mammary gland [59]. It is be-
lieved that P-cadherin is not just an adhesion molecule, also acting as a signalling protein 
involved in breast tissue remodelling, and that its soluble fragment present in human milk 
may result from the proteolysis of the extracellular domain [58,59].
In this series, a significant overexpression of P-cadherin by luminal epithelial cells was ob-
served in carcinomas, when compared to benign mammary tumours. Furthermore, P-cad-
herin expression was positive in all mucinous carcinomas and carcinosarcomas a fact that 
points to a basal/myoepithelial cell histogenesis origin or line of differentiation of these tu-
mour types [16,60,61], since P-cadherin is a well-recognized biomarker of basal mammary 
carcinomas in humans [6,62-65]. However, the association between P-cadherin expression 
and the histological type of carcinomas was not achieved in the present study, has not been 
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yet demonstrated in humans [5] and is not consensual in other animal models such as dogs 
[16,56]. A significant association was found between P-cadherin expression and histologi-
cal grade of carcinomas, as previously reported by other authors in human breast cancer 
[11,21,23,24,26,27,62,66-68] and canine mammary tumours [16,56], suggesting that this 
molecule may be regarded as a prognostic indicator of aggressiveness in feline mammary 
carcinomas. Moreover, P-cadherin expression was more evident in the most periphery cells 
of the tumour and in the invasive clusters, denoting its importance in invasion and re-enforc-
ing its value as a marker of adverse behaviour in feline mammary carcinomas.
To the best of our knowledge, this is the first study addressing the association between the 
expression of P-cadherin and the invasive/metastatic capacity of feline mammary tumours. 
All tumours with lymph node metastases and all, except one, with evident neoplastic intra-
vascular emboli were P-cadherin positive, which indicates that the aberrant expression of P-
cadherin may constitute an important step in the invasion/metastatic process. This hypoth-
esis is reinforced by the fact that P-cadherin positive tumours were 8.46 times more likely to 
invade vessels than negative tumours. However, this result must be regarded with caution, 
since the wide confidence interval (CI) reveals a low precision of the estimate. Although in 
human breast cancer P-cadherin overexpression has been associated with decreased sur-
vival and relapse-free intervals [36,64], other studies failed to find a significant association 
between P-cadherin and lymph node metastases at the time of diagnosis [11,21,27]; how-
ever, Gamallo et al. (2001) found an association between P-cadherin expression and lymph 
node-positive breast tumours [26]. In this study we failed to establish a relationship between 
P-cadherin expression and lymph node metastases. Our findings suggest that, in spite of 
the importance of this cadherin in infiltrative/invasive process (increased cell motility, vas-
cular invasion), the arrest and establishment of neoplastic cells in sites of metastases may 
require the acquisition of other morphological and functional features, not so closely related 
to P-cadherin. To the best of our knowledge there are no survival studies in feline mammary 
tumours related with P-cadherin expression. 
Nearly half of the carcinomas included in this series exhibited reduced E-cadherin expres-
sion, a significant difference compared to benign tumours, where only one case showed E-
cadherin down-expression. An association was also established between specific histologi-
cal types of carcinomas and the E-cadherin expression pattern. All cribriform carcinomas 
and carcinosarcomas showed preserved E-cadherin expression, while the majority of mu-
cinous carcinomas had a reduced expression of the protein. In cats, E-cadherin expression 
has been documented to be reduced in tubulopapillary [19], cribriform and solid carcinomas 
[18], although the statistical significance of such associations has never been assessed. 
Moreover, several studies demonstrated that a reduced/loss membrane expression of E-
cadherin is significantly associated with histological types of mammary tumours, namely 
lobular carcinomas in women [9,10,13,69] and solid carcinomas in bitches [15,17,54,56,70]. 
In our study, E-cadherin expression was not related to histological grade of carcinomas. In 
fact, the association between this two factors is not consensual both in humans [9,10,71] 
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and dogs [54,56] and the studies performed in cats have not proved this association, to date 
[19,31].
In the present study, the expression of E-cadherin was not associated to the presence 
of neoplastic intravascular emboli and lymph node metastases, corroborating the human 
breast cancer [4,9,10,72-74] and feline mammary tumours [19,31] literature in which there 
is no consensus regarding the prognostic value of E-cadherin. Furthermore, and in accor-
dance with previous studies [72,75], the pattern of E-cadherin expression differ between pri-
mary tumours and their lymph node metastases, reinforcing the concept that, during breast 
carcinoma progression, there is a dynamic and reversible modulation of the E-cadherin 
complex [4,76,77].
When analysing the combined expression of P- and E-cadherin, two different patterns 
emerged: while 90% of the benign tumours preserved the expression of E-cadherin, irre-
spective of the P-cadherin status, 80% of the malignant tumours exhibited an overexpres-
sion of P-cadherin, independently of the E-cadherin staining pattern. These results suggest 
that the abnormal expression of P-cadherin is a better indicator of the malignant potential 
of feline mammary neoplasm than the loss of E-cadherin. Furthermore, the combined ex-
pression of P- and E-cadherin was significantly associated with the histological grade of 
the tumours, with the majority (90%) of grade II and III carcinomas exhibiting a P
+
/E
+
 or P
+
/
E
−
 immunophenotype. The fact that half of the grade III P
+
 malignant tumours were also 
E
+
 deserves the evaluation of the prognostic value of aberrant P-cadherin expression in a 
context of preserved E-cadherin expression through follow-up studies. Ribeiro et al. (2013) 
hypothesized that, in breast cancer cells, the E- and P-cadherin co-expression could be 
involved in a more aggressive biological behaviour, and that the establishment of strong 
adhesion complexes is compromised by the interaction of both molecules at the cell mem-
brane [74]. Moreover, they demonstrate that E
+
/P
+
 cells have deregulated cadherin/catenin 
complexes at the cellular membrane, when compared with cells expressing only one of the 
cadherins and have a higher invasive capacity [74]. In fact, P-cadherin overexpression in 
an E-cadherin wild type context leads to disruption of the interaction between E-cadherin 
and intracellular catenins, an alternative mechanism for cancer invasion [5,74,78,79]. The 
co-expression of both molecules was significantly correlated with high-grade, biologically 
aggressive, breast carcinomas and poor patient survival [5,39,74].
The association between P- and E-cadherin expression and four clinicopathological param-
eters with known prognostic value in feline mammary tumours, namely ulceration [46,47], 
necrosis [47], infiltrative growth [44], and tumour largest diameter [47-49], was also ad-
dressed in this study. Interestingly, the E- and P-cadherin immunostaining pattern observed 
in infiltrative carcinomas was very similar to the findings in grade III tumours, i.e. the ma-
jority expressing P-cadherin, and surprisingly, nearly half of the P
+
 infiltrative carcinomas 
preserved E-cadherin expression. This is in accordance with data from immunofluores-
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cence analysis that revealed P- and E-cadherin co-expression, particularly at the malignant 
tumour periphery. When considered together (neoplastic intravascular emboli and/or lymph 
node metastases), none of the invasive tumours was P
−
/E
−
, suggesting that the simple re-
duction of E-cadherin, when not accompanied by an aberrant expression of P-cadherin, is 
insufficient for an invasive tumour behaviour. Furthermore, more than half of the P-cadherin 
positive tumours associated with vascular emboli and lymph node metastases were also 
E-cadherin positive. In fact, in P
+
/E
+
 malignant tumours, double immunofluorescence evi-
denced a co-expression of the two cadherins, a pattern also observed in the intravascular 
neoplastic emboli and in lymph nodes metastatic cells. These results reinforce the need 
for the study of the prognostic value of P-cadherin positivity in tumours that preserve E-
cadherin expression in feline mammary species.
Besides its prognostic value, P-cadherin has been recently considered as a therapeutic 
target. A highly selective human monoclonal antibody against P-cadherin (PF-03732010, 
Pfizer, Inc) may constitute a novel anticancer therapy in high P-cadherin expressing tu-
mours [40]. Furthermore, azurin is pointed as a therapeutic tool for poor-prognosis breast 
carcinomas overexpressing P-cadherin in a wild type E-cadherin context [39]. Within this 
scenario, the highly aggressive P-cadherin positive feline mammary tumours with preserved 
E-cadherin expression may benefit from one of these novel therapeutic approaches.
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CONCLUSIONS
The present study demonstrated an association between the aberrant expression of P-
cadherin and a malignant phenotype, higher histological grade and invasive behaviour, sug-
gesting that this protein may constitute a reliable independent biomarker of poor prognosis 
in feline mammary tumours. Moreover, it suggests that P-cadherin aberrant expression may 
represent a relevant prognostic factor, being associated with an aggressive biological be-
haviour in feline mammary carcinomas, better than the reduction of E-cadherin expression. 
The prognostic value of P-cadherin expression in E-cadherin positive carcinomas in feline 
species should be evaluated in further investigation with follow-up studies.
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ABSTRACT
Background: Abnormal catenin expression has been related to mammary carcinogen-
esis in both human and canine species and they are considered tumour and invasion sup-
pressor molecules; however, in feline mammary tissues they have been scarcely studied. 
Materials and Methods: The immunohistochemical expression of α-, β- and p120-
catenin was studied in a series of normal feline mammary glands, hyperplastic/dysplastic 
lesions and benign and malignant mammary tumours. Their relationship with clinicopatho-
logical parameters and with E- and P-cadherin expression was assessed. 
Results: Normal tissues, hyperplastic/dysplastic lesions and benign tumours expressed 
α-, β- and p120-catenin in the membrane of more than 75% of the luminal epithelial cells, 
while in malignant tumours, there was a reduction in their membranous expression and 
a p120-catenin cytoplasmic expression in 40%. Reduced α- catenin expression was re-
lated to tumour features with prognostic value, namely tumour size (p=0.0203) and necrosis 
(p=0.0205). The expression of α-, β- and p120-catenin were individually related to each 
other and collectively associated with E-cadherin expression. 
Conclusions: The results demonstrate a relationship between feline mammary carci-
nogenesis and decreased expression of catenins, suggesting that they may represent a 
valuable tool in the diagnosis of feline mammary neoplasms. 
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BACKGROUND
Tumour progression depends on the ability of tumour cells to overcome cell–cell adhesion 
and to invade, metastasize, and colonize distant sites [1]. The cadherin–catenin complex, 
localized in the adherens junctions, is involved in cell-cell adhesion and the stability of this 
complex is required to maintain the integrity of epithelial tissues [2, 3]. There exists evi-
dence that the abnormal expression or function of the cadherin–catenin complex molecules 
results in decreased intercellular adhesion, tumour cell migration, invasion and metastatic 
dissemination in human breast cancer [3-6]. 
The classical E- and P-cadherin are transmembrane molecules responsible for calcium-
dependent cell–cell adhesion that have three distinct domains: i) an extracellular domain 
that contains five cadherin repeats and forms homophilic bonds with cadherins on adjacent 
cells; ii) a single-pass transmembrane domain; and iii) a highly conserved cytoplasmic do-
main that forms complexes with a group of proteins collectively known as catenins (α-, β-, 
γ- and p120-catenin) [1-3, 7]. Both β- and γ-catenin interact directly with the cytoplasmic 
carboxy-terminal catenin-binding domain of the cadherins in a mutually exclusive manner. 
α-Catenin is recruited to the complex through its interaction with β- or γ-catenin, linking 
the cadherin complex to the actin cytoskeleton, while p120-catenin connects directly to the 
juxtamembrane domain of the cytoplasmic tail of the cadherin molecules [2, 8]. 
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The three catenins have distinct functions: α-catenin in addition to linking to the actin network, 
plays an important role in the regulation of distinct signaling pathways involved in cell prolif-
eration, apoptosis, growth, migration and invasion, hence being considered a tumour sup-
pressor molecule [9, 10]; β-catenin is involved in cell–cell adhesion and cell signaling, as a 
member of the WNT/wingless signal transduction pathway [3], and in the regulation of the 
transcription of several proliferation and differentiation genes [11]; p120-catenin stabilizes 
the cadherin–catenin complex and modulates cadherin intracellular trafficking, stability, ad-
hesive capacity and cell motility [3, 12].
Although the expression of cadherins has been reported in canine and feline mammary tumours, 
to the best of our knowledge only β-catenin expression was studied in these species [13-19] 
and the characterization of the whole cadherin–catenin system in feline mammary carcino-
genesis has not yet been described. In this context, we assessed the immunoexpression 
of α-, β- and p120-catenin in a series of normal feline mammary glands, hyperplastic/dys-
plastic lesions and benign and malignant mammary tumours, as well as their relation with 
the expression of classical P- and Ecadherin and with clinicopathological parameters with 
recognized prognostic value.
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MATERIALS AND METHODS
Tissue samples
Samples from 75 queens with naturally-occurring mammary lesions, surgically excised with 
curative intent, and nine normal mammary glands (obtained from queens that were humanely 
euthanized for reasons unrelated to neoplastic disease) were included in this study. In each 
case, an informed consent was granted by the owners. All specimens were fixed in 10% neu-
tral buffered formalin and processed routinely. Consecutive histological sections (2 μm) were 
cut from each paraffin block. One was stained with haematoxylin and eosin (HE) for histologi-
cal examination, and the others were used for immunohistochemistry (IHC). When available, 
local and regional lymph nodes were also processed and examined for the presence of metas-
tases as described in Figueira et al. (2014) [20]. 
Histological classification of the tumours was performed independently by three observers 
(ACF, PDP and FG) based on the criteria of the World Health Organization (WHO) for the his-
tological classification of mammary tumours of domestic animals [21].
Carcinomas were graded in accordance with the Nottingham grading system for human 
breast carcinomas, based on the assessment of three morphological features: tubule for-
mation, nuclear pleomorphism, and mitotic counts, and tumours were classified as grade I 
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(well-differentiated), grade II (moderately differentiated) and grade III (poorly differentiated) 
[22]. Variables with known prognostic value, such as the mode of growth (infiltrative or ex-
pansive), tumour diameter (<2 cm, 2-3 cm, >3 cm), presence of necrosis, skin ulceration, 
lymph node metastases, and intravascular neoplastic emboli [23, 24] were also recorded.
α-, β- and p120-Catenin expression by immunohistochemistry
Immunohistochemistry was performed using a polymer-based system (Novolink Max Poly-
mer Detection System, Product No: RE7280-K; Leica Biosystems, Newcastle, UK), according 
to the manufacturer’s instructions. Sections were dewaxed in xylene and rehydrated through 
graded alcohols. Sections for β-catenin evaluation were treated with extran for 10 minutes in a 
microwave oven for antigen retrieval, while sections for α-catenin and p120-catenin evaluation 
were treated with 10 mM citrate buffer, pH 6.0, for 3 minutes in a pressure cooker. Endogenous 
peroxidase activity was blocked by treating the sections with 3% hydrogen peroxide in metha-
nol for 10 minutes and rinsing in Tris-buffered saline (TBS, pH 7.6, 0.5 M). Sections were incu-
bated overnight at 4˚C in a humid chamber with specific mouse monoclonal antibodies against 
human α-catenin (clone αCAT-7A4; Zymed/Invitrogen, Camarillo, CA, USA), β-catenin (clone 
CAT-5H10; Zymed/Invitrogen), and p120-catenin (clone 98/pp120; BD Transduction Laborato-
ries, Lexington, KY, USA). The antibodies were diluted 1:100, 1:300 and 1:1,000, respectively 
in TBS with 5% bovine serum albumin. Labelling was performed using 3,3’-diaminobenzidine 
at room temperature and sections were then counterstained with Mayer’s haematoxylin, dehy-
drated and mounted. For negative controls, the primary antibody was replaced by TBS. Sec-
tions of human normal mammary gland were used as positive controls. 
The immunoexpression evaluation of α-, β- and p120-catenin was assessed semiquantita-
tively according to the percentage of immunoreactive luminal epithelial cells with a mem-
branous pattern, and graded as 0: <25%; 1: 25-50%; 2: 51-75% and 3: >75%, adapted from 
Penafiel-Verdu et al. (2012) [18]. For statistical analysis, whenever >75% of luminal epithelial 
cells had membranous staining, the sample was considered to have preserved catenin ex-
pression, while all other cases were considered as having reduced expression. The staining 
pattern of primary tumours, lymph node metastases and intravascular neoplastic emboli 
was evaluated according to this described method.
The staining and evaluation methods for E- and P-cadherin expression were performed as 
described by Figueira et al. (2014) [20]. To evaluate the combined expression of E-cadherin 
and catenins, samples were grouped according to the pattern of E-cadherin expression, as 
preserved or reduced and to the pattern of catenin expression as preserved expression of 
all catenins or reduced expression of at least one catenin. 
117
Cadherin-catenin complex molecules in feline mammary tumours Chapter 04
Statistical methods
Data were organized in contingency tables and the likelihood ratio Chi-square test of asso-
ciations was used to determine the significance of the relationship between the expression 
of the catenins and the tumours’ clinicopathological parameters, as well as the cadherin 
expression. Whenever biologically consistent, 2x2 tables of contingency were built and 
Fisher’s exact test was performed. All statistical analysis was performed using SAS/STAT, 
1989 (SAS Institute Inc., Cary, NC, USA) [25] and, in all instances, p ≤ 0.05 was considered 
to be statistically significant.
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RESULTS
Nine normal mammary gland samples, 13 hyperplastic/ dysplastic lesions (7 fibrocystic 
disease cases and 6 of fibroadenomatous changes), 10 benign tumours (7 simple adeno-
mas and 3 fibroadenomas) and 60 malignant tumours (32 tubulopapillary carcinomas, 16 
solid carcinomas, 4 cribriform carcinomas, 6 mucinous carcinomas and 2 carcinosarcomas) 
were analyzed. Seven (11.67%) malignant tumours were grade I, 25 (41.67%) grade II and 
28 (46.67%) grade III. In 21 (36.21%) carcinomas, neoplastic intravascular emboli were 
observed and in 18 (51.43%) out of the 35 cases where lymph nodes were available, metas-
tases were identified. The P- and E-cadherin expression in this series has been previously 
analyzed and described by Figueira et al. (2014) [20].
Expression of α-catenin
In all normal mammary tissues, hyperplastic/dysplastic lesions, and benign tumours, α-catenin 
was expressed in the membrane of more than 75% of luminal epithelial cells (Figure 1a). The 
protein expression was reduced in 23 (38.33%) carcinomas (Figure 1b), a significant differ-
ence when compared with benign tumours (p=0.0245). Statistically significant relationships 
were also found between reduced α-catenin expression and larger tumour size (p=0.0203) 
and the presence of necrosis (p=0.0205) (Table 1). Almost two-thirds (64.7%) of tumours 
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larger than 3 cm had decreased α-catenin expression, while 72.1% of those of 3 cm or less 
had preserved the expression. The majority of non-necrotic carcinomas (91.7%) preserved 
α-catenin expression, while almost half of those with necrosis had reduced expression. 
There were no significant relationships between carcinoma α-catenin expression and histo-
logical type, grade or mode of growth, ulceration, neoplastic intravascular emboli or lymph 
node metastases (Table 1).
Table 1. Association of α-catenin, β-catenin and p120-catenin expression in malignant tumours 
with clinicopathological parameters
Clinicopathological  
parameter n
α-Catenin β-Catenin p120-Catenin
Preserved Reduced Preserved Reduced Preserved Reduced
Histological type
Tubulopapillary carcinoma
Solid carcinoma
Cribriforme carcinoma
Mucinous carcinoma
Carcinosarcoma
32
16
4
6
2
21 (65.63%)
9 (56.25%)
2 (50%)
4 (66.67%)
1 (50%)
11 (34.38%)
7 (43.75%)
2 (50%)
2 (33.33%)
1 (50%)
16 (50%)
9 (56.25%)
3 (75%)
3 (50%)
1 (50%)
16 (50%)
7 (43.75%)
1 (25%)
3 (50%)
1 (50%)
25 (78.13%)
11 (68.75%)
2 (50%)
3 (50%)
2 (100%)
7 (21.88%)
5 (31.25%)
2 (50%)
3 (50%)
0
p 0.9369 0.9052 0.3834
Histological grade
Grade I
Grade II
Grade III
7
25
28
6 (85.71%)
15 (60%)
16 (57.14%)
1 (14.29%)
10 (40%)
12 (42.86%)
5 (71.43%)
12 (48%)
15 (53.57%)
2 (28.57%)
13 (52%)
13 (46.43%)
7 (100%)
18 (72%)
18 (64.29%)
0
7 (28%)
10 (35.71%)
p 0.3254 0.5368 0.0678
Mode of growth
Expansive
Infiltrative
3
56
3 (100%)
33 (58.93%)
0
23 (41.07%)
1 (33.33%)
30 (53.57%)
2 (66.67%)
26 (46.43%)
3 (100%)
39 (69.64%)
0
17 (30.36%)
p 0.2741 0.5995 0.5498
Tumour largest diameter
<2 cm
2-3 cm
>3 cm
33
10
17
25 (75.76%)
6 (60%)
6 (35.29%)
8 (24.24%)
4 (40%)
11 (64.71%)
21 (63.64%)
6 (60%)
5 (29.41%)
12 (36.36%)
4 (40%)
12 (70.59%)
26 (78.79%)
6 (60%)
11 (64.71%)
7 (21.21%)
4 (40%)
6 (35.29%)
p 0.0203 0.0611 0.3890
Ulceration
Absent
Present
48
12
31 (64.58%)
6 (50%)
17 (35.42%)
6 (50%)
28 (58.33%)
4 (33.33%)
20 (41.67%)
8 (66.67%)
36 (75%)
7 (58.33%)
12 (25%)
5 (41.67%)
p 0.5081 0.1953 0.2930
Necrosis
Absent
Present
12
48
11 (91.67%)
26 (54.17%)
1 (8.33%)
22 (45.83%)
9 (75%)
23 (47.92%)
3 (25%)
25 (52.08%)
10 (83.33%)
33 (68.75%)
2 (16.67%)
15 (31.25%)
p 0.0205 0.1155 0.4793
Neoplastic intravascular emboli
Absent
Present
37
21
21 (56.76%)
14 (66.67%)
16 (43.24%)
7 (33.33%)
18 (48.65%)
13 (61.9%)
19 (51.35%)
8 (38.1%)
26 (70.27%)
16 (76.19%)
11 (29.73%)
5 (23.81%)
p 0.5794 0.4154 0.7636
Lymph node metastases
Absent
Present
17
18
14 (82.35%)
9 (50%)
3 (17.65%)
9 (50%)
10 (58.82%)
10 (55.56%)
7 (41.18%)
8 (44.44%)
13 (76.47%)
13 (72.22%)
4 (23.53%)
5 (27.78%)
p 0.0750 1.0000 1.0000
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Sixteen (88.89%) out of the 18 cases with neoplastic emboli (in three cases it was not 
possible to obtain representative sections for immunohistochemistry), exhibited preserved 
α-catenin expression (Figure 1c), while half of the 18 lymph node metastases also had pre-
served α-catenin expression (Figure 1d). The embolic and nodal metastatic patterns were 
unrelated to the expression of primary tumours. 
There was a significant direct relationship between the expression of α-catenin and E-
cadherin (p=0.0336), with preserved α-catenin expression in 75% of the carcinomas with 
preserved E-cadherin, and reduction in half of the tumours with reduced E-cadherin. No 
relationship was observed with the expression of P-cadherin (Table 2).
Expression of β-catenin
In normal mammary glands, hyperplastic/dysplastic lesions, and benign tumours, β-catenin 
was expressed in the membrane of more than 75% of luminal epithelial cells (Figure 1e), 
while 38 (46.67%) carcinomas had reduced β-catenin expression (Figure 1f), a significant 
difference when compared with benign tumours (p=0.0045). In addition, nuclear β-catenin 
expression was observed in three carcinomas. 
There were no statistical significant relationship between the expression of β-catenin and 
tumour histological type or grade, mode of growth, size, necrosis, or ulceration, nor with the 
presence of intravascular neoplastic emboli or lymph node metastases (Table 1). The majority 
of cases with evidence of neoplastic emboli (n=16/18; 88.89%) (in three cases it was not 
possible to obtain representative sections for immunohistochemistry) preserved β-catenin 
expression by intravascular neoplastic cells (Figure 1g), while eight (44.44%) out of the 18 
lymph node metastases had preserved β-catenin expression (Figure 1h). No significant 
relationships were established between the β-catenin expression pattern in the intravascular 
emboli and lymph node metastases and their primary tumours. There was no significant re-
lationship between the expression of β-catenin, P- and E-cadherin in carcinomas (Table 2).
Table 2. Association between expression of catenins and P- and E-cadherin in feline 
malignant mammary tumours
α-Catenin β-Catenin p120-Catenin
Reduced Preserved p Reduced Preserved p Reduced Preserved p
P-Cadherin
Positive
Negative
20 (41.67%)
3 (25%)
28 (58.33%)
9 (75%) 0.3404
23 (47.92%)
5 (41.67%)
25 (52.08%)
7 (58.33%) 0.7560
16 (33.33%)
1 (8.33%)
32 (66.67%)
11 (91.67%) 0.1505
E-Cadherin
Reduced
Preserved
15 (53.57%)
8 (25%)
13 (46.43%)
24 (75%) 0.0336
5 (71.43%)
12 (48%)
11 (39.29%)
21 (65.63%) 0.0687
14 (50%)
3 (9.38%)
14 (50%)
29 (90.63%) <0.001
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Expression of p120-catenin
In normal mammary tissues, hyperplastic/dysplastic lesions, and benign tumours, p120-
catenin was expressed in the membrane of more than 75% of the luminal epithelial cells 
(Figure 1i). In 17 (28.33%) carcinomas, there was a reduction in p120-catenin expression 
(Figure 1j), although this was not related to any of the evaluated clinicopathological pa-
rameters (Table 1). Nuclear p120-catenin expression was observed in three carcinomas 
and one case of fibrocystic disease (Figure 2a). Although diffuse cytoplasmic p120-catenin 
expression was also observed in 40% of carcinomas (Figure 2b), it was not significantly as-
sociated with clinicopathological parameters or cadherin expression.
From the 20 cases with evidence of neoplastic emboli (in one case it was not possible to ob-
tain representative sections for immunohistochemistry), the majority (n=18; 90%) exhibited 
preserved p120-catenin expression by intravascular neoplastic cells (Figure 1k), while 12 
(66.67%) out of the 18 lymph node metastases preserved p120-catenin expression (Figure 
1l).
There was a significant relationship between the protein expression in the primary tumours, 
their intravascular emboli (p=0.0316) and lymph node metastases (p=0.0217), all with pre-
served p120-catenin expression also exhibiting the same pattern in intravascular neoplastic 
cells (n=16; 100%), as well as in the majority of the lymph node metastases (n=11; 84.6%).
There was a significant relationship between the expression of p120-catenin and E-cadherin 
(p<0.001), with 90% of the malignant tumours with preserved E-cadherin also preserving 
p120-catenin. No relationship was demonstrated with the expression of P-cadherin (Table 2).
The expressions of α-, β- and p120-catenin in malignant tumours were individually related 
to each other. Moreover, most carcinomas (n=21; 60%) with reduced expression of at least 
one catenin also had reduced expression of E-cadherin, and the majority of the tumours 
with preserved expression of all catenins (n=18; 72%) also preserved E-cadherin expres-
sion (p=0.0191). Considering the four elements of the complex (E-cadherin, and α-, β-, and 
p120-catenin), most benign tumours (n=9; 90%) preserved expression of all molecules, while 
70% of the carcinomas had a reduction in at least one of the molecules that constitute the 
cadherin–catenin complex.
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Figure 1. 
α- β- and p120-catenin expression by immunohistochemistry (IHC) in feline mammary tissue. (a) Normal 
mammary gland with strong expression of α-catenin immunoreactivity in the membrane of luminal epithelial 
cells, x400. (b) Reduced membranous α-catenin expression in neoplastic cells in a grade II tubulopapillary car-
cinoma, x400. (c) Neoplastic intravascular embolus showing strong α-catenin expression, x400. (d) Lymph node 
metastases showing α-catenin expression in neoplastic cells, x400. (e) Normal mammary gland with strong 
expression of β-catenin immunoreactivity in the membrane of luminal epithelial cells, x400. (f) Reduced mem-
branous β-catenin expression in neoplastic cells in a grade II tubulopapillary carcinoma, x400. (g) Neoplastic in-
travascular embolus showing strong β-catenin expression, x400. (h) Lymph node metastases showing β-catenin 
expression in neoplastic cells, x400. (i) Normal mammary gland with strong expression of p120-catenin immu-
noreactivity in the membrane of luminal epithelial cells, x400. (j) Reduced membranous p120-catenin expres-
sion in the membrane of epithelial cells in a grade III solid carcinoma, x400. (k) Neoplastic intravascular embolus 
showing strong p120-catenin expresion, x400. (l) Lymph node metastases showing p120-catenin expression in 
neoplastic cells, x400. Bar=50 μm.
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Figure 2.
(a) Nuclear p120-catenin expression in a grade II tubulopapillary carcinoma as shown by immunohistochem-
istry. x400. (b) Diffuse cytoplasmic p120-catenin expression (*) in a grade III solid carcinoma as shown by im-
munohistochemistry. x400. Bar=50 μm.
124
Chapter 04 Cadherin-catenin complex molecules in feline mammary tumours
DISCUSSION
Numerous studies have reported the expression of the cadherin–catenin complex mole-
cules and their association with breast cancer [4-6]. Although E-cadherin is considered a 
tumour and metastasis suppressor [26], it is questionable that the single loss of E-cadherin 
explains the neoplastic or metastatic phenotype, as the loss of adhesiveness does not nec-
essarily induce cells to become motile or invasive [8]. Since E-cadherin function is regulated 
by catenins [26], combined studies of cadherins and catenins may add information to the 
characterization of this phenotype. Such studies are scarce for feline mammary tumours 
[18, 19] and, to the best of our knowledge, this is the first time that the major catenins and 
cadherins have been simultaneously evaluated in normal and neoplastic feline mammary 
tissue.
The present investigation documented consistent membranous expression of α-, β-, and 
p120-catenin in luminal epithelial cells of the normal feline mammary gland, reflecting the 
importance of catenins in the maintenance of the structural and functional integrity of the 
normal mammary tissue in this species, mimicking similar roles in human breast [4, 27, 28].
Hyperplastic/dysplastic lesions and benign tumours maintained a similar pattern, while 
nearly 60% of carcinomas exhibited reduced expression of the three catenins, suggesting 
that, as previously shown for human [4, 5, 29, 30] and canine [13-15, 17] species, their loss 
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contributes to the development of a malignant phenotype in queens. Our data support the 
widely accepted concept that the underexpression of cell adhesion molecules and loss of 
intercellular cohesion represent crucial events in the process of the typical architectural 
disorganization of mammary cancer [1, 3]. α-Catenin is able to inhibit tumour formation and 
progression by maintaining the integrity of the cadherin–catenin complex and by regulating 
several signalling pathways involved in tumourigenesis such as WNT/β-catenin, Hippo/Yes-
associated protein (Hippo-YAP), nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-kB), and Hedhehog pathways [10, 31]. Abnormal α-catenin expression (such as 
reduced membrane expression and cytoplasmic or nuclear location) has been described 
in breast cancer [4, 27, 32, 33]. Furthermore, several reports documented an association 
between down-regulation or loss of α-catenin in breast cancer and high tumour grade [10], 
metastasis [4, 10, 34] and poor survival [10], which raises the possibility that it may be con-
sidered a prognostic marker.
Our results also demonstrated a significant association between α-catenin expression and 
two parameters with known prognostic value, namely tumour size and necrosis. In larger 
tumours, a hostile metabolic microenvironment emerges, characterized by ischaemia, nutri-
ents and energy deprivation, as a result of the discrepancies between cancer cell multiplica-
tion and the slower development of the supporting vascular network. It is widely accepted 
that changes in the tumour microenvironment influence several steps of carcinogenesis 
and neoplastic spread, acting as a potent modulator in the progression of the disease [35]. 
Recently, Plumb et al. (2009) demonstrated that a stressful microenvironment contributes to 
the under-expression of α-catenin, being able to confer a selective survival and growth ad-
vantage to the neoplastic cells under ischaemic conditions [36]. Furthermore, a borderline 
association between reduced α-catenin expression and larger tumour size in breast cancer 
was described by Bukholm et al. (2006) [37]. Under such stressful conditions, the loss of 
α-catenin results in increased proliferation, decreased apoptosis and increased growth-
factor signalling, thus promoting faster tumour growth that can account for larger tumour 
volumes and ischaemic necrosis at diagnosis [31, 36].
In our series, a significant reduction in β-catenin expression was observed in carcinomas 
compared to benign tumours. A similar loss of membrane-bound β-catenin, as well as its 
cytoplasmic or nuclear expression, have been described in human [4, 11, 34], canine [15-
17] and feline [18, 19] mammary tumours. However, the prognostic value of β-catenin in 
human [4, 9, 34, 38] and canine [13-15] mammary tumours has not been clarified, with 
different studies revealing contradictory results. Similarly, this subject is not unequivocal 
in cats: while Penafiel-Verdu et al. (2012) associated preserved β-catenin expression with 
low-grade non-metastatic feline mammary carcinomas and its underexpression with meta-
static carcinomas [18], Zappulli et al. (2012) failed to demonstrate an association between 
reduced β-catenin expression and clinicopathological features with known prognostic value 
[19].
126
Chapter 04 Cadherin-catenin complex molecules in feline mammary tumours
Another interesting finding in this study relates to the subcellular p120-catenin location. 
While in normal mammary gland, hyperplastic and benign lesions p120-catenin was exclu-
sively membranous, in 40% of carcinomas it was also identified in the cytoplasm. Further-
more, nearly 96% (23/24) of mammary tumours with cytoplasmatic p120-catenin expres-
sion were moderate- or high-grade carcinomas. Although significant correlation between 
sub-cellular p120-catenin location and the histological grade of carcinomas was not estab-
lished, possibly due to the small number of tumours with this aberrant expression pattern, 
our data suggest that it may be relevant for the development and progression of feline 
mammary cancer. Previous reports on humans hypothesized that p120-catenin may play 
a dual role in breast carcinogenesis, acting as a tumour/metastasis suppressor as an ele-
ment of the cell membrane cadherin–catenin complex, and as an oncogene/metastasis 
promoter when translocated to the cytoplasm [8, 26]. Cytoplasmic p120-catenin interacts 
with members of the Rho family GTPases [8, 12, 39] that regulate cell shape, adhesion, 
migration and polarity, thus promoting the invasive behaviour of neoplasms [8, 40]. Its cyto-
plasmic translocation may also be responsible for structural changes in adherens junctions 
and disruption of actin filament organization, leading to significant modifications of cellular 
morphology and differentiation, hence justifying the higher histological grade of the lesions 
exhibiting this feature [39].
Expressions of α- and β-catenin in neoplastic intravascular emboli and lymph node metas-
tases were unrelated to their expression in corresponding primary tumours. In contrast, the 
expression pattern of p120-catenin in neoplastic emboli and lymph node metastases was 
very similar to that of the corresponding primary carcinomas. This finding corroborates the 
observations by Johnson et al. (2010) in breast cancer, where p120-catenin expression was 
maintained in distant metastases [40]. Our data suggest that the staining pattern of p120-
catenin is preserved during tumour progression, contradicting the previous concept that 
p120-catenin is lost during the metastatic process [5, 26].
In the course of metastasis, neoplastic cells must breakaway from the primary tumour, move 
into the surrounding stroma, invade the lymphatic or vascular circulation, and reestablish 
growth at a secondary site. In this process, the loss or reduction of intercellular adhesion 
molecules has been postulated to facilitate detachment from the primary mass. However, 
during transit through the circulation, cohesive cell migration seems to provide a survival 
advantage compared to that of single dissociated cells [41]. In fact, in approximately 90% 
of carcinomas with emboli, neoplastic intravascular cells preserve the expression of α-, β- 
and p120-catenin, irrespective of the expression in the primary tumour. This feature raises 
the possibility that the expression of the catenins in embolic cells may represent a strategy 
ensuring an effective spread of neoplastic cells. Cancer cells may migrate and invade both 
individually or as cohesive groups [42]. During group cell migration, the maintenance of 
epithelial characteristics, namely a preserved cell–cell adhesion system, provides the group 
with strong mechanical, structural and functional properties; this allows the group to operate 
as a unit, increasing the individual chances of survival and metastasis [42-44]. Our findings 
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emphasize this concept, suggesting that catenins may contribute to intercellular physical 
and functional cohesion within emboli. Once at metastatic sites, the suitability of the mi-
croenvironment is an important factor in determining whether colonization occurs or not. 
In the lymph node metastases, we observed that the expression was preserved in 50%, 
44.4% and 66.7% for α-, β- and p120-catenin, respectively. In order to overcome vascu-
lar extravasation, survive, proliferate and invade in a harsh microenvironment, metastatic 
cells undergo modifications that may include modifications of catenin expression that are 
advantageous for metastasized cells, such as the demonstrated association between un-
derexpression of α-catenin and increased proliferation, decreased apoptosis and survival in 
hostile microenvironments [36].
In 70% of the carcinomas included in this series, underexpression of at least one of the 
members of the E-cadherin–catenin complex was observed; supporting the concept that 
dysfunction of the cadherin–catenin adhesion system is intimately related to malignancy in 
feline mammary carcinogenesis. Moreover, we found that carcinomas with underexpression 
of E-cadherin frequently lose α- and p120-catenin expression. Concurrent loss of β- catenin 
was also observed, but this feature was not statistically significant. Considering that α-, β- 
and p120-catenin work together in the cadherin–catenin complex, it was not surprising that 
their expressions were individually related in our series of carcinomas, as has previously 
been described in breast cancer [4, 27].
Efforts to unveil the prognostic value of catenins in mammary carcinomas have not been 
conclusive in humans [29, 30, 38, 45], dogs [13-15] or cats [18, 19]. While some studies 
associated a down-regulation of catenins with metastatic disease and poor prognosis [4, 5, 
34, 45], others were unable to relate the expression of the catenins with traditional prognos-
tic indicators (lymph node status, tumour size, steroid receptor expression, age and overall 
survival) [9, 27, 28].
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CONCLUSIONS
This study describes membranous expression of α-, β- and p120-catenin in the luminal 
epithelium of normal feline mammary glands and demonstrates an association between 
decreased expression of these adhesion molecules and carcinogenesis in this species. 
In fact, underexpression of catenins was observed only in carcinomas, suggesting that 
catenins may represent a valuable tool assessing in the diagnosis of mammary neoplasm 
in queens.
Furthermore, data from this investigation point to the importance of the E-cadherin–catenin 
complex in mammary carcinogenesis in feline species. However, the prognostic value of 
these cell adhesion molecules seems to be limited in cats. Further prospective studies, with 
larger series of mammary carcinomas and of different carcinoma grades and types, as well 
as functional molecular studies, are warranted to evaluate the importance of the cadherin–
catenin complex in feline mammary carcinogenesis, as well as its prognostic relevance.
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ABSTRACT
Background: The need of reliable prognostic markers and promising therapeutic ap-
proaches to feline mammary carcinomas, has led to an intensive research aiming to accom-
plish a molecular characterization of feline mammary tumours that reflects their biological 
behaviour, similarly to what has been previously performed in human breast cancer.
Materials and Methods: The aim of this study was to characterize by immunohisto-
chemistry the molecular markers of normal mammary gland, hyperplastic/dysplastic mam-
mary lesions, and benign and malignant feline mammary tumours applying phenotypical 
molecular markers (AE1/AE3, vimentin, p63), hormonal receptor status (ER, PR) and mark-
ers of proliferative activity (Ki-67), as well as the classical cadherins P- and E-cadherin 
expression. 
Results: In feline mammary carcinomas there was overexpression of vimentin and p63, 
higher proliferation index and a reduction of estrogen receptors expression, when com-
pared with benign tumours. Carcinomas that were simultaneously P-cadherin-positive, 
vimentin-positive and oestrogen negative were associated to a higher histological grade. 
Moreover, P-cadherin and vimentin positive tumours were also associated to the presence 
of neoplastic emboli, presenting a threefold likelihood of intravascular dissemination than 
negative tumours.
Conclusions: P-cadherin, vimentin and ER expression seem to be relevant molecular 
markers in feline mammary carcinomas associated with a more aggressive behaviour.
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BACKGROUND
Mammary tumours are the third most common neoplasm in queens, with more than 90% 
classified as malignant. The prognosis is guarded for most cases, with a mean post-diag-
nosis survival time of 10-12 months, and death or euthanasia mainly attributable to local 
recurrence or metastasis [1, 2]. Several features have been studied as prognostic indicators 
in feline mammary tumours, including clinical features such as tumour size, lymph node 
status, and metastases; pathological features, namely histological grade; and molecular 
markers, such as cell-cycle associated molecules, oestrogen and progesterone receptors 
(ER and PR), cell adhesion molecules, among others [3-8]. Currently, lymph node involve-
ment, lymphovascular invasion, and tumour histological grade are the most widely accept-
ed prognostic parameters [9]. Constitutional and functional changes of cell–cell adhesion 
molecules, such as E- and P-cadherin, have been implicated in the progression of human 
breast cancer and related to a more aggressive behaviour and poor prognosis [10-14], and 
changes of the expression of E- and P-cadherin are associated with feline mammary carci-
nogenesis [7, 15-19]. 
The search for prognostic and predictive factors has led to development of studies direct-
ed to molecular and immunophenotypic markers in order to classify feline mammary tu-
mours more accurately, and provide additional information in terms of diagnosis, prognosis 
and therapeutic targets [20-22], similarly to what has previously been performed in human 
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breast cancer [23, 24]. The identification of those molecular markers in carcinogenesis re-
quires the knowledge of the pathways involved in the process, not only in laboratory models 
but also in spontaneous cases, both for the benefit of the animals and humans affected by 
cancers with similar development and clinical behaviour. Feline mammary tumours have 
been pointed as suitable spontaneous animal model for some sub-types of human breast 
cancer, thus our aim was to evaluate, by immunohistochemistry, samples of normal, and 
hyperplastic/dysplastic mammary tissue, benign and malignant feline mammary tumours 
using phenotypical markers (AE1/AE3, vimentin, p63), hormone receptors (ER, PR) and 
cell-cycle associated molecules (Ki-67), as well as cell adhesion molecules (namely P- and 
E-cadherin), in order to contribute to the molecular characterization of feline mammary tu-
mours, enhancing their value as models of human breast cancer. 
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MATERIALS AND METHODS
Tissue samples
Samples from 75 queens with naturally occurring mammary lesions surgically excised with 
curative intent and nine normal mammary glands (obtained from queens that were hu-
manely euthanized for reasons unrelated to neoplastic disease) were included in this study. 
In each case, an informed consent was granted by the owners. All specimens were fixed in 
10% neutral buffered formalin and routinely processed. Consecutive histological sections (2 
µm) were cut from each paraffin block. One was stained with haematoxylin and eosin (HE) 
for histological examination, and the others were used for immunohistochemistry (IHC). 
When available, local and regional lymph nodes were also processed and examined for the 
presence of metastases as described in Figueira et al. [19].
The histological classification of the tumours was performed independently by three observ-
ers (ACF, PDP and FG) based on the criteria of the World Health Organization (WHO) for 
the histological classification of mammary tumours of domestic animals [25]. 
Carcinomas were graded in accordance with the Nottingham grading system for human 
breast carcinomas, based on the assessment of three morphological features: tubule for-
mation, nuclear pleomorphism, and mitotic counts, and classified as grade I (well-differenti-
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ated), grade II (moderately differentiated) and grade III (poorly differentiated) [26]. Variables 
with known prognostic value, such as mode of growth (infiltrative or expansive), tumour 
diameter (<2 cm, 2-3 cm, >3 cm), presence of necrosis, skin ulceration, lymph node metas-
tases, and intravascular neoplastic emboli [2, 27] were also recorded.
Immunoexpression
Immunohistochemistry (IHC) was performed using a polymer-based system (Novolink Max 
Polymer Detection System, Product No: RE7280-K Leica Biosystems, Newcastle, UK), ac-
cording to the manufacturer’s instructions. Sections were dewaxed in xylene, rehydrated 
through graded alcohols and treated with 10mM citrate buffer, pH 6.0, for 3 minutes in a 
pressure cooker. Endogenous peroxidase activity was blocked by treating the sections with 
3% hydrogen peroxide in methanol for 10 minutes and rinsing in Tris-buffered saline (TBS, 
pH 7.6, 0.5 M). Sections were incubated overnight at 4ºC in a humid chamber with specific 
mouse monoclonal antibodies against human pan-cytokeratin AE1/AE3 (clone AE1/AE3, 
Zymed/Invitrogen, Camarillo, CA, USA), vimentin (clone V9, Dako, Gostrup, Denmark), p63 
(clone 4A4, Thermo Scientific, Fremont, USA), ER (clone 6F11, Novocastra, Newcastle 
Upon Tyne, United Kingdom), PR (clone 1A6, Novocastra, Newcastle Upon Tyne, United 
Kingdom), and Ki-67 (clone MIB-1, DakoCytomation, Denmark). Antibodies were diluted 
1:300, 1:500, 1:200, 1:40, 1:40 and 1:50, respectively, in TBS with 5% bovine serum albu-
min (BSA). Immunolabelling was detected with 3,3’-diaminobenzidine tetrahydrochloride 
(DAB) incubated at room temperature and sections were then counterstained with Mayer’s 
haematoxilin, dehydrated and mounted. For negative controls, the primary antibody was re-
placed by TBS. Sections of feline normal mammary glands were used as positive controls. 
Evaluation of immunolabelling
All samples were evaluated regarding the expression of pan-cytokeratin AE1/AE3 (epitheli-
al cells), vimentin (mesenchymal cells), and p63 (myoepithelial cells) for phenotypical char-
acterization. Positivity was indicated by the presence of distinct dark brown nuclear (p63), 
cytoplasmic (vimentin) or cytoplasmic and/or membranous (AE1/AE3) staining. 
The AE1/AE3 imunoexpression was considered reduced when less than 75% of the epithe-
lial cells were stained. Vimentin and p63 were considered overexpressed when epithelial 
cells showed cytoplasmic and nuclear staining, respectively. For data analysis, tumours 
with less than 10% positive cells were considered negative and those with ≥10% stained 
cells were considered positive (adapted from [28-30]) .
The assessment of ER and PR was also based on a semi quantitative analysis, according 
to the percentage of stained nuclei and the intensity of staining. The percentage of tumour 
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cells with nuclear staining (proportion score, PS) was graded as 0 - < 5%; 1 - 5–19%; 2 
- 20–60%, and 3 > 60%. The staining intensity (intensity score, IS) was estimated accord-
ing to the average staining intensity of positive cells and scored as 0 = negative, 1 = light 
staining, 2 = moderate staining, 3 = strong staining. PS and IS were added to obtain a total 
hormone-receptor score (TS) (range 0–6). Tumours were considered hormone-receptor 
positive when PS was ≥ 1 and TS ≥ 2 [31]. 
The proliferation activity was determined by assessing the Ki-67 index [32], determined 
by counting 1000 neoplastic cells, in 10 representative fields, at high magnification (40x 
objective) and expressing the percentage of positive cells (nuclear staining, regardless of 
the intensity) [6, 33]. For statistical analysis, tumours were grouped according to quartiles, 
following the approach of Castagnaro et al. (1998) [6]. 
The staining and evaluation method for the expression of P- and E-cadherin was previously 
described [19]. 
Statistical Methods
Data was organized in contingency tables and the likelihood ratio chi-square test was used 
to determine the significance of the relationship between the expression of the catenins and 
the tumours’ clinicopathological parameters as well as the cadherins expression. When-
ever biologically consistent, 2x2 tables of contingency were built and Fisher´s exact test 
was performed. All statistical analysis was performed using SAS/STAT, 1989 (SAS Institute 
Inc., Cary, NC, USA) [34] and, in all instances, p < 0.05 was considered to be statistically 
significant. 
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RESULTS
Nine normal mammary gland samples, 13 hyperplastic/dysplastic lesions (seven fibrocys-
tic disease cases and six fibroadenomatous changes), 10 benign tumours (seven simple 
adenomas and three fibroadenomas) and 60 malignant tumours (32 tubulopapillary car-
cinomas, 16 solid carcinomas, four cribriform carcinomas, six mucinous carcinomas and 
two carcinosarcomas) were analysed. Seven (11.67%) malignant tumours were grade I, 25 
(41.67%) grade II and 28 (46.67%) grade III. Neoplastic intravascular emboli were observed 
in 21 (36.21%) carcinomas, while lymph node metastases were identified in 18/35 (51.43%) 
cases with available lymph nodes. The expression of P- and E-cadherin in this series was 
previously described [19].
AE1/AE3
In normal mammary tissues, pan-cytokeratin AE1/AE3 was expressed in the membrane 
and cytoplasm of luminal epithelial cells, with a lighter staining in myoepithelial cells. A simi-
lar pattern was observed in hyperplastic/dysplastic lesions, benign and malignant tumours, 
with the exception of a reduced expression in five (8.33%) carcinomas. Both intravascular 
emboli and lymph node metastases were positive to AE1/AE3, with only one lymph node 
metastasis revealing less than 75% of positive metastatic cells. 
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Vimentin
In normal mammary tissues, the expression of vimentin was present in myoepithelial and 
mesenchymal cells, as well as in the luminal compartment of the ducts. Similar patterns 
were observed in hyperplastic/dysplastic lesions and benign tumours, with the exception 
of the fibroadenomatous changes cases where we observed a cytoplasmic expression in 
more than 10% of the ductal and acinar epithelial cells. In the two carcinosarcomas, the 
sarcomatous component was vimentin positive and cytokeratin negative.
An overexpression of vimentin was observed in the cytoplasm of neoplastic epithelial cells 
in 35 (58.33%) carcinomas, a significant difference when compared with benign tumours 
(p<0.0001) (Figure 1a and 1b) (Figure 2).
Moreover, a significant association was found between the overexpression of vimentin and 
the histological grade of carcinomas (p=0.0318), with no immunoreactivity observed in most 
low-grade carcinomas (n=6; 85.71%) and positivity in nearly two-thirds of moderate and 
high grade carcinomas (n=34; 64.15%) (Table 1). There was a significant direct association 
between the overexpression of vimentin and P-cadherin in the epithelial cells of malignant 
tumours (p<0.0001) (Table 2), and those that expressed both proteins were significantly 
related with the presence of intravascular neoplastic emboli (p=0.0307). Although there was 
no direct association between the expression of vimentin and E-cadherin, the combined 
expression of P- and E-cadherin was statistically related with the expression of vimentin, 
with P-cad+/E-cad- being the most predominant pattern (n=20; 57.14%) amongst vimentin-
positive tumours. Vimentin expression in primary tumours was not always consistent with 
the expression observed in the intravascular neoplastic emboli and in corresponding lymph 
node metastasis (Table 3). 
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Figure 1. Vimentin, p63, estrogen receptor, progesterone receptor and Ki-67 expression by immuno-
histochemistry in feline mammary carcinomas. (a) Vimentin expression in more than 50% of the epithelial 
neoplastic cells of a grade III tubulopapillary carcinoma. x100; (b) Detail of the increased vimentin expression. 
x400; (c) p63 expression in the epithelial cells of a grade III mucinous carcinoma. x100; (d) Detail of the p63 
overexpression. x400; (e) Estrogen receptor negative grade II cribriform carcinoma (*positive internal control). 
x200; (f) Detail of the negative estrogen receptor carcinoma x400; (g) Progesterone receptor reduction in a 
grade III solid carcinoma. x200; (h) Detail of the PR expression x400. (i) Ki-67 high expression in a grade III solid 
carcinoma. x100 (j) Detail of the Ki-67 expression: x400.
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Figure 2. Pan-cytokeratin AE1AE3 (a) and vimentin (b) co-expression in a grade III tubulopapillary carcinoma. 
IHC. x200.
P63
In normal mammary tissues, hyperplastic/dysplastic lesions and benign tumours, the ex-
pression of p63 was restricted to the nuclei of myoepithelial cells, while luminal epithelium 
was consistently negative. 
In malignant tumours, p63-positive myoepithelial cells were identified surrounding some 
areas of epithelial tumour cells. P63 immunostainning was also found in the squamous 
metaplastic (basal and parabasal) carcinoma cells. In three malignant tumours, p63 immu-
noexpression revealed the existence of a myoepithelial cell phenotype not easily identified 
by routine HE evaluation.
P63 expression was also observed, albeit less intense than in myoepithelial cells, in the 
nuclei of epithelial cells in 23 (38.33%) carcinomas (Figure 1c and 1d), significantly different 
when compared to benign tumours (p=0.0245). There was a significant direct relationship 
between p63 aberrant expression and the histological grade of carcinomas (p=0.0072), with 
all grade I tumours being p63-negative and more than half (n=15; 53.57%) of grade III being 
p63-positive (Table 1). Furthermore, significant p63 expression differences were observed 
between different histological types (p=0.0026), with both carcinosarcomas, most muci-
nous carcinomas, and half of the solid carcinomas being p63-positive, while all cribriform 
and three quarters of the tubulopapillary carcinomas were p63-negative (Table 1). The vast 
majority of P-cadherin-negative tumours were also p63-negative (p=0.0205), but there was 
no significant association between the expression of p63 and E-cadherin. When the P- and 
E-cadherin combined expression was considered, P+/E- was the most predominant pattern 
(n=13; 56.52%) amongst the p63-positive tumours. 
In the vast majority of cases, p63 was similarly expressed by primary tumours and their 
intravascular neoplastic emboli and lymph node metastases (Table 3). 
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Table 1. Association between vimentin, p63, PR, ER expression, Ki-67 index and clinicopathological                 parameters in feline malignant mammary tumours       
Clinicopathological parameters n
Vimentin p63 ER*  ER*  PR Ki-67 index*
Positive Negative Positive Negative Negative Positive Negative Positive <47.46% 47.46-61.1% 61.1-74.8% >74.8%
Histological type         
Tubulopapillary carcinoma 32 17 (53.13%) 15 (46.88%) 8 (25%) 24 (75%) 21 (65.63%) 11 (34.38%) 8 (25%) 24 (75%) 10 (31.25%) 7 (21.88%) 7 (21.88%) 8 (25%)
Solid carcinoma 16 9 (56.25%) 7 (43.75%) 8 (50%) 8 (50%) 12 (80%) 3 (20%) 4 (25%) 12 (75%) 3 (20%) 4 (26.67%) 5 (33.33%) 3 (20%)
Cribriform carcinoma 4 3 (75%) 1 (25%) 0 4 (100%) 3 (75%) 1 (25%) 0 4 (100%) 1 (25%) 2 (50%) 0 1 (25%)
Mucinous carcinoma 6 5 (83.33%) 1 (16.67%) 5 (83.33%) 1 (16.67%) 6 (100%) 0 0 6 (100%) 0 1 (16.67%) 3 (50%) 2 (33.33%)
Carcinosarcoma 2 1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 0 0 1 (50%) 0 1 (50%)
P NS 0.0026 NS NS 0.0243 NS
Histological grade        
Grade I 7 1  (14.29%) 6 (85.71%) 0 7 (100%) 1 (14.29%) 6 (85.71%) 2 (28.57%) 5 (71.43%) 7 (100%) 0 0 0
Grade II 25 17 (68%) 8 (32%) 8 (32%) 17 (68%) 21 (84%) 4 (16%) 4 (16%) 21 (84%) 2 (8%) 9 (36%) 7 (28%) 7 (28%)
Grade III 28 17 (60.71%) 11 (39.29%) 15 (53.57%) 13 (46.43%) 21 (77.78%) 6 (22.22%) 8 (28.57%) 20 (71.43%) 5 (18.52%) 6 (22.22%) 8 (29.63%) 8 (29.63%)
P 0.0318 0.0072 0.0018 0.0018 NS 0.0003
Mode of growth        
Expansive 3 0 3 (100%) 0 3 (100%) 1 (33.33%) 2 (66.67%) 0 3 (100%) 1 (33.33%) 1 (33.33%) 0 1 (33.33%)
Infiltrative 56 34 (60.71%) 22 (39.29%) 23 (41.07%) 33 (58.93%) 42 (76.36%) 13 (23.64%) 13 (23.21%) 43 (76.79%) 12 (21.82%) 14 (25.45%) 15 (27.27%) 14 (25.45%)
P NS NS NS NS NS NS
Tumour largest diameter        
<2 cm 33 17 (51.52%) 16 (48.48%) 11 (33.33%) 22 (66.67%) 21 (65.63%) 11 (34.38%) 7 (21.21%) 26 (78.79%) 6 (18.75%) 12 (37.5%) 8 (25%) 6 (18.75%)
2-3 cm 10 7 (70%) 3 (30%) 5 (50%) 5 (50%) 8 ( 80%) 2 (20%) 2 (20%) 8 (80%) 2 (20%) 2 (20%) 3 (30%) 3 (30%)
>3 cm 17 11 (64.71%) 6 (35.29%) 7 (41.18%) 10 (58.82%) 14 (82.35%) 3 (17.65%) 5 (29.41%) 12 (70.59%) 6 (35.29%) 1 (5.88%) 4 (23.53%) 6 (35.29%)
P NS NS NS NS NS NS
Ulceration        
Absent 48 26 (54.17%) 22 (45.83%) 16 (33.33%) 32 (66.67%) 33 (70.21%) 14 (29.79%) 9 (18.75%) 39 (81.25%) 12 (25.53%) 13 (27.66%) 11 (23.4%) 11 (23.4%)
Present 12 9 (75%) 3 (25%) 7 (58.33%) 5 (41.67%) 10 (83.33%) 2 (16.67%) 5 (41.67%) 7(58.33%) 2 (16.67%) 2 (16.67%) 4 (33.33%) 4 (33.33%)
P NS NS NS NS NS NS
Necrosis        
Absent 12 5 (41.67%) 7 (58.33%) 1 (8.33%) 11 (91.67%) 5 (45.45%) 6 (54.55%) 3 (25%) 9 (75%) 5 (45.45%) 1 (9.09%) 4 (36.36%) 1 (9.09%)
Present 48 30 (62.50%) 18 (37.50%) 22 (45.83%) 26 (54.17%) 38 (79.17%) 10 (20.83%) 11 (22.92%) 37 (77.08%) 9 (18.75%) 14 (29.17%) 11 (22.92%) 14 (29.17%)
P NS 0,0205 NS NS NS NS
Neoplastic intravascular emboli        
Absent 37 18 (48.65%) 19 (51.35%) 12 (32.43%) 25 (67.57%) 25 (67.57%) 12 (32.43%) 10 (27.03%) 27 (72.97%) 11 (29.73%) 8 (21.62%) 7 (18.92%) 11 (29.73%)
Present 21 16 (76.19%) 5 (23.81%) 10 (47.62%) 11 (52.38%) 16 (80%) 4 (20%) 4 (19.05%) 17 (80.95%) 3 (15%) 7 (35%) 6 (30%) 4 (20%)
P NS NS NS NS NS NS
Lymph node metastases        
Absent 17 10 (58.82%) 7 (41.18%) 5 (29.41%) 12 (70.59%) 12 (70.59%) 5 (29.41%) 2 (11.76%) 15 (88.24%) 5 (29.41%) 2 (11.76%) 6 (35.29%) 4 (23.53%)
Present 18 13 (72.22%) 5 (27.78%) 9 (50%) 9 (50%) 13 (76.47%) 4 (23.53%) 6 (33.33%) 12 (66.67%) 3 (17.65%) 6 (35.29%) 4 (23.53%) 4 (23.53%)
P   NS NS NS NS NS NS
P- probability value. 
NS -not significant.
* - one case was excluded because there was no positive stainning in the internal poistive control of the sample.
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Table 1. Association between vimentin, p63, PR, ER expression, Ki-67 index and clinicopathological                 parameters in feline malignant mammary tumours       
Clinicopathological parameters n
Vimentin p63 ER*  ER*  PR Ki-67 index*
Positive Negative Positive Negative Negative Positive Negative Positive <47.46% 47.46-61.1% 61.1-74.8% >74.8%
Histological type         
Tubulopapillary carcinoma 32 17 (53.13%) 15 (46.88%) 8 (25%) 24 (75%) 21 (65.63%) 11 (34.38%) 8 (25%) 24 (75%) 10 (31.25%) 7 (21.88%) 7 (21.88%) 8 (25%)
Solid carcinoma 16 9 (56.25%) 7 (43.75%) 8 (50%) 8 (50%) 12 (80%) 3 (20%) 4 (25%) 12 (75%) 3 (20%) 4 (26.67%) 5 (33.33%) 3 (20%)
Cribriform carcinoma 4 3 (75%) 1 (25%) 0 4 (100%) 3 (75%) 1 (25%) 0 4 (100%) 1 (25%) 2 (50%) 0 1 (25%)
Mucinous carcinoma 6 5 (83.33%) 1 (16.67%) 5 (83.33%) 1 (16.67%) 6 (100%) 0 0 6 (100%) 0 1 (16.67%) 3 (50%) 2 (33.33%)
Carcinosarcoma 2 1 (50%) 1 (50%) 2 (100%) 0 1 (50%) 1 (50%) 2 (100%) 0 0 1 (50%) 0 1 (50%)
P NS 0.0026 NS NS 0.0243 NS
Histological grade        
Grade I 7 1  (14.29%) 6 (85.71%) 0 7 (100%) 1 (14.29%) 6 (85.71%) 2 (28.57%) 5 (71.43%) 7 (100%) 0 0 0
Grade II 25 17 (68%) 8 (32%) 8 (32%) 17 (68%) 21 (84%) 4 (16%) 4 (16%) 21 (84%) 2 (8%) 9 (36%) 7 (28%) 7 (28%)
Grade III 28 17 (60.71%) 11 (39.29%) 15 (53.57%) 13 (46.43%) 21 (77.78%) 6 (22.22%) 8 (28.57%) 20 (71.43%) 5 (18.52%) 6 (22.22%) 8 (29.63%) 8 (29.63%)
P 0.0318 0.0072 0.0018 0.0018 NS 0.0003
Mode of growth        
Expansive 3 0 3 (100%) 0 3 (100%) 1 (33.33%) 2 (66.67%) 0 3 (100%) 1 (33.33%) 1 (33.33%) 0 1 (33.33%)
Infiltrative 56 34 (60.71%) 22 (39.29%) 23 (41.07%) 33 (58.93%) 42 (76.36%) 13 (23.64%) 13 (23.21%) 43 (76.79%) 12 (21.82%) 14 (25.45%) 15 (27.27%) 14 (25.45%)
P NS NS NS NS NS NS
Tumour largest diameter        
<2 cm 33 17 (51.52%) 16 (48.48%) 11 (33.33%) 22 (66.67%) 21 (65.63%) 11 (34.38%) 7 (21.21%) 26 (78.79%) 6 (18.75%) 12 (37.5%) 8 (25%) 6 (18.75%)
2-3 cm 10 7 (70%) 3 (30%) 5 (50%) 5 (50%) 8 ( 80%) 2 (20%) 2 (20%) 8 (80%) 2 (20%) 2 (20%) 3 (30%) 3 (30%)
>3 cm 17 11 (64.71%) 6 (35.29%) 7 (41.18%) 10 (58.82%) 14 (82.35%) 3 (17.65%) 5 (29.41%) 12 (70.59%) 6 (35.29%) 1 (5.88%) 4 (23.53%) 6 (35.29%)
P NS NS NS NS NS NS
Ulceration        
Absent 48 26 (54.17%) 22 (45.83%) 16 (33.33%) 32 (66.67%) 33 (70.21%) 14 (29.79%) 9 (18.75%) 39 (81.25%) 12 (25.53%) 13 (27.66%) 11 (23.4%) 11 (23.4%)
Present 12 9 (75%) 3 (25%) 7 (58.33%) 5 (41.67%) 10 (83.33%) 2 (16.67%) 5 (41.67%) 7(58.33%) 2 (16.67%) 2 (16.67%) 4 (33.33%) 4 (33.33%)
P NS NS NS NS NS NS
Necrosis        
Absent 12 5 (41.67%) 7 (58.33%) 1 (8.33%) 11 (91.67%) 5 (45.45%) 6 (54.55%) 3 (25%) 9 (75%) 5 (45.45%) 1 (9.09%) 4 (36.36%) 1 (9.09%)
Present 48 30 (62.50%) 18 (37.50%) 22 (45.83%) 26 (54.17%) 38 (79.17%) 10 (20.83%) 11 (22.92%) 37 (77.08%) 9 (18.75%) 14 (29.17%) 11 (22.92%) 14 (29.17%)
P NS 0,0205 NS NS NS NS
Neoplastic intravascular emboli        
Absent 37 18 (48.65%) 19 (51.35%) 12 (32.43%) 25 (67.57%) 25 (67.57%) 12 (32.43%) 10 (27.03%) 27 (72.97%) 11 (29.73%) 8 (21.62%) 7 (18.92%) 11 (29.73%)
Present 21 16 (76.19%) 5 (23.81%) 10 (47.62%) 11 (52.38%) 16 (80%) 4 (20%) 4 (19.05%) 17 (80.95%) 3 (15%) 7 (35%) 6 (30%) 4 (20%)
P NS NS NS NS NS NS
Lymph node metastases        
Absent 17 10 (58.82%) 7 (41.18%) 5 (29.41%) 12 (70.59%) 12 (70.59%) 5 (29.41%) 2 (11.76%) 15 (88.24%) 5 (29.41%) 2 (11.76%) 6 (35.29%) 4 (23.53%)
Present 18 13 (72.22%) 5 (27.78%) 9 (50%) 9 (50%) 13 (76.47%) 4 (23.53%) 6 (33.33%) 12 (66.67%) 3 (17.65%) 6 (35.29%) 4 (23.53%) 4 (23.53%)
P   NS NS NS NS NS NS
P- probability value. 
NS -not significant.
* - one case was excluded because there was no positive stainning in the internal poistive control of the sample.
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ER
As expected, all normal mammary gland tissues expressed ER in the nuclei of more than 
60% of the epithelial cells, with moderate to strong intensity and a heterogeneous lobular 
distribution. A similar pattern was observed in hyperplastic/dysplastic lesions and benign 
tumours, with the exceptions of one fibroadenomatous change and one fibroadenoma, both 
ER-negative. The majority of malignant tumours (n=43; 72.88%) was ER-negative (Figure 
1e and 1f), a significant difference when compared to benign tumours (p<0.0001). One car-
cinoma was excluded from the study because we were unable to stain its internal positive 
control. The staining intensity was also heterogeneous in carcinomas, with neighbouring 
areas of poor and strong nuclear expression. There was a significant inverse relationship 
between the expression of ER and the histological grade of carcinomas (p=0.0018), with 
most of grade I (n=6; 85.71%) being ER-positive while the majority of grades II and III 
(n=42; 80.77%) were ER-negative (Table 1). ER expression was also statistically related 
with P-cadherin (p=0.0114) and E-cadherin (p=0.0027) expression. The majority of ER-neg-
ative tumours (n=38; 88.37%) were P-cadherin-positive, while the majority of ER-positive 
tumours (n=14; 87.5%) were also E-cadherin-positive (Table 2). ER negativity was signifi-
cantly related to the combined expression of P- and E-cadherin (p=0.0031), with P-cad+/E-
cad- being the most predominant pattern (n=23; 53.49%). The ER expression in primary 
tumours was coincident with the expression in the corresponding intravascular emboli in all 
cases, while in lymph node metastases there were some discrepancies (Table 3). 
PR
Nuclear expression of PR was identified in more than 60% of the epithelial cells of all normal 
mammary gland tissues, with a moderated to strong intensity. The distribution of positive 
nuclei was heterogeneous amongst lobules and/or ducts. The same pattern was observed 
in hyperplastic/dysplastic lesions and benign tumours, with the exception of one fibroad-
enoma, that was PR-negative. 
Less than one quarter of the malignant tumours (n=14; 23.33%) were PR-negative (Figure 
1g and 1h), not significantly different from benign tumours. The staining intensity in carcino-
mas was heterogeneous, with neighbouring areas of poor and strong nuclear expression. 
All cribriform and mucinous carcinomas and three quarters of tubulopapillary and solid car-
cinomas were PR-positive, while both carcinosarcomas were PR-negative, being PR stain-
ing associated with histological sub-type of carcinomas (p=0.0243) (Table 1). There were 
no significant associations between PR and other clinicopathological parameters, nor P- or 
E-cadherin expression. The PR expression in primary tumours was coincident with the ex-
pression in the corresponding intravascular emboli in all cases, albeit some discrepancies 
with lymph node metastases (Table 3). 
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Ki-67
Ki-67 immunostaining in normal mammary gland tissues was nuclear, with a mean Ki-67 
index of 14.6%, ranging from 0.2% to 52.4%. In hyperplastic/dysplastic lesions the mean 
Ki-67 index was 30.83%, ranging from 3.42% to 67.38%. A marked difference was observed 
in the mean Ki-67 index between fibrocystic disease (15%, range 3.42% to 30.75%) and 
fibroadenomatous change (49.29%, range 27.32% to 67.38%).
The mean Ki-67 index of benign tumours (16.08%, range 3.48% to 43.35%) was lower 
than that of malignant ones (58.28%, range 13.7% to 86.61%) and when indexing the Ki-67 
by quartiles a significant association (p<0.0001) was observed with the neoplastic lesions 
(benign and malignant tumours) (Figure 1i and 1j). One carcinoma was excluded from the 
study because no staining in the internal positive control of the sample was achieved. When 
malignant tumours were grouped by Ki-67 index quartiles, a significant relationship with 
histological grade (p=0.0003) was observed (Table 1). All grade I tumours were included in 
the first quartile (Ki-67 index < 47.46%) while more than half of grades II and III belonged 
to the higher two quartiles (Ki-67 index > 61.1%). It was possible to observe an association 
between Ki-67 index quartiles and the expression of P-cadherin (p=0.0258), ER (p=0.0069) 
and p63 (p=0.0181) (Table 2). The first quartile was equally distributed between P-cadherin-
negative and -positive tumours, while more than 90% of tumours in the highest quartile (Ki-
67 > 74.8%) were P-cadherin-positive. Most of the ER-negative carcinomas (n=38; 84.44%) 
were in the higher quartiles, while the majority of p63-negative tumours (n=13; 99.86%) 
were in the lowest Ki-67 quartile. No association with the expression of E-cadherin, vimentin 
and PR was observed. 
Analysis of the combined expression of molecular markers and clinicopathological param-
eters in carcinomas allowed for the conclusion that P-cad+/vim+/ER- tumours were of mod-
erate to high histological grades (n=25; 100%) (p=0.0038), and the majority of tumours with 
intravascular neoplastic emboli were P-cad+/vim+ (n=16; 76.19%) (p=0.0307). Moreover, 
P-cad+/vim+ tumours were associated to a 3.76 odds ratio (CL 95%: 1.14-12.43) for vascu-
lar invasion. In the opposite, tumours simultaneously Pcad-/vim-/ER+/E-cad+ and with the 
lowest Ki-67 index were all low grade carcinomas. 
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DISCUSSION 
Spontaneous feline mammary carcinomas have been proposed by the World Health Or-
ganization as a good model for human breast cancer, based on the similarities in the age 
of onset, incidence, histopathological features, biological behaviour, and poor prognosis 
of the malignant mammary tumours in both species [1, 2]. Consequently, it is important 
to evaluate feline mammary tumours at the molecular level in order to identify prognostic 
markers and develop targeted therapies, thus enhancing their value as models of human 
breast cancer and the approach to feline mammary tumours. On that basis, the expression 
of three phenotypic markers: pan-cytokeratin AE1/AE3 (an epithelial cell marker); vimentin 
(a mesenchymal cell marker); and p63 (a myoepithelial cell marker) was evaluated both in 
normal mammary tissues and in mammary lesions. 
In normal mammary glands, AE1/AE3 was expressed by luminal epithelial and myoepithe-
lial cells (although with less intensity) and p63 was restricted to myopithelial cells. Besides 
being present in myoepithelial and stromal cells, vimentin was co-expressed with AE1/AE3 
by ductal luminal epithelial cells. This co-expression was described for the first time by Ca-
liari et al. (2014) [22], and interpreted as a hallmark of a non-terminally differentiated luminal 
component, diffusely distributed in the mammary ducts. Although the cat seems to be the 
only species where the mammary non-neoplastic luminal epithelium is described to express 
vimentin, the phenomenon has been described in the so-called “cap cells” of mice and the 
“side-population” of human breast containing the progenitor cell compartment [22]. 
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P63 is a member of the p53-family of transcription factors found in the basal cell layer in-
cluding cap cells and myoepithelium of the mammary gland [35]. In both benign and malig-
nant human breast tumours, the expression of p63 is restricted to myoepithelial cells [36] 
although some authors described a less intensive nuclear p63 expression in epithelial cells 
of some particular breast carcinomas [36, 37]. More than one third of the carcinomas of our 
series presented epithelial p63 expression and, although the staining intensity was weaker 
than in myoepithelial cells, it was related to higher histological grade. This expression may 
be due to the p63 expression in the early stages of epithelial differentiation [38] or reflect 
a potential myoepithelial differentiation in a subset of neoplastic cells [36, 37]. P63 [39, 40] 
and P-cadherin [41] are both considered stem cell markers with p63 being known to act as 
a transcription factor of the P-cadherin promoter [42, 43]. In fact, the relationship found be-
tween these two molecules in our carcinomas series can be in part justified by the existence 
of an association at the genetic level. 
In more than half of the malignant tumours in our series, epithelial cells revealed an aberrant 
co-expression of vimentin and AE1/AE3, a pattern that has been previously described in hu-
man breast cancer [30] and feline malignant mammary tumours [7, 22]. Such phenomenon 
may be a hallmark of the direct myoepithelial histogenesis; a sign of the epithelial-mesen-
chymal transition (EMT) reflecting the end-stage of tumour dedifferentiation; or derive from 
breast progenitor cells with a bilinear (glandular and myoepithelial) differentiation potential 
[44]. The expression of vimentin by epithelial breast cancer cells has been associated with 
increased drug resistance, cancer invasive behaviour and metastasis [45, 46]. 
Epithelial-mesenchymal transition is a multistep program characterized by the loss of epi-
thelial characteristics, such as downregulation of epithelial markers (e.g. E-cadherin), and 
acquisition of a mesenchymal phenotype, namely through the upregulation of mesenchymal 
markers (e.g. vimentin) [41, 47, 48]. These changes result in the loss of cell-cell adhesion 
and polarity, and the acquisition of migratory and invasive properties as well as metastatic 
potential [41, 48, 49]. More than half of the P-cad+/vim+ carcinomas in our series revealed 
a reduction of E-cadherin expression, suggesting the acquisition of mesenchymal features 
while losing epithelial characteristics, respectively. However, some P-cad+/vim+ carcino-
mas were simultaneously E-cad+ (n=14; 41.17%), possibly due to an incomplete EMT. This 
intermediate state is described as a partial EMT, in which the cells retain some characteris-
tics of epithelial cells albeit acquiring migratory ability, a feature of mesenchymal cells [41]. 
It has been proposed that P-cadherin may be considered an EMT marker, able to identify 
intermediate and transient EMT states associated with metastatic phenotypes, by interfer-
ing with epithelial cell-cell adhesion in the presence of E-cadherin [41]. 
Although hormone receptors are not currently considered to be prognostic markers in feline 
mammary tumours, they may represent key regulators of other important molecular mark-
ers in mammary carcinogenesis [8, 21]. In this series, the expression of ER and PR de-
creased from benign to malignant tumours, corroborating previous studies [1, 5, 8, 50] and 
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suggesting that the role of steroid hormones in carcinogenesis is more pronounced at the 
early stages of tumour development, with a more autonomous growth in advanced stages 
of malignancy [50]. In fact, an inverse association was found, in carcinomas, between the 
expression of ER and the histological grade. The downregulation of ER was, however, 
more evident than that of PR, in agreement with previous reports of consistent loss of ER 
in carcinomas [5, 8, 51]. Although it has been proposed that the presence of PR is a good 
indicator of the integrity of the ER molecular pathway in human breast cancer [52], the high 
number of ER-/PR+ feline carcinomas, similar to previous observations [5, 8], and an ab-
sent association between ER and PR expression in our series, suggests the presence of 
other non-oestrogen-dependent regulators of PR [2]. 
It has been postulated that estrogens stimulate the expression of E-cadherin in mice and 
that there are progesterone-responsive elements in the promoter region of the mouse E-
cadherin gene [53], although the association between E-cadherin expression and ER/PR 
status in breast cancer is not consensual [12, 54-57]. In feline mammary carcinomas we 
observed that the majority of ER positive tumours were also E-cadherin-positive, reinforcing 
the concept of an estrogen-regulated expression of E-cadherin. Several studies revealed a 
negative association between the overexpression of P-cadherin and the ER and PR status 
of breast cancer [11-13, 58, 59]. The lack of ER signalling is responsible for P-cadherin 
overexpression, categorizing the P-cadherin gene/CDH3 as an oestrogen-repressed gene 
[59-62]. Our results support this association, with the vast majority of ER-negative carcino-
mas being P-cadherin-positive. Thus, in feline mammary tumours the ER expression seems 
to be associated with both cadherins, suggesting a regulatory role in their expression.
Basal-like human breast carcinomas (BLBC) are a molecular sub-group of breast cancer 
that have been considered the end-result of EMT and associated with poor prognosis [49, 
63, 64]. The immunohistochemical profile of this subtype of human breast cancer is still 
not consensual [65]. It is recognized that BLBC are usually triple negative cancers (ER-/
PR-/HER2-) and several different panels have been used to identify them, including basal 
cytokeratins, P-cadherin, vimentin, EGFR, and p63 [28, 38, 63, 66-69]. Several studies ap-
proached the molecular classification of feline mammary tumours [20, 22, 29] similarly to 
what has been done in human breast cancer [23, 24], albeit with some differences. Caliari 
et al. (2014) described the feline mammary carcinomas as mainly aggressive hormone 
receptors-negative tumours, with basal cytokeratin and vimentin expression [22]. Brunetti 
et al. (2013) classified one tenth of the carcinomas as basal [29], while Wiese et al. (2013) 
characterized almost half of feline mammary tumours as triple negative basal-like, propos-
ing that they are a valuable natural occurring animal model for the study of human triple-
negative breast cancer with basal-like subtype [20]. In our series, although the majority of 
carcinomas was P-cadherin positive (n=48; 80%), ER negative (n=43; 72.88%), PR nega-
tive (n=14; 23.33%), p63 negative (n=37; 61.66%) and vimentin positive (n=35; 58.33%), 
only five tumours (8.47%) were simultaneously P-cad+, ER-, PR-, p63+ and vim+, repre-
senting those that could be considered similar to BLBC.
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The Ki-67 proliferative index increased from non-neoplastic and benign lesions to malignant 
tumours, in agreement with previous studies [3, 6, 33, 51]. The use of Ki-67 as a prognos-
tic factor in cats is, however, controversial [3, 6, 33, 51] and its use in clinical decisions is 
still unsubstantiated [3]. Interestingly, in our series higher Ki-67 indexes were related with 
P-cadherin overexpression, higher histological grades, and ER negative status, supporting 
its association with tumour aggressiveness. However, the cut-off values from our and other 
studies [3, 6] hamper the proposal of useful cut-off limits with prognostic significance. To 
compare the results from different studies it is mandatory that standard methodologies are 
followed.
When the combined expression of molecular markers was compared to the tumour clinico-
pathological features, we observed that tumours simultaneously P-cad-/vim-/ER+/E-cad+ 
and with the lowest Ki-67 index were all well-differentiated carcinomas, which suggest a 
molecular profile characteristic of carcinomas with low aggressiveness. On the contrary, 
P-cad+/vim+/ER- with high Ki-67 index tumours presented significantly higher histological 
grades. Moreover, P-cad+/vim+ tumours were 3.76 times more likely to invade vessels, 
corroborating the human breast cancer concept that both P-cadherin [66] and vimentin [45] 
are invasion-associated molecules. Taken together, our results suggest that the immunohis-
tochemical classification of feline carcinomas based on P-cadherin, ER, vimentin and Ki-67 
expression may represent a reliable prognostic indicator. Furthermore, the large number 
of P-cadherin-positive tumours suggests that this protein may be a good therapeutic target 
[70, 71]. 
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CONCLUSIONS
This study suggests that overexpression of P-cadherin and vimentin, and negative expres-
sion of ER can be considered as hallmarks of feline mammary carcinomas. Moreover, it 
raised the possibility that P-cadherin, ER and vimentin can be used together as poor prog-
nostic indicators such as high histological grade and high proliferative activity in the identi-
fication of feline mammary tumours with a more aggressive behaviour.
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ABSTRACT
Background: Mammary cancer in cats have high recurrence and metastatic potential. 
Abnormal expression or function in the major molecules of the cadherin-catenin adhesion 
complex have been related to breast cancer development and associated to cell migra-
tion, invasion and metastatic dissemination. In feline mammary tumours, cadherins and 
catenins´ role is still poorly known. Therefore we seek for suitable in vitro and in vivo model 
systems to study the leading role of P-cadherin and the molecules of the cadherin-catenin 
complex in feline mammary carcinogenesis. 
Materials and Methods: Major molecules from the cadherin-catenin complex (E- and 
P-cadherin, α-, β- and p120-catenin) were evaluated in a feline metastatic mammary carci-
noma cell line (FMCm), by Western blot analysis, immunofluorescence, imunoprecipitation 
and in situ proximity ligation assay. The FMCm cell line tumourigenic and metastatic capac-
ity were assessed by orthotopically inoculation of a cell suspension in the mammary fat pad 
of athymic nude mice (N:NIH(S)II-nu/nu). Mice xenografts, as well as metastatic lesions, 
were evaluated immunohistochemically for cadherins and catenins expression. P- and E-
cadherin double-labelling immunofluorescence was also assessed.
Results: The FMCm cell line expressed E- and P-cadherin as well as α-, β- and p120-
catenin. Moreover, E-cadherin was showed to interact with each one of the catenins, re-
vealing a putative complete cadherin-catenin complex. The cells had E- and P-cadherin 
co-expression and a close proximity between these two molecules. The FMCm cell line 
revealed to be high tumourigenic and showed a great metastatic capacity as the orthotopic 
inoculation in nude mice lead to the formation of primary and metastatic lesions in all mice. 
Those lesions expressed all of the molecules from the cadherin-catenin complex studied. 
Conclusions: FMCm cell line is a high tumourigenic and metastatic cell line in nude 
mice. It can be proposed as a useful model for in vitro and in vivo studies of P-cadherin and 
associated molecules of the cadherin-catenin complex for study of feline mammary carci-
noma progression. 
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BACKGROUND
Cadherins are members of a large family of transmembrane glycoproteins that mediate 
calcium-dependent homotypic cell-cell adhesion [1]. Two members of the cadherin family 
are expressed by the normal mammary gland: E-cadherin, a 120kDa glycoprotein [2, 3], 
that is present in luminal epithelial and myoepithelial cells [4-6], and P-cadherin, a 118kDa 
glycoprotein [7-10], which is confined to the myoepithelium [4, 11, 12]. Cadherins connect 
indirectly to the actin cytoskeleton, through their cytoplasmic domain, via a group of pro-
teins, collectively known as catenins [13, 14]. β-Catenin is a 95 kDa protein that associates 
directly with cadherins, while α-catenin is a 102 kDa protein that indirectly associates with 
cadherins through its interaction with β-catenin, thus mediating the interaction between 
cadherin-catenin complex and actin cytoskeleton [15, 16]. p120-Catenin it’s a protein with 
multiples isoforms, that range in size from 90-120 kDa, and binds to the cadherin juxtamem-
brane region, but does not link the complex to the actin cytoskeleton [16, 17]. Changes in 
the major molecules of the cadherin-catenin adhesion complex are related to the develop-
ment of human breast cancer and their abnormal expression or function are associated to 
decreased intercellular adhesion, cell migration, invasion and metastatic dissemination [14, 
18-21]. Loss or delocalization of E-cadherin and catenins from the membrane is usually re-
lated to an invasive breast cancer phenotype [14, 22-24], while P-cadherin overexpression 
is associated to breast cancer progression and worse patient survival [21, 25]. 
Mammary neoplasia is the third most common tumour type affecting female cats, with 85 to 
90% being malignant [26-28]. Affected cats have a high mortality rate and a mean survival 
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time of one year [29, 30], due to local recurrence and/or metastatic disease [26, 27], par-
ticularly to the regional lymph nodes, lungs, pleura and liver [28, 29], which are the cause of 
most therapeutic failures [26, 27]. Colonization of distant tissues by tumour cells represents 
the most dangerous attribute of cancer and prevention of metastasis and effective treat-
ments of already established metastases are necessary in order to increase survival. Thus, 
it is of extreme importance to identify and characterize biologic, biochemical and molecular 
basis mechanisms that drive metastasis, in order to develop therapeutic agents to inhibit 
this process [31].
Only a small number of studies assessed the expression of cadherins and catenins in fe-
line mammary tumours [32-35], and their role in feline mammary carcinomas is still poorly 
known. Thus, molecular studies of these proteins in spontaneously lesions, as well as in 
both in vitro and in vivo models, are extremely valuable to assess their roles in feline mam-
mary tumours. We have been focused on studying P-cadherin in feline mammary tumours 
as it revealed to be associated to aggressive feline mammary carcinomas. To the best of 
our knowledge there is no feline mammary carcinoma cell line characterized in what con-
cern P-cadherin expression, nor studies of this protein in an in vivo model for feline species. 
Thus, we search a feline mammary carcinoma cell line in order to establish a suitable in vi-
tro and in vivo model systems to evaluate the expression and functions of cadherin-catenin 
complex molecules, namely P and E-cadherin, as well as α-, β-, and p120-catenin, point 
toward a better understanding of their role in feline mammary tumours progression. In this 
context we studied the feline mammary carcinoma cell line (FMCm) [36], by evaluating the 
expression of the P-cadherin molecule as well as the other cadherin-catenin complex mol-
ecules, namely E-cadherin, and α-, β- and p120-catenins. Moreover, in order to mimic as 
much as possible the spontaneous lesions we used xenograft mice aiming to develop an in 
vivo model for the study of P-cadherin in feline mammary carcinomas, with both prognosis 
and therapeutic purpose. 
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MATERIAL AND METHODS
In vitro studies 
Cell culture
The FMCm cell line was established and characterized by Uyama et al. (2005) [36] and 
kindly provided by Professor Sasaki, of the Laboratory of Veterinary Surgery, University of 
Tokyo, Japan. 
FMCm cell line was established from a regional lymph node metastatic lesion of a 12 years 
old Japanese domestic female cat with a primary mammary adenocarcinoma in stage III 
(T3cN1(+) M0) [36], collected by surgery.
FMCm cells were grown in monolayer culture in RPMI 1640 with Glutamax medium (Gibco, 
Invitrogen), supplemented with 10% fetal bovine serum (Gibco, Invitrogen) and 1% penicil-
lin-streptomycin (Gibco, Invitrogen). Culture was maintained at 37ºC in humidified 5% CO2 
atmosphere. Culture medium was replaced every two days. 
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Western blot analysis
Confluent T75 cm2 flasks were incubated with NP40 lysis buffer (1% NP40, 20 mmol/L 
Tris-HCl (pH 8.0), 137 mmol/L NaCl, 10% glycerol, 2 mmol/L EDTA, 1 mmol/L sodium or-
thovanadate, and protease inhibitor cocktail tablet (Roche)) and cells were scraped. Total 
cell lysates were centrifuged at 14000 rpm for 10 minutes to remove pellet cell debris. Pro-
tein concentration was determined by the bicinchoninic acid (BCA) protein assay (Pierce). 
Proteins from cell lysates were separated according to their molecular weight by gel elec-
trophoresis, in 7.5% acrylamide/bis acrylamide (Sigma) SDS-PAGE. A 25 µg of total protein 
extract was used. Gels were transferred onto a nitrocellulose membrane (Amersham) in a 
semi-dry system. Membranes were blocked with 5% non-fat milk, washed three times with 
phosphate buffer saline with 0.005% tween (PBS-T), and incubated overnight at 4ºC with 
primary antibodies (Table 1). After incubation, membranes were washed three times with 
PBS-T and incubated 1 hour with secondary antibodies. Secondary antibodies conjugated 
with horseradish peroxidase (DAKO) were used at 1:2000. Analysis was performed by che-
miluminescence using the ECL Western blotting detection reagent and films (both from GE 
Healthcare). 
Immunofluorescence
FMCm cells were cultured in glass slides placed in 24 well plates until they reached approxi-
mately 80% confluence. After washing with phosphate buffered saline (PBS) three times, 
cells were fixed with methanol for 15 minutes at 4ºC. Cells were rehydrated using PBS for 
10 minutes and unspecific detection was blocked using normal goat serum (1:5) in 10% 
BSA for 20 minutes. Incubation was performed with primary antibody (Table 1) diluted in 
5% BSA, overnight, in a wet chamber. After three washes with PBS, slides were incubated 
with secondary antibodies diluted 1:500 in 5% BSA for one hour. Cells were then washed 
with PBS, followed by incubation with 4,6-diamidine-2-phenylindolendihydrochoride (DAPI) 
100µg/mL for 10 minutes. Slides were mounted in glycerol-based Vectashield medium 
(Vector, Burlingame, CA, USA) and observed by fluorescence microscopy (Zeiss Imager 
Z1 microscope) with appropriated filters. Separate images for Alexa 488 and Alexa 594 
were captured at x200 magnification and then merged to allow a double immunostaining. 
For negative controls, the primary antibody was replaced by PBS.
In situ proximity ligation assay 
Cells were deposited on glass slides and fixed with methanol. In situ proximity ligation as-
say (PLA) was performed using the Duolink kit (Olink Bioscience, Uppsala, Sweden) ac-
cording to the manufacturer’s recommendations. Slides were analysed with fluorescence 
microscopy (Zeiss Imager Z1 microscope). 
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E-cadherin immunoprecipitation
Two µL of rabbit anti-E-cadherin antibody (clone 24E10, Cell Signaling) were coupled to 60 
µL of ProteinG Sepharose beads (Sigma) for 2 hours at 4ºC. Protein cell lysates (750 µg) 
were pre-cleared in 30 µL of ProteinG Sepharose beads during 2 hours in order to block 
protein unspecific linkage to beads. Following the lysate pre-clear and antibody linkage 
to the beads, pre-cleared lysates were incubated overnight in antibody-proteinG beads. 
Beads’ washes were performed with PBS and after protein incubation 1% of Triton X-100 
(Sigma) were added to PBS to clear unspecific protein binding. Three independent immu-
noprecipitation assays were performed and each immunoprecipitation procedure was done 
in triplicate in order to have enough protein for the different western blots. The immunopre-
cipitated proteins were eluted in SDS Laemmeli buffer and used for E-cadherin, P-cadherin, 
α-, β- and p120-catenin Western blots. Negative controls were performed using rabbit im-
munoglobulins instead of E-cadherin antibody in protein G-beads.
In vivo studies
Animals
N:NIH(S)II-nu/nu athymic nude mice [37], a strain produced by Instituto de Patologia e 
Imunologia Molecular da Universidade do Porto (IPATIMUP) was used. Animal experiments 
were carried out in accordance with the European Guidelines for the Care and Use of Labo-
ratory Animals, Directive 2010/63/UE and the National Regulation published in 2013 (Diário 
da República, 1.ª série — N.º 151 — 7 de agosto de 2013). In all experiments the following 
Humane Endpoints for euthanasia were established: any signals of distress, suffering or 
pain, body weight loss greater than 20-25% of the body mass and anorexia, related or not 
to the experimental procedure. The endpoint for the experiment was established at day 185.
FMCm tumourigenic and metastatic capacity assessment
Six female NIH(S)II-nu/nu, aged 8 to 9 weeks-old, were orthotopically inoculated with 1x107 
viable FMCm cells suspension in the mammary fat pad using a 25 gauge needle, in order 
to determine the FMCm tumourigenic potential, as previously described [38]. Mice were 
monitored every day for development of primary xenografts tumours. When nodules be-
come palpable, tumour size was measured using callipers that allowed estimating three 
dimensions (length, width and thickness). Tumour volumes (mm3) were assessed using the 
formula: W x L2 x ½, where W is the width and L is the length of the tumour. Tumours were 
surgically removed when volumes reached approximately 850-1000 mm3. Exception was 
made in cases where tumours developed large skin ulcers in the overlying epidermis and 
tumours were removed earlier. For tumours surgical excision purpose, mice were anesthe-
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tized by intraperitoneal injection with 100 μL of a mixture containing 75 mg/kg of ketamine 
hydrochloride (Imalgene 1000®, Merial) and 1 mg/kg of medetomidine hydrochloride (Mede-
tor®, Virbac). To antagonize the effect of anaesthesia a solution of 100 μL containing 2.5 mg/
kg of atipamezole hydrochloride (Revertor®, Virbac) per mice was used also intraperitoneal. 
An oral solution of 10 mg/kg tramadol hydrochloride (Tramal®, Grunenthal GmbH), was 
given every 8 hours for 24-48 hours for pain control. At the time of surgery, tumours were 
collected and fixed in 10% neutral buffered formalin. All mice were humanely euthanized ac-
cording to the predefined Humane Endpoints and necropsies were performed. At necropsy, 
mice were examined visually for macro-metastases and both tumour masses and target 
organs (lymph nodes, lungs and liver) were removed and fixed in 10% neutral buffered 
formalin. After routine histological processing, all tissues were embedded in paraffin and 
sequential 3µm sections were obtained from each block. One section was stained with hae-
matoxylin and eosin (HE) for histological examination and subsequent sections were used 
for immunohistochemical studies.
The histological classification of tumours was performed independently by two observers 
(ACF and FG) and based on the criteria of the World Health Organization (WHO) for the 
histological classification of mammary tumours of domestic animals [39]. Carcinomas were 
graded in accordance with the Nottingham grading system for human breast carcinomas 
[40]. 
Immunohistochemistry of mice xenografts
For the immunohistochemical study, paraffin sections were dewaxed in xylene, rehydrated 
through graded alcohols and treated for antigen retrieval at high temperature (98ºC) with 
Tris-EDTA (NovocastraTM Epitope Retrieval Solution Tris-EDTA buffer pH9, Newcastke, 
United Kingdom, RE7119). Endogenous peroxidase activity was blocked with 3% H2O2 in 
methanol for 10 minutes and washed in PBS three times. Then, sections were incubated 
with normal goat serum diluted 1:5 in 10% BSA in PBS during 30 minutes, followed by in-
cubation with the primary monoclonal antibodies overnight, at 4ºC in a humid chamber. The 
antibodies (Table 1) were diluted in 5% BSA in PBS. Incubation with biotinylated secondary 
antibodies (DAKO) was done during 30 minutes at room temperature, followed by avidin-bi-
otin complex incubation (Vectastain). Immunolabelling was detected with 3,3´-diaminoben-
zidine tetrahydrochloride (DAB) (Sigma) containing 0.02% hydrogen peroxide and sections 
were then counterstained with Mayer’s hematoxylin. Evaluation of immunostainning was 
performed in a blind fashion manner by two independent observers. For negative controls, 
the primary antibody was replaced by PBS. Sections of feline normal mammary gland were 
used as positive controls. In the lymph nodes, liver and lung sections, additional immuno-
histochemical analysis with antibody anti-pancytokeratin AE1/AE3 was performed in order 
to confirm the presence of metastases or to determine the existence of micrometastases.
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P-cadherin and E-cadherin double-labelling
immunofluorescence in mice xenografts
Double-label immunofluorescence (DIF) was performed for simultaneous visualization 
of P- and E-cadherin expression. Tissue sections were dewaxed in xylene, rehydrated 
through a series of graded alcohols and treated at high temperature (98ºC) with Tris-EDTA 
(NovocastraTM Epitope Retrieval Solution Tris-EDTA buffer pH9, Newcastke, United Kingdom, 
RE7119) for antigen retrieval. Then, tissues sections were blocked with 10% BSA for 20 
minutes, followed by incubation with the primary antibodies anti P-cadherin and anti E-cad-
herin (Table 1) diluted in 5% BSA for two hours in a wet chamber. After washing with PBS, 
slides were incubated with Alexa 488 and Alexa 594 secondary antibodies diluted 1:500 in 
5% BSA, for one hour. Washes were performed with PBS and slides incubated with DAPI 
100 μg/mL for 10 minutes. Slides were mounted in glycerol-based Vectashield medium 
(Vector, Burlingame, CA, USA). Immunostained sections were analyzed by fluorescence 
microscopy (Zeiss Imager Z1 microscope) with appropriated filters. Separate images for 
Alexa 488 and Alexa 594 were captured at x200 magnification and then merged to allow for 
the visualization of P-cadherin and E-cadherin double immunostaining. For negative con-
trols, the primary antibody was replaced by PBS. 
For immunofluorescence assays, the secondary antibody for P-cadherin, α-catenin, 
β-catenin, p120-catenin was Alexa Fluor® 488 goat anti-mouse IgG (A11029, Life Technol-
ogy, Carlsbad, CA, USA) while for E-cadherin was Alexa Fluor® 594 goat anti-rabbit IgG 
(A11037, Life Technology, Carlsbad, CA, USA). 
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RESULTS
Characterization of the FMCm cell line
FMCm cell line formed a monolayer of epithelial-like cells in culture, round to spindle in 
shape, with large nuclei and often two or more nucleoli (Figure 1).
Figure 1. Morphology of FMCm cell line in culture. FMCm cells grown as a monolayer of epithelial-like cells, 
round to spindle in shape, with large nuclei and often two or more nucleoli. x100 (A) and x200 (B) magnification.
Western blot characterization of cadherin and catenin proteins showed that FMCm cells 
expressed both E- and P- cadherin as well as p120-, α- and β- catenin (Figure 2). For E-
A B
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cadherin two main bands were observed at approximately 135 and 110 kDa. Regarding 
P-cadherin, two bands were formed near 120 and 90kDa. Western blot for catenins demon-
strated the expression of α- and β-catenin both at approximately 100 kDa, and the expres-
sion of p120-catenin at different weights with the major bands formed at 100 and 120 kDa. 
FMCm cells also expressed epithelial and mesenchymal markers, such as cytokeratins in 
the 45 kDa position and vimentin at approximately 80 kDa (Figure 2). 
              
Figure 2. Western blot analysis of the expression of proteins from the cadherin-catenin complex, as well 
as phenotypic markers, of the FMCm total cell lysate. FMCm cells showed expression of (A) E-cadherin, (B) 
P-cadherin (B) as well as (E) p120-catenin, (F) α-catenin and (G) β-catenin. The expression of epithelial and 
mesenchymal markers was also evaluated by expression of (C) cytokeratins and (D) vimentin. 
Immunofluorescence revealed that E-cadherin, p120-, α- and β- catenins were present 
at the membrane of the majority of the cells, while P-cadherin was restricted to the cell 
membrane of a smaller population of cells (Figure 3). Double immunofluorescence analysis 
showed the co-expression of E-cadherin with each catenin (α-, β- and p120-catenin) at the 
cell membrane, as well as with P-cadherin. In addition, immunofluorescence analysis of 
FMCm cells confirmed the expression of both cytokeratins and vimentin (Figure 3). 
Immunoprecipitation assays were performed in order to evaluate the possible interaction 
of E-cadherin with the other proteins of the cadherin-catenin complex. E-cadherin was im-
munoprecipitated from total cell lysates of FMCm cells and Western blot analysis for P-cad-
herin and p120, α- and β- catenins was performed (Figure 4). The results demonstrated that 
along with E-cadherin it was possible to detect the presence of each one of the catenins as 
well as P-cadherin (Figure 4), indicating that E-cadherin interacts with all the catenins and 
P-cadherin. Furthermore, the P-cadherin Western blot analysis of E-cadherin immunopre-
cipitates identified the P-cadherin at a lower molecular weight (approximately 80-90 kDa) 
when compared with the expression of P-cadherin in the total cell lysate (of 120 kDa). This 
result was very consistent in all the experiments. Despite many improvements in the immu-
noprecipitation protocol, we were not able to have a clear negative control for p120-catenin 
western blot after E-cadherin immunoprecipitation. We reasoned that the rabbit immuno-
globulins used in the negative control have some cross reactivity to feline p120 protein.
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Figure 3. Immunofluorescence and double-label immunofluorescence analysis in FMCm cell line. Imuno-
fluorescence expression of (A, D, G, J) E-cadherin (red color), (K) P-cadherin (green color), (B) α-catenin (green 
color), (E) β-catenin (green color) and (H) p120 catenin (green color) in FMCm cells. Double-label immunofluo-
rescence co-expression of (C) E-cadherin and α-catenin (yellow color), (F) E-cadherin and β-catenin (yellow 
color), (I) E-cadherin and p120-catenin (yellow color) and (L) E-cadherin and P-cadherin (yellow color). Immu-
nofluorescence expression of (M) cytokeratins (green color) and (N) vimentin (green color). x200 magnification.
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Figure 4. E-cadherin immunoprecipitation and evaluation of cadherin-catenin complex in FMCm cells. 
Immunoprecipitation of E-cadherin was performed in FMCm cell lysates and the presence of P-cadherin, p120-
catenin, α-catenin and β-catenin were evaluated. The results show that the immunoprecipitation assay was 
capable of capture E-cadherin from FMCm total cell lysates. Furthermore, along with E-cadherin also P-cad-
herin, p120-catenin, α-catenin and β-catenin proteins were detected after immunoprecipitation. A) E-cadherin 
immunoprecipitates; B) Rabbit IgG immunoprecipitates (immunoprecipitation control); C) Protein input from 
E-cadherin immunoprecipitates; D) Protein input from rabbit IgG immunoprecipitates.
In order to validate the interaction between E- and P-cadherin observed in the immuno-
precipitation experiments, an in situ proximity ligation assay was performed, which demon-
strated the close proximity of P- and E-cadherin observed by the red dots in cultured cells 
(Figure 5).
Figure 5. In situ proximity ligation assay for E- and P-cadherin. Positive signals (red dots) was observed in 
FMCm cells, showing a proximity and putative interaction between these two proteins.
In vivo behaviour of FMCm cell line –
– tumourigenic and metastatic capacity
All mice presented a palpable nodule in the mammary fat pad at days two or three post-
inoculation with FMCm cells. The growths of the nodules start to be noticeable from day 7 
post-inoculation onwards. The kinetic curve of tumour growth is shown in Graphic 1. The 
FMCm cell line was able to induce local nodules (Figure 6) in the six inoculated mice. 
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Graphic 1. Kinetic curve of tumours growth at the selected timepoints. Data shown represent the mean tumours 
volumes (mm3) ± SD calculated for each timepoint for 5 mice. The mouse whose tumour did not grow following 
the overall kinetics was excluded.
        
Figure 6. (A) Development of primary xenograft tumours in the mice; (B) excised tumour.
Two of the 6 mice developed tumours with large areas of skin ulceration leading to its early 
removal (625mm3 and 550mm3 at the removal) and one mouse had a tumour that did not 
grow following the overall kinetics (158mm3 at day 51). All mice, except the one that tumour 
did not grow as the overall, showed signs of body-weight loss and were euthanized. Table 2 
displays the time intervals (in days) between inoculation (day 0) and surgical excision of pri-
mary tumours (as well as tumour volumes at the time of surgeries) and euthanasia. Organs 
with histological confirmed metastases at the time of euthanasia are also indicated. It was 
possible to detect metastases in all mice at the time of euthanasia, including in the one that 
the tumour did not grow as fast as the majority.
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Characterization of mice xenografts 
All tumours were classified as solid carcinomas, characterized by a predominant solid pat-
tern with areas of tubular differentiation, high mitotic counts, and marked nuclear pleo-
morphism. Tumours were classified as grade III solid carcinomas (poorly differentiated) 
and exhibited extensive areas of necrosis and invasive growth. In four cases (66.67%) the 
masses ulcerated and all mice developed nodal macro or micrometastases. In two animals 
(33.33%) lung metastases were also documented. Histologically, metastases showed fea-
tures similar to those observed in mice xenografts. There was no evidence of metastases 
in the liver. Neoplastic lesions expressed both cytokeratin and vimentin, however immuno-
reactivity to p63 was not observed (Figure 7). 
All tumours showed immunopositivity for E-cadherin (Figure 8). α-, β- and p120-catenin 
(Figure 9) had a membranous expression in approximately 75% of the neoplastic cells. 
The expression of P-cadherin was also membranous and found in more than half of the 
neoplastic epithelial cells (Figure 8). The pattern of expression in metastases matched their 
xenografts (Figure 8 and 9). 
P- and E-cadherin double-labelling immunofluorescence analysis revealed a co-expression 
of the two molecules, particularly at the tumours´ peripheral invasive front. The same ex-
pression pattern was observed in lymph node metastases (Figure 10).
Table 2. Time interval (in days) between inoculation (day 0) and tumour excision, and tumour volume at the time 
of surgery. Time between inoculation and euthanasia and between tumour excision and euthanasia. Metastases 
location at time of euthanasia.
Mice Surgery (days)/  Tumour volume (mm3)
Euthanasia 
 (days inoculation/ 
days tumour excision)
Metastases location
1 52 / 847 185 /133 Lymph node
2 51 / 963 104 / 53 Lymph node/Lungs
3 52 / 550 146 / 94 Lymph node
 4* 74 / 158 185 / 111 Lymph node
5 52 / 625 114 / 62 Lymph node/Lungs
6 51 / 1080 114 / 63 Lymph node
*mice excluded from the kinetic curve of tumour growth; the tumour did not grow after day 51
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Figure 7. AE1/AE3, vimentin and p63 expression by immunohistochemistry in mice xenografts. (A) 
Strong AE1/AE3 immunoreactivity in the membrane and cytoplasm of epithelial cells, x200; (B) Detail of AE1/
AE3 expression, x400; (C) Strong vimentin immunoreactivity in the membrane of epithelial cells, x200; (D) Detail 
of vimentin overexpression, x400;.(E) Absence of p63 immunoreactivity in epithelial cells, x200. (F) Detail of the 
carcinoma, x400.
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Figure 8. E- and P-cadherin expression by immunohistochemistry in mice lesions. (A) Carcinoma with 
E-cadherin expression in more than 75% of the epithelial cells, x200; (B) Detail of E-cadherin expression, x400; 
(C) E-cadherin expression in lymph node metastase, x100; (D) E-cadherin expression in lung metastase, x100; 
(E) Carcinoma with P-cadherin expression expression in more than 50% of the epithelial cells, x200; (F) Detail 
of P-cadherin expression, x400; (G) P-cadherin expression in lymph node metastase, x100; (H) P-cadherin 
expression in lung metastase, x100.
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Figure 9. α- β- and p120-catenin expression by immunohistochemistry in mice lesions. (A) α-catenin im-
munoreactivity in the membrane of epithelial cells of carcinoma, x400. (B) α-catenin expression in lymph node 
metastase, x400. (C) β-catenin immunoreactivity in the membrane of epithelial cells of carcinoma, x400. (D) 
β-catenin expression in lymph node metastase, x400. (E) p120-catenin immunoreactivity in the membrane of 
epithelial cells of carcinoma, x400. (F) p120-catenin expression in lymph node metastase, x400.
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Figure 10. E- and P-cadherin expression by double-label immunofluorescence in mice lesions x200. (A) 
Carcinoma with E-cadherin in epithelial cells (red colour) and (B) P-cadherin in epithelial cells (green colour) 
x200; (C) Carcinoma with co-expression of P-cadherin and E-cadherin (yellow colour). x200; (D) Lymph node 
metastatic cells expressing E-cadherin (red colour) and (E) P-cadherin (green colour); (F) Lymph node meta-
static cells co-expressing P-cadherin and E-cadherin (yellow colour). x200.
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DISCUSSION
Experimental model systems are required for cancer research and several established fe-
line mammary carcinoma cell lines have been reported [36, 41-44]. However, in vitro models 
are limited in the representation of real cancer at various levels, including the lack of three 
dimensional structures and absence of matrix and stromal cells interactions, endocrine in-
fluences, immune response, amongst others, which can be achieved only using an in vivo 
model [45]. The in vivo xenograft models permits heterotransplantation of cancer cells or 
tumour biopsies into immunodeficient rodents, allowing for the growth of tumours with direct 
stromal interactions [45, 46]. 
Our main goal was to determine an in vitro and in vivo model for the study of P-cadherin 
and the associated molecules of the cadherin-catenin complex, E-cadherin and α-, β-, and 
p120-catenin, in feline mammary carcinomas. In this context, we choose the FMCm cell 
line, established from a nodal metastases of a feline mammary carcinoma [36].
The FMCm cell line in culture revealed an epithelial-phenotype with an intense immunore-
activity for the epithelial cell marker cytokeratin. However, cells also expressed vimentin, 
an intermediate filament of mesenchymal cells that has been associated with a loss of cell-
to-cell contact and acquisition of migration and invasion capacities by breast cancer cell 
[47-49]. This cell line was also characterized by the expression of E-cadherin, α-, β- and 
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p120-catenin, and it was determined a link between E-cadherin and each one of the caten-
ins. This may indicate a preserved cadherin-catenin complex, a characteristic of intercel-
lular adhesion system of luminal epithelial mammary cells [23]. The FMCm cell line also 
expressed P-cadherin, which is a cadherin not usually present in epithelial luminal cells of 
the breast, being normally found in myoepithelial cells [21]. In Western blot analysis, for 
each one of the cadherins (E- and P-cadherin) we detected two bands with distinct molecu-
lar weight that probably correspond to the cadherins molecule (higher weight) and to the 
cadherins fragment sE-cad and sP-cad (lower weight), that results from the cleavage and 
shedding of the extradomain of the cadherins [50, 51]. By immunofluorescence, P-cadherin 
was co-localized with E-cadherin, representing a small population of cells, possibly indi-
cating a sub-clone population. There was an interaction between these two cadherins, as 
demonstrated by the in situ proximity ligation assay and confirmed by immunoprecipitation. 
However, in the immunoprecipitation assay with E-cadherin it was identified the smaller 
weight P-cadherin. Thus, E-cadherin probably is only able to interact with the small weight 
P-cadherin, which possibly corresponds to the described fragment of P-cadherin (sP-cad)
[50]. Thus, this in vitro cell model displays in the same cell line the major molecules of the 
cadherin-catenin cell complex.  
Aiming to develop an in vivo model for the study of feline mammary carcinomas that could 
mimic as much as possible the spontaneous lesions, an FMCm cell suspension was inocu-
lated in the mammary fat pad of athymic nude mice. The mouse mammary fat pad permits 
the interaction of the breast tumour cells with matrix and stromal cells from the proper 
anatomical site and when compared to the subcutaneous area (interscapular), it is a more 
favourable site for the growth of xenografts of breast cell lines and also to favour metasta-
sis [52-54]. Furthermore, it has been reported as the best in vivo model for accurately as-
sessing breast cancer metastatic potential [55]. The FMCm cells were able to induce local 
tumours in all animals revealing to be high tumourigenic cell line in nude mice, with develop-
ment of high grade mammary carcinoma. 
A significant characteristic of spontaneous feline mammary tumours is the high incidence of 
metastases, which is the cause of most therapeutic failures [26, 27]. Metastasis is a com-
plex multistep process by which tumour cells escape from the primary site, and disseminate 
through blood or lymphatic vessels to form new lesions in other organs. To metastasize, 
tumour cells must degrade and cross the extracellular matrix, intravasate, travel through 
blood or lymphatic vessels, extravasate at the secondary site, and finally, establish second-
ary tumours. To understand metastization it is imperative to have a research model that 
mimics a number of steps of this process [56, 57]. Therefore the mice of this study were 
not euthanized by the time of surgical excision of the primary tumour, in order to permit 
metastization and mimic the medical procedure usually applied in the clinical practice to 
felines’ mammary tumours. At the time of death all mice had developed nodal metastases 
or micro metastases and in two mice pulmonary metastases were also found. This meta-
static pattern is similar to the one described in queens [29], with regional lymph nodes and 
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lungs being most frequently involved. The behaviour of the tumours induced by the FMCm 
cell line underlines the high aggressive, with high metastastic potential of this cell line. The 
immunohistochemical analysis of the mammary lesions revealed the presence of all mole-
cules of the cadherin-catenin complex and also P-cadherin, both in primary and metastastic 
lesions. Moreover, double-immunofluorescence revealed co-expression of E-cadherin and 
P-cadherin. 
P-cadherin is normally not expressed by luminal epithelial mammary cells, and its overex-
pression in breast cancer cells is correlated with increased tumour cell motility, migration 
and invasiveness [50] and associated to a worse prognosis [58]. Moreover, the expression 
of P-cadherin in E-cadherin positive breast cancer is associated to aggressive behaviour, 
invasion, metastasis and poorest prognosis than that of carcinomas that express only one 
of the cadherins [50, 59, 60]. The invasive and metastastic potencial of the FMCm cells de-
rived tumours in vivo is possibly related to the presence of both E- and P-cadherin. 
The most widely used treatment approach to feline mammary tumours is surgical excision 
[28, 61]. However, cats with mammary cancer have a high rate of post-mastectomy recur-
rence or metastatic disease [26, 27]. In spite of attempts to develop better surgical ap-
proaches, chemotherapeutic or radiotherapeutic protocols, the treatment options for feline 
mammary carcinomas are limited and the overall patient treatment outcome has not been 
substantially improved. Therefore, the development of novel adjuvant therapies is crucial 
[28, 29]. P-cadherin has been recently considered as a potential therapeutic target in hu-
man breast cancer [62, 63], and considering the large number of P-cadherin positive feline 
mammary tumours [33, 64], this molecule may be hypothesised as a potential therapeutic 
target in this species too. Therefore, an in vivo model that expresses P-cadherin is funda-
mental to study the potential anti-P-cadherin therapy in feline mammary tumours. 
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CONCLUSIONS
The in vitro and in vivo model exposed herein, with co-expression of E- and P-cadherin as 
well as catenins, might be useful to study the role of these molecules in feline mammary 
carcinomas development, progression and clinical approach. 
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SUPPLEMENTARY DATA
1) In vitro invasion capacity of FMCm cell line
In order to evaluate the in vitro invasive capacity of FMCm cell line, we performed a clas-
sical Transwell Matrigel Invasion Chamber assay.  As preliminary in vitro results the analy-
sis revealed that FMCm cell line present capacity to in vitro invade the matrigel chamber 
(Supplementary Figure 1).
Supplementary Figure 1. In vitro invasion capacity of FCMm cell line.
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2) P-cadherin transcript sequencing
In order to evaluate the role of P-cadherin in the invasive capacity of FMCm cell line we 
started to determine the sequence of P-cadherin transcript. We specifically design different 
PCR primers that flack all the P-cadherin exons. Supplementary Table 1 depicts the infor-
mation about the PCR primers.
Supplementary Table 1. Primers for PCR amplification of P-cadherin cDNA from FCMm cell line.
In this analysis we could amplified the sequences from exons 3-8, 8-11 and 10-14. We did 
not succeeded in the amplification of the exon 1-3 (Supplementary Figure 2). 
Supplementary Figure 2. Different P-cadherin PCR analysis of FMCm cDNA. 
Further, we specifically sequence the exons 3-8, 8-11 and 10-14 by PCR sequencing in 
order to have the sequence of exons 3-14 of P-cadherin from FMCm cell line. The overall 
sequence obtained by the different exon sequencing was the following:  
EXON 3-14 sequencing
AATGGCAAGGGTCCCTTCCCCCAGAAGCTCAATCAGCTCAAATCTAATA-
AGGACAGAGGCACCAAGATTTTCTACAGCATCACAGGCCCTGGAGCAGA-
CAGCCCCCCTGAGGGTGTCTTCACCATAGAGAAGGAA[ACAGGCTGGTTG
Exons Primers sequence (5´-3)
1-3
F: GACCAATCAGCACCCACCT
R:TTCAACAACAACCAGCCTGT
3-8
F: AGGCACCAAGATTTTCTACAGC
R: GGGTGGTGATGGTAAAATGG
8-11
F: AGCCAATGACAATGCTCCTG
R: CTGGAAAGGGGAGGTGTG
10-14
F: AGTGCTGAACATCACGGACA
R: GTTGCTAAGGCCACTTCTTGA
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TTGTTGAATAAGCCGCTGGACCGGGAGAAGATTGCGAAGTATGAGCTCTTTGGCCAC-
GCTGTATCAGAGAACGGTGCCTCAGTGGAAGACCCCATGAACATCTCCATCATTGTA-
ACTGACCAGAACGACCACAAGCCCAAGTTCACCCAGGATGTTTTCAGAGGGAGC-
GTCTTGGAAGGGGTACTACCCGGCACTTCTGTGATGCAGGTGACAGCCACAGAT-
GAGGACGATGCCATCAACACCTACAATGGGGTGGTTGCTTACTCTATCCATAGC-
CAAGAGCCAAAGGACCCACATGACCTCATGTTCACCGTCCACCGGAGCACGGGTAC-
CATCAGCGTCATCTCCAGTGGCCTGGACCGGGAGAGAGTCCCTGAGTACACACT-
GACCATCCAGGCTACAGACATGGATGGGGATGGTTCTACCACCACAGCAGTGGC-
CATAGTGGAAATCCTCGATGCCAATGACAATGCTCCTGTGTTTGATCCTCAGAAG-
TACGAGGCCCAAGTGCCTGAGAACCTGGTGGGGTACGAGGTGCAGAGGCTGA-
CAGTGACTGATCTGGATGCCCCCAACTCACCCGCATGGCACGCCACCTACCGCAT-
CTTGGAAGGTGACGATGGGGACCATTTTACCATCACCACCCACCCCGAGAGCAAC-
CAGGGCATTCTGACAACCAGGAAGGGCTTGGACTTCGAGGCCAAAAACCAACA-
CACCCTGTACGTTGAAGTGACCAATGAGGCTCCCTTTGTGGTGAAGCTCCCAACCTC-
CACGGCCACCATAGTAGTCCGTGTGGAGGATGTGAATGAGGCACCTGTGTTT-
GTCCCACCCTCCAAAGTCATCGAGGTCCAGGAGGGCATCTCTGTCGGGGAGTCT-
GTCTGCACCTACACTGCGCAGGACCCTGACGAGGGAAATCAGAAGATCAGCTAC-
CACATCCTCAGAGACCCAGCAGGGTGGCTAGCAATGGACCCAGACAGTGGACAG-
GTCACTGCCACGGGGGTTTTAGACCGTGAGGATGAACGGTTTGTGAAGAACAAT-
GTCTATGAAGTCATGGTCTTGGCCACAGATGATGGGAGCCCTCCCACCACTG-
GCACTGGGACCCTCCTGCTAACACTTATGGACATCAATGACCATGGCCCGGTCCCC-
GAACCCCGACAGATCACTATCTGCAACCAAAGCCCTGTGCCCCAAGTGCTGAACAT-
CACGGACAAGGACCTGTCCCCCCACACCTCCCCTTTCCAGGCCCAGCTCACACAT-
GACTCGGATATCTACTGGACAGCAGAGGTCAATGAGAAAGGAAACACAGTGGCCCT-
GTCCTTGAAGAAGTTCCTGAAGCAAGACACATACAATGTGCACCTTTCTCTATCT-
GACCATGGCAACAAGGAACAGCTGACAGTGATCAGCGCCACGGTGTGTGACTGC-
CACGGCCATGTGGAGACCTGCCCCAAACCCTGGAAGGGGGGCTTCCTCCTCCCG-
GTCCTGGGGGCTGTCCTGGCTCTGCTGCTTCTCCTGCTGGTCCTCCTCTTGTTG-
GTGAGGAAGAAGAGGAAGGTCAAGGAGCCCCTTCTGCTCCCAGAAGATGACACCC-
GTGACAATGTCTTCTACTATGGCGAAGAGGGAGGTGGTGAGGAGGACCAGGAC-
TATGACATCACCCAACTCCACCGTGGTCTGGAGGCCCGGCCTGAGGTTGTTCTCC-
GCAATGATGTGGCGCCGTCCTTCATCCCCACACCCATGTACCGTCCACGTCCAGC-
CAACCCAGATGAGATTGGGAACTTCATCATCGAGAACCTGAAGGCGGCAAACAC-
GGACCCCACAGCCCCGCCGTACGACTCCCTGCTGGTGTTTGACTACGAGGGCAGC-
GGCTCTGATGCCGCGTCCCTGAGCTCCCTCACTTCCTCAGCCTCTGACCAGGAC-
CAAGACTATGACTATCTGAACGAGTGGGGCAGTCGCTTCAAGAAGCTGGCAGACATG-
TATGGTGGTGGCCAGGACGACTAGGCGGCCTTCCAACAGGACCCGGGCTAAAGGT-
GGGCCGCAGTGGCATTTCCAAGGAGCCTGAGTCCTCTCCTCGGCCAAGAACTT-
GGGAGCTTGTCAAGAAGTGGCCTTAGCAACTTGG
This result will enable us to design siRNAs that will specifically down regulate the P-cadherin 
protein expression, in order to determine the role of P-cadherin in the invasive capacity of 
FMCm cell line.
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SOLUBLE FRAGMENT OF P-CADHERIN IN
SERUM OF QUEENS WITH MAMMARY TUMOURS
Ana Catarina Figueira, Catarina Gomes, Sofia Anastácio, Anália do Carmo, 
Augusto J.F. de Matos, Patrícia Dias-Pereira, Fátima Gärtner
Preliminary data
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BACKGROUND 
Classical E- and P-cadherin are members of a superfamily of transmembrane molecules 
responsible for calcium-dependent cell-cell adhesion [1]. They have an extracellular do-
main that forms homophilic bonds with cadherins on adjacent cells, whereas its intracellular 
domain interacts with a group of proteins called catenins, linking the cadherins to the actin 
cytoskeleton [2]. In normal mammary gland, E-cadherin is expressed in luminal epithelial 
cells [3, 4], while P-cadherin is a molecule restricted to myoepithelial cells [3, 5]. Alterations 
in their expression are involved in human breast cancer [6], with reduction or absence of 
E-cadherin expression related with mammary tumourigenesis [7-14] and P-cadherin over-
expression associated with poorly differentiated, high grade breast carcinomas [3, 5, 15-20] 
and related to poor prognosis [15, 18-22]. 
The protein ectodomain shedding is a mechanism that involves the proteolytic process-
ing and release of membrane proteins, which alter their functional properties [23, 24]. The 
ectodomain shedding is not an event typically associated with cancer and is a normal part 
of their turnover in cell [23, 24]. Upon the ectodomain cleavage of E- and P-cadherin, a 
soluble 80 kDa E-cadherin fragment (sE-cad) and a 80 kDa soluble P-cadherin (sP-cad) 
are generated and released into the extracellular space [24-26]. During tumourigenesis, 
the abundance of proteolytic enzymes, namely metalloproteases (MMPs), in the tumour 
microenvironment may increase the ectodomain shedding and augment the serum levels 
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of cadherins [25-27]. Increased serum levels of sE-cad were detected in breast cancer 
patients [24, 28, 29], and were associated with clinical stage, tumour grade, lymph node 
metastases, overall and disease-free survival [24, 29]. sE-cad levels were proposed as a 
marker for predicting response to therapy [24, 28, 30]. Discordantly, Knudsen et al. (2000) 
found no correlation between sE-cad serum levels and the presence of breast cancer [25]. 
Although P-cadherin also suffers proteolytical cleavage, the serum levels of sP-cad are 
considerably lower (approximately one twentieth) than sE-cad [25]. The P-cadherin ectodo-
main has been detected in serum/plasma both from healthy and breast cancer patients, 
although the sP-cad were not related with the presence of breast cancer [25, 26], nor with 
the presence of a P-cadherin positive tumour [25]. It was hypothesised that the secretion 
of sP-cad in nipple fluids may represent a potential early biomarker to identify patients at 
higher breast cancer risk [26]. Divergent results between studies hamper a consensus on 
the clinical significance of serum cadherin levels (sE-cad and s-P-cad) in patients with can-
cer [24, 25, 29, 31].
Circulating tumour markers may be useful in screening, diagnosis, staging, prognosis, pre-
diction of tumour relapse, and therapeutic monitoring [23]. In this context, we planned to 
determine the serum levels of sP-cad in a group of queens with spontaneous mammary 
lesions and to compare them with a group of healthy queens.
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MATERIALS AND METHODS
Sample collection
Twenty one queens affected by naturally occurring mammary lesions, surgically excised 
with curative intents, and 31 clinically healthy queens were included in this study. Animals 
with a history of previous tumours or with any other concomitant diseases were excluded.
Blood samples were collected from 31 queens with normal mammary gland, three with hy-
perplastic/dysplastic lesions, one benign tumour (fibroadenoma) and 17 malignant tumours 
(seven tubulopapillary carcinomas, six solid carcinomas, two cribriform carcinomas, one 
mucinous carcinoma and one carcinosarcoma). One (5.88%) malignant tumour was grade 
I, eight (47.06%) were grade II and eight (47.06%) were grade III. In 9 (52.94%) carcinomas 
neoplastic intravascular emboli were identified, and in 11 (78.57%) out of 14 cases, where 
lymph nodes were available, metastases were diagnosed. Blood samples were collected 
once from healthy queens and in tumour-bearing animals all had blood collection prior to 
surgery. In six queens, blood samples were also collected at the post-operative follow-up 
visits. 
Samples were collected into plain collection tube, waited until blood clotting, centrifuged 
and the serum was drawn and stored at -20ºC. Tumour specimens were processed and 
evaluated as previously described [32]. 
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Patients follow-up
Queens with mammary lesions were examined prior to surgery and 6 tumour-bearing 
queens were followed three weeks after surgery and every two months thereafter for a 
two-year period. Each examination consisted of a complete physical examination, thoracic 
radiographs (three views) and complete abdominal ultrasound. In control visits, blood sam-
ples were also collected. Necropsies were performed whenever the owner´s consent and 
suspected metastases were histologically confirmed.
Overall survival (OS) was calculated from the date of tumour removal to the date of death/
euthanasia. Disease-free interval (DFI) was calculated from the date of surgery to the date 
of detection of the first recurrence or development of distant metastases. 
Detection and quantification of soluble P-cadherin by ELISA
P-cadherin concentrations were measured using an enzyme-linked immunosorbent assay 
(ELISA) kit (DuoSet® ELISA Development System, R&D Systems, Abingdon, UK) accord-
ing to the manufacturer’s instructions. Briefly, a 96-well immunoplate was coated with 100 
μL/ well of the monoclonal mouse anti-human P-cadherin and incubated overnight at room 
temperature. The wells were washed 3 times with 400 μL phosphate buffered saline (PBS) 
containing 0.05% Tween-20 at pH 7.4. Plates were then blocked with 300 μL of PBS con-
taining 1% bovine serum albumin (BSA) for 1 hour at room temperature. After a total of 
three washes, 100 μL/well of samples or standards were added and incubated for 2 hours 
at room temperature. The plates were again washed for three times and subsequently in-
cubated with 100 μL of diluted biotinylated goat anti-human P-cadherin (detection antibody) 
for 2 hours at room temperature. After three new washings, 100 μL of streptavidin–horse-
radish peroxidase was added to each well and incubated at room temperature for 20 min-
utes. The three wash step was repeated for the last time and 100 μL of substrate solution 
containing a mixture of hydrogen peroxide and tetramethylbenzidine (color reagents) was 
added to each well and incubated for 20 minutes at room temperature. The reaction was 
finished by adding 50 μL of the stop solution to each well. The optical density of each well 
was determined using a microplate reader set to 450 nm and to 570 nm (Molecular Devices, 
SPECTRA max PLUS 384). The readings at 570 nm were subtracted to the readings at 450 
nm. Four negative controls were used: 1 - all the procedure was done, skipping the addition 
of serum, which was replaced by reagent diluents; 2 – a negative sample without the detec-
tion antibody; 3 – a positive sample without the detection antibody; 4 – a negative serum 
and the detection antibody replaced by a goat anti-human IgA antibody. For positive control 
we used negative serum sample added with the recombinant human P-cadherin from the 
kit. The sensibility limits of this ELISA kit were 62.50-4.000 pg/ml.
A standard curve was generated for each set of samples assayed, using serial dilutions of 
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P-cadherin. A linear regression equation was created from standards of known P-cadherin 
concentrations and P-cadherin levels of unknown samples were fit to the standard curve 
regression equation, corrected for aliquot volume and expressed as pg of P-cad/mL. The 
standard curve and serum samples were run in duplicate and the average of the two values 
was reported.
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RESULTS AND DISCUSSION
Table 1 represents a resume of the clinicopathological features of the queens that had posi-
tive sP-cad serum levels and of those that what was possible to have a clinical follow-up. In 
our series, soluble sP-cad was not detected in serum from healthy queens or from queens 
with benign or hyperplasic lesions. Amongst the 17 malignancies, sP-cad was detected in 
two queens diagnosed with grade III carcinomas (Table 1): one cat had measurable levels 
at the time of surgery and two (including the former) had measurable values during the 
follow-up visits. The DFI and OS of seven malignant cases are represented in table 1. The 
metastatic lesions were positive to P-cadherin (Figure 1).
Several molecular and cellular alterations occur with cancer progression, including prote-
olysis and release of membrane proteins, such as cadherins, as the result of a proteases 
enrichment of the tumour environment [23, 24, 33]. In vitro studies revealed a self-sustained 
loop where the overexpression of P-cadherin induces the secretion of matrix metallopro-
teinases capable of cleaving the P-cadherin ectodomain and releasing sP-cad, which, in 
turn, is able to induce and maintain the secretion of active MMP´s [34]. The serum levels 
of sP-cad were, therefore, proposed as potential early biomarkers of breast cancer risk or 
diagnosis, although this hypothesis has not been proved [25, 26].
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Figure 1. P-cadherin expression by immunohistochemistry. (A) Lung metastases with P-cadherin expres-
sion by neoplastic cells. x100; (B) Detail of the lung metastatic lesion with P-cadherin expression. x200.
Although the small size of the series hampers any results interpretation, it seems possible 
that the sensibility limit of this ELISA kit may difficult the detection of sP-cad in low concen-
trations. Therefore, we aim to improve the sensitivity of the test and to study a larger group 
of cats with neoplastic mammary lesions. 
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CONCLUSIONS 
It is possible to detect and determine the serum concentration of the soluble P-cadherin 
fragment in queens using an enzyme-linked immunosorbent assay kit, although the tech-
nique needs to be improved or complemented in order to be considered of interest in the 
evaluation of cats with mammary tumours. 
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GENERAL DISCUSSION
The majority of feline mammary tumours are carcinomas with an aggressive behaviour and 
high metastatic potential [1, 2]. Affected queens have a poor prognosis with death or eu-
thanasia generally due to local recurrence and/or metastatic disease [1, 3]. It is manifestly 
evident that the assessment of histological type is not sufficient per se for individual prog-
nosis in cats [4], often being complemented, for such purpose, with grading [5-8], and the 
search for lymphatic and/or blood invasion as well as regional lymph node metastases [8].
Recently, several studies have been directed to the search of molecular markers in feline 
mammary tumours, in order to provide additional information in the diagnosis, prognosis 
and to select patients that are likely to suffer from progressive disease and that may be sub-
mitted to adjuvant therapies [9-12], as is currently standard in human breast cancer [13, 14]. 
The cadherin-catenin complex is a cell-cell adhesion system that is also involved in major 
mechanisms of specific genes transcription modulation, hence regulating several cellular 
processes, namely proliferation, survival, polarization, differentiation, shape and migration 
[15-17]. Thus, disorders of its components are known to be involved in breast cancer de-
velopment [18-25]. 
The cadherin-catenin complex is important for the maintenance of the overall architecture 
of the feline normal mammary gland, as revealed by the expression of the molecules that 
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compose this complex. In this study, E-cadherin and catenins were consistently expressed 
in the membrane of epithelial luminal cells while P-cadherin was restricted to mioepithelial 
cells. This selective cadherin-catenin expression seems to be necessary for the correct ar-
chitecture of normal mammary gland, and alterations of this pattern of expression were only 
observed in mammary lesions. 
P-cadherin overexpression is associated to increased cell proliferation, motility, invasive-
ness, and metastatic progression in breast cancer cells, being P-cadherin considered an 
invasion-promoting protein [15, 16, 20, 26-29], and is related to poor prognosis in breast 
carcinoma patients [15, 20, 22, 24, 30-32]. In 80% of the feline carcinomas included in this 
study there was a significant overexpression of P-cadherin by luminal epithelial cells when 
compared with benign mammary lesions. P-cadherin expression was more evident in the 
most peripheral cells of the tumour invasion front and in the invasive neoplastic cell clus-
ters, denoting its important role in invasion. Moreover, it was associated to high histological 
grade of carcinomas and high proliferative index revealing a close relationship with less 
differentiated tumours, as previously reported by other authors in human breast cancer [18-
20, 22, 24, 25, 30, 33-35]. These features suggest that P-cadherin may be regarded as a 
promising prognostic indicator of aggressiveness in feline mammary carcinomas. Although 
we were unable to demonstrate a relationship between P-cadherin expression and nodal 
metastases, similar to what is described in humans [18, 19, 22], our results indicate that 
the aberrant expression of P-cadherin may constitute an important step in the invasion and 
tumours progression, as P-cadherin positive tumours were 8.46 times more likely to show 
invasion to vessels than negative ones. This finding suggests that the arrest and fixation 
of neoplastic cells in distant sites may require the acquisition of other morphological and 
functional features, other than P-cadherin per se. 
Alterations of the E-cadherin expression, particularly partial or total loss, have been also 
associated to breast cancer [21, 23, 36-42]. We observed that the feline normal mammary 
tissue presented E-cadherin expression in luminal epithelial cells while nearly half of the 
carcinomas exhibited reduced expression. E-cadherin was not related to histological grade 
or to the presence of neoplastic intravascular emboli or lymph node metastases. Several 
studies suggested that the combined study of cadherins and catenins may contribute to bet-
ter characterize their role in breast carcinogenesis [43-45]. 
Our study revealed that nearly 60% of feline mammary carcinomas exhibited reduced mem-
branous expression of α-, β- and p120-catenin, suggesting that their loss contributes to the 
development of a malignant phenotype in queens, as previously shown in human breast 
cancer [43, 44, 46, 47]. In breast carcinomas, down-regulation or loss of α-catenin has been 
associated to high tumour grade [48], metastasis [43, 48, 49] and poor survival [48], which 
raised the possibility that it may be considered a good prognostic marker. We observed an 
association between reduced α-catenin expression and larger tumour size and necrosis, 
which can be justified by the fact that under a stressful tumour microenvironment, loss of 
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α-catenin results in increased proliferation, decreased apoptosis and increased growth-
factor signalling, and leads to larger tumour volumes and ischemic necrosis [50, 51].
A significant reduction in β-catenin expression was observed in feline mammary carcino-
mas compared to benign tumours, but this reduction had no association with clinicopatho-
logical features with known prognostic value. In fact, the prognostic value of β-catenin in 
both human [43, 49, 52, 53] and feline mammary tumours [54, 55] has not been clarified, 
with different studies revealing contradictory results. 
Another interesting finding from this study was the cytoplasmic p120-catenin subcellular 
location in 40% of the feline mammary carcinomas in our series. In human breast carcino-
mas, this phenomenon is associated to an invasive behaviour [56, 57] and higher histologi-
cal grades [58]. Although we were unable to establish a relationship between sub-cellular 
p120-catenin location and the histological grade of carcinomas (probably due to the low 
number of cases included in this series), nearly 96% of mammary tumours with cytoplas-
matic p120-catenin expression were moderate- or high-grade carcinomas, suggesting 
that it may be relevant for the development and progression of feline mammary cancer. 
Approximately 90% of carcinomas showing emboli preserve the expression of α-, β- and 
p120-catenin in the neoplastic intravascular cells, irrespective of the expression depicted in 
the primary tumor, which may indicate that catenins in embolic cells represent a strategy for 
effective spread of neoplastic cells. 
Our study supports the concept that dysfunction of the E-cadherin–catenin adhesion com-
plex is related to feline malignant mammary tumours, based on the demonstration that 70% 
of the carcinomas underexpressed at least one member of this complex. Furthermore, we 
observed that the overexpression of P-cadherin is a better indicator of the malignant behav-
iour of feline mammary carcinomas than the loss of E-cadherin and/or catenins.
The results besides denoting the importance of P-cadherin in malignant mammary tumours 
highlights the need for the study of the prognostic value of P-cadherin positivity in tumours 
that preserve E-cadherin expression in cats. Curiously, nearly half of the P-cadherin-posi-
tive carcinomas studied also preserved a normal pattern of E-cadherin expression. More-
over, more than half of the P-cadherin positive tumours that presented vascular emboli and 
lymph node metastases were also E-cadherin positive. Thus the P+/E+ expression seems 
to be related to aggressive tumour behaviour similar to what happens in women [16, 59, 60]. 
In an effort to contribute to the molecular characterization of feline mammary tumours and 
explore molecular reliable markers that could be helpful as prognostic and therapeutic tar-
gets we analysed phenotypic cell markers (AE1/AE3, vimentin, p63), hormonal receptors 
status (ER, PR) and proliferative activity (Ki-67) and their relationship with the cadherins 
molecules (P- and E-cadherin). 
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Beyond the normal nuclear p63 expression in myoepithelial cells, it was also found labelling 
in the nucleus of epithelial cells in 38% of carcinomas, although with less intensity. P63 is 
thought to be expressed early in epithelial differentiation and may contribute to a commit-
ted stem cell and/or progenitor phenotype, such as P-cadherin and CK5 [61]. In fact, p63 is 
known to act as a transcription factor of the P-cadherin promoter [62, 63] which denotes a 
functional relationship between these two molecules. Our results suggest that this associa-
tion at the genetic level can probably be equated to feline mammary tumours, as we were 
able to demonstrate a relationship between p63 and P-cadherin expression.
Half of the carcinomas in our study co-expressed vimentin and cytokeratin, a feature pre-
viously described in human [64] and feline [11, 54] malignant mammary tumours. These 
vimentin positive cancer cells could be a hallmark of the direct myoepithelial histogenesis, 
be a sign of the epithelial-mesenchymal transition (EMT) reflecting the end-stage of tumour 
dedifferentiation or derive from mammary progenitor cells with bilinear (glandular and myo-
epithelial) differentiation potential [65]. 
In our series P-cad+/vim+ mammary tumours were 3.76 times more prone to invade ves-
sels, corroborating the human breast cancer concept that both P-cadherin [15] and vimentin 
[66] are invasion-associated molecules. Curiously, half of the P-cad+/vim+ carcinomas also 
preserved E-cadherin expression. This condition may represent a partial EMT phenome-
non, in which cells retain some epithelial characteristics albeit acquiring features of mesen-
chymal cells, leading some authors to propose that P-cadherin could be considered an EMT 
marker, able to identify intermediate and transient EMT states, associated with metastatic 
phenotypes [67]. 
Steroid hormones are associated with the development of mammary tumours, as evi-
denced by the different expression of HR in normal and neoplastic mammary tissues [68-
70]. In our series, the expression of ER and PR in malignant tumours was significantly 
lower when compared to benign tumours, corroborating data from previous studies [1, 69, 
71, 72]. Moreover, ER was associated with expression of both P- and E-cadherin, the vast 
majority of ER-negative carcinomas being P-cadherin-positive and the majority of ER posi-
tive tumours being E-cadherin-positive. The lack of ER signalling seems to be responsible 
for P-cadherin overexpression, categorizing the P-cadherin gene/CDH3 as an oestrogen-
repressed gene [26, 33, 35, 73]. The role of ER in the regulation of E-cadherin expression 
is still obscure [19, 43, 74-77]. 
The Ki-67 index was higher in carcinomas than in non-neoplastic and benign lesions, cor-
roborating data from previous studies [7, 70, 78, 79]. Moreover, higher Ki-67 indexes were 
related with the overexpression of P-cadherin, higher histological grade, and ER negative 
status, supporting its association with tumour aggressiveness. The combined analysis of 
the molecular markers and the tumour clinicopathological features allowed the conclusion 
that P-cad-/vim-/ER+/E-cad+/low Ki-67 malignant tumours were well-differentiated carcino-
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mas, which suggests that this molecular profile identifies low-aggressive carcinomas. On 
opposition, P-cad+/vim+/ER-/high Ki-67 tumours were of higher histological grades, thus 
suggesting that an immunohistochemical classification based on the combined expression 
of P-cadherin, ER, vimentin and Ki-67 may be of prognostic value in mammary carcinomas 
in this species. 
Cancer is a complex biologic process and the events involved in the development and pro-
gression of feline mammary carcinomas are still poorly known [80], namely the cadherins 
and catenins role, about which there is still few and contradictory information [54, 81-83]. 
The development of in vitro and in vivo models to study the molecules of the cadherin-
catenin complex, would allow a better understanding of their role in feline mammary carci-
nogenesis and in this context we worked with the FMCm cell line [84]. This cell line revealed 
co-expression of E-cadherin and α-, β- and p120-catenin and a close relationship between 
E-cadherin and each one of the catenins studied, which points to a preserved E-cadherin-
catenin complex. These cells also expressed P-cadherin that was co-localized with E-cad-
herin, and it was possible to determine an interaction between these two molecules.
Aiming to develop an in vivo model for the study of feline mammary carcinomas that could 
mimic as much as possible the spontaneous lesions, we transplanted the FMCm cancer 
cells into the mammary fat pad of nude mice. Those cells were able to induce local forma-
tion of high grade metastatic carcinomas in all mice, revealing that this cell line is highly 
tumourigenic, and with high metastastic potential. Both xenograft and metastatic lesions 
expressed P- and E-cadherin as well as α-, β- and p120-catenin. This corroborates data 
from recent studies describing that the co-expression of both P- and E-cadherin is signifi-
cantly associated to aggressive behaviour, invasion and metastasis in breast carcinomas 
[16, 59, 60].
The metastatic pattern observed in mice was similar to the one described in queens [85], 
with regional lymph nodes and lungs being the major sites involved. This in vivo model 
seems to be suitable to identify and characterize molecular mechanisms that drive metas-
tasis in feline mammary carcinomas and thus could constitute a valuable tool in order to 
develop strategies to inhibit the metastatic process in feline species.
Although surgical excision will probably continue to be the treatment of choice, feline mas-
tectomized patients present a high incidence of recurrences and metastases [1, 3]. Despite 
aggressive surgery and some attempts of adjuvant therapies, the clinical outcome has not 
been substantially improved and there is still a lack of effective post-operative therapeutic 
plans for feline mammary carcinoma [2, 85]. It was suggested that interruption of the P-
cadherin signalling pathway could be a novel therapeutic approach for breast cancer, as 
P-cadherin inhibition has anti-tumoural and anti-metastatic effects [16, 59, 86]. Both human 
monoclonal antibody against P-cadherin [86] and bacterial protein azurin [59] are pointed 
as novel therapeutic tools in P-cadherin expressing malignant tumours. Azurin decreased 
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membranous P-cadherin expression and presented anti-invasive effects in P-cadherin 
overexpressing breast cancer cells and the monoclonal antibody against P-cadherin, in a 
xenograft model, resulted in inhibition of growth and metastatic progression of high P-cad-
herin expression tumours [86]. This scenario sparked our interest in the study of P-cadherin 
in feline mammary carcinoma, as a potential therapeutic target. Thus, the FMCm cells both 
in vitro and in vivo can be used for therapeutic studies concerning P-cadherin molecules 
in order to determine if the highly aggressive P-cadherin positive feline mammary tumours 
may benefit from one of these novel therapeutic approaches [59, 86]. 
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CONCLUSIONS
The results presented and discussed in this thesis allowed us to reach the following conclusions:
- Aberrant expression of P-cadherin detected in feline mammary tumours is associated to 
malignant phenotypes, higher histological grade and invasive behaviour, suggesting that 
this protein may be a relevant prognosis biomarker;
- P-cadherin overexpression seems to be a more reliable indicator of prognosis in feline 
mammary carcinomas than the aberrant expression of E-cadherin;
- Co-expression of P- and E-cadherin was related with high grade carcinomas;
- Development of mammary carcinomas in cats is associated to a decreased expression of 
α-, β- and p120-catenin, suggesting that these catenins may represent a valuable diagnos-
tic tool, although their prognostic value was not supported by our results;
- Aggressive feline mammary carcinomas are characterized by high histological grade, high 
proliferative activity, absence of ER, aberrant expression of P-cadherin and vimentin. The 
identification of these five characteristics in the same tumour may be regarded as the basis 
for the decision to submit affected animals to post-operative adjuvant therapy;
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- The FMCm cell line besides expressing P-cadherin also co-expressed E-cadherin and α-, 
β- and p120-catenins, and those molecules were in close relation with each other pointing 
to a preserved E-cadherin-catenin complex;
- FMCm cell line showed high tumourigenic, aggressive and metastatic characteristics in 
nude mice, with xenograft and metastatic lesions expressing P- and E-cadherin as well as 
α-, β- and p120-catenin. It can be proposed as a useful model for in vitro and in vivo studies 
of P-cadherin and associated molecules of the cadherin-catenin complex of feline mam-
mary carcinoma progression.
Considering the initial aims of this PhD project, we believe that we have successfully ad-
dressed most of the questions we have wished for to answer. In conclusion, the results 
presented in this study highlighted P-cadherin as a relevant molecule in tumour aggressive-
ness of feline mammary carcinomas.
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FUTURE PERSPECTIVES
In general, our results added more knowledge on P-cadherin as a biomarker of feline mammary 
tumours, as well as on E-cadherin-catenin complex. However, data resulting from this work 
raises many interesting questions and challenges that remain to be elucidated.
- Clarify the role of P-cadherin expression in FMCm cell line and the possible involvement 
in the invasive capacity of these cells. We intend to specifically knock down P-cadherin ex-
pression and evaluate the in vitro invasive capacity of that cell line upon P-cadherin silencing. For 
that purpose we specifically will design siRNA according to the cDNA sequencing results 
described in Chapter 6 (Supplementary data) and perform silencing of P-cadherin expres-
sion in this cell line. Further studies on the tumourigenic and metastatic capacity of the cell 
line in nude mice with the aim of elucidating the role of P-cadherin expression in mammary 
carcinoma biology behaviour;
- To explore the functional effects of the co-expression of P-cadherin and E-cadherin in 
FMCm cell line;
- Study P-cadherin as a potential therapeutic target in feline mammary carcinomas in in vitro 
and in vivo assays;
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- Determination of P-cadherin as a potential stem cell marker in feline mammary carcino-
mas, by co-expression with known stem cell markers such as CD44 and CD24;
- Further prospective studies, with larger series of mammary carcinomas showing different 
grade and type characteristics, since to the best of our knowledge there are no survival 
studies in feline mammary tumours related with P-cadherin expression;
- Study additional molecular markers that improve the feline molecular classification, name-
ly HER2, EGFR or CK5/6 helping in the identification of the molecular subtypes with prog-
nostic and therapeutic relevance;
- To enhance the sensibility of the ELISA assay in order to determine de sP-cad in serum 
of feline mammary tumour patients, with the aim to develop a diagnostic kit to monitor the 
metastatic process.
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